Results for Announcement to the Market

James Hardie Industries plc

ARBN 097 829 895

Appendix 4E - Preliminary Final Report Year Ended 31 March 2019						
Key Information	Y	ear Ended 3	1 March			
	FY 2019 US\$M	FY 2018 US\$M	Moven	nent		
Net Sales From Ordinary Activities	2,506.6	2,054.5	Up	22%		
Profit From Ordinary Activities After Tax Attributable to Shareholders	228.8	146.1	Up	57%		
Net Profit Attributable to Shareholders	228.8	146.1	Up	57%		
Net Tangible Assets (Liabilities) per Ordinary Share	US\$1.35	US\$(0.52)	Up	360%		

Dividend Information

- A FY2019 second half ordinary dividend ("FY2019 second half dividend") of US26.0 cents per security is payable to CUFS holders on 2 August 2019.
- A FY2019 first half ordinary dividend ("FY2019 first half dividend") of US10.0 cents per security was paid to CUFS holders on 22 February 2019.
- The record date to determine entitlements to the FY2019 second half dividend is 6 June 2019 (on the basis of proper instruments of transfer received by the Company's registrar, Computershare Investor Services Pty Ltd, Level 4, 60 Carrington Street, Sydney NSW 2000, Australia, by 5:00pm if securities are not CHESS approved, or security holding balances established by 5:00pm or such later time permitted by ASTC Operating Rules if securities are CHESS approved).
- The FY2019 first half dividend, the FY2019 second half dividend and future dividends will be unfranked for Australian taxation purposes.
- The Company will be required to deduct Irish DWT (currently 20% of the gross dividend amount) from this dividend and future dividends, unless the beneficial owner has completed and returned a non-resident declaration form (DWT Form).
- The Australian currency equivalent amount of the FY2019 second half dividend to be paid to CUFS holders will be announced after the record date. The amount payable to shareholders who have elected to receive their dividend in NZ dollars or British pounds will also be announced on the same date.
- No dividend reinvestment plan is currently in operation for the FY2019 second half dividend.
- The FY2018 second half ordinary dividend ("FY2018 second half dividend") of US30.0 cents per security was paid to CUFS holders on 3 August 2018.

Movements in Controlled Entities during the Year Ended 31 March 2019

The following entities were created or acquired:

XI (DL) Holdings GmbH (3 April 2018) (n/k/a James Hardie Europe Holdings 2), Fermacell GmbH (3 April 2018) (n/k/a James Hardie Europe GmbH), SNC Parc 3 (3 April 2018), Fermacell B.V (3 April 2018), Fermacell Spain S.L.U. (3 April 2018), Fermacell Schraplau GmbH (3 April 2018), FELS Recycling GmbH (3 April 2018), Fermacell SAS (3 April 2018)

Associates and Joint Venture Entities

FELS Recycling GmbH (51%); Aplicaciones Minerales S.A. (28%)

Audit

The results and information included within this Preliminary Final Report have been prepared using US GAAP and have been subject to an independent audit by external auditors.

Results for the 4th Quarter and Year Ended 31 March 2019

Contents

- 1. Media Release
- 2. Management's Analysis of Results
- 3. Management Presentation
- 4. Consolidated Financial Statements

James Hardie Industries plc is incorporated under the laws of Ireland with its corporate seat in Dublin, Ireland. The liability of members is limited. The information contained in the above documents should be read in conjunction with the James Hardie 2019 Annual Report which can be found on the company website at www.jameshardie.com.



James Hardie Announces Adjusted Net Operating Profit of US\$73.8 million for Q4 Fiscal Year 2019 and US\$300.5 million for the full year ended 31 March 2019

James Hardie announces a fiscal year 2019 second half dividend of US 26.0 cents per security

James Hardie today announced results for the fourth quarter of fiscal year 2019 and the full year ended 31 March 2019:

- Group Adjusted net operating profit of US\$73.8 million for the quarter and US\$300.5 million for the full year, a decrease of 9% and an increase of 3%, respectively, compared to the prior corresponding periods ("pcp");
- Group Adjusted EBIT of US\$100.0 million for the quarter and US\$404.6 million for the full year, a decrease of 3% and an increase of 2%, respectively, compared to pcp;
- Group net sales of US\$624.8 million for the quarter and US\$2,506.6 million for the full year, an increase of 19% and 22%, respectively, compared to pcp;
- North America Fiber Cement Segment volume increased 1% for the quarter and 3% for the full year, compared to pcp;
- North America Fiber Cement Segment EBIT margin excluding product line discontinuation expenses of 22.5% for the quarter and 23.1% for the full year;
- Asia Pacific Fiber Cement Segment EBIT margin of 20.0% for the quarter and 22.3% for the full year;
- Europe Building Products Segment Adjusted EBIT margin excluding costs associated with the acquisition of 11.3% for the quarter and 10.6% for the full year; and
- The Fermacell acquisition closed on 3 April 2018 and is included in the financial results for the full year of fiscal year 2019.

CEO Commentary

James Hardie CEO Jack Truong said, "Our North America Fiber Cement segment delivered solid revenue growth of 3% for the quarter and 6% for the full year while generating good EBIT margins within our target range in a challenging input cost environment. The North America housing market demand was soft across most geographies and customer segments the last six months of fiscal year 2019. Our exteriors business grew 1% above our addressable market for fiscal year 2019 compared to negative 2% in fiscal year 2018. It was a good improvement over our fiscal year 2018 performance, albeit below our internal expectations. We have encouraging signs of early momentum on our recent commercial transformation and implementation of lean manufacturing in our North American plants. We are confident these transformations will lead to marked improvement in our ability to execute and deliver on expected results."

He continued, "Our Asia Pacific Fiber Cement segment continued to deliver excellent top line growth of 7% and 11% in Australian dollars for the quarter and full year, respectively. Our Australian and Philippines businesses lead the way in gaining volume growth above their underlying market growth. This strong growth was achieved despite a continued, softening Australian housing market throughout the year. Further, our EBIT margins were significantly impacted by input cost rapid inflation during most of fiscal year 2019."

Dr Truong added, "Our Europe Building Products segment delivered strong pro-forma revenue growth in Euros of 7% with an Adjusted EBIT margin of 10.6% for the full fiscal year after excluding costs associated with the acquisition and integration. We are encouraged by the positive first year results. We are excited about our European business gaining significant momentum in fiber cement growth in fiscal year 2020 while continually improving on our fiber gypsum business."

Media Release

21 May 2019



He concluded, "Our consolidated group results reflected good and disciplined financial performance in a significant inflationary cost environment. We enter fiscal year 2020 with our global team aligned on one global strategy that is centered around delivering growth above the market in all of our regions with strong financial returns."

Outlook

We expect to see modest growth in the US housing market in fiscal year 2020. The single family new construction market and repair and remodel market growth rates in fiscal year 2020 are expected to grow, albeit at a growth rate lower than that in fiscal year 2019. The Company expects new construction starts between approximately 1.2 million and 1.3 million.

We expect our North America Fiber Cement segment EBIT margin to be in the top half of our range of 20% to 25% for fiscal year 2020. This expectation is based upon the Company continuing to improve operating performance in our plants, improved net average sales price and mix, continued inflation for input costs and modest underlying housing growth.

In Australia, it is anticipated that our addressable underlying market will decrease in fiscal year 2020 compared to fiscal year 2019. Net sales from our Australian business are expected to continue to trend above the average growth of the domestic repair and remodel and single family detached housing markets in the eastern states of Australia.

We expect our Europe Building Product segment to achieve year on year net sales and EBIT margin growth.

Further Information

Readers are referred to the Company's Consolidated Financial Statements and Management's Analysis of Results for the fourth quarter and full year ended 31 March 2019 for additional information regarding the Company's results, including information regarding income taxes, the asbestos liability and contingent liabilities.

As of 30 June 2018, the Company changed its reportable operating segments. Previously, the Company reported on four operating segments: (i) North America Fiber Cement, (ii) International Fiber Cement, (iii) Other Businesses, and (iv) Research and Development. As of 30 June 2018, the Company began reporting on five operating segments: (i) North America Fiber Cement, (ii) Asia Pacific Fiber Cement, (iii) Europe Building Products, (iv) Other Businesses, and (v) Research and Development. The significant changes to how certain businesses are reported in the new segment structure are as follows: Our European Fiber Cement business as well as the newly acquired Fermacell business are now reported as the Europe Building Products segment, and the remaining businesses that were historically reported in the International Fiber Cement segment are now reported in the Asia Pacific Fiber Cement segment. The Company has revised its historical segment information at 31 March 2018 and for the years ended 31 March 2018 and 2017 to be consistent with the new reportable segment structure. The change in reportable segments had no effect on the Company's financial position, results of operations or cash flows for the periods presented. Readers are referred to Note 18 of our consolidated financial statements for further information on our segments.

Use of Non-GAAP Financial Information; Australian Equivalent Terminology

This Media Release includes financial measures that are not considered a measure of financial performance under generally accepted accounting principles in the United States (GAAP), such as Adjusted net operating profit and Adjusted EBIT. These non-GAAP financial measures should not be considered to be more meaningful than the equivalent GAAP measure. Management has included such measures to provide investors with an

Media Release

21 May 2019



alternative method for assessing its operating results in a manner that is focused on the performance of its ongoing operations and excludes the impact of certain legacy items, such as asbestos adjustments. Additionally, management uses such non-GAAP financial measures for the same purposes. However, these non-GAAP financial measures are not prepared in accordance with US GAAP, may not be reported by all of the Company's competitors and may not be directly comparable to similarly titled measures of the Company's competitors due to potential differences in the exact method of calculation. For additional information regarding the non-GAAP financial measures presented in this Media Release, including a reconciliation of each non-GAAP financial measure to the equivalent US GAAP measure, see the section titled "Non-US GAAP Financial Measures" included in the Company's Management's Analysis of Results for the fourth quarter and full year ended 31 March 2019.

In addition, this Media Release includes financial measures and descriptions that are considered to not be in accordance with US GAAP, but which are consistent with financial measures reported by Australian companies, such as operating profit, EBIT and EBIT margin. Since the Company prepares its Consolidated Financial Statements in accordance with US GAAP, the Company provides investors with a table and definitions presenting cross-references between each US GAAP financial measure used in the Company's Consolidated Financial Statements to the equivalent non-US GAAP financial measure used in this Media Release. See the sections titled "Non-US GAAP Financial Measures" included in the Company's Management's Analysis of Results for the fourth quarter and full year ended 31 March 2019.

Forward-Looking Statements

This Media Release contains forward-looking statements and information that are necessarily subject to risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of James Hardie to be materially different from those expressed or implied in this release, including, among others, the risks and uncertainties set forth in Section 3 "Risk Factors" in James Hardie's Annual Report on Form 20-F for the year ended 31 March 2019; changes in general economic, political, governmental and business conditions globally and in the countries in which James Hardie does business; changes in interest rates; changes in inflation rates; changes in exchange rates; the level of construction generally; changes in cement demand and prices; changes in raw material and energy prices; changes in business strategy and various other factors. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein. James Hardie assumes no obligation to update or correct the information contained in this Media Release except as required by law.

END

Media/Analyst Enquiries:

Jason Miele Vice President, Investor and Media Relations

Telephone: +61 2 8845 3352

Email: media@jameshardie.com.au



Management's Analysis of Results

This Management's Analysis of Results forms part of a package of information about James Hardie Industries plc's results. It should be read in conjunction with the other parts of this package, including the Media Release, the Management Presentation and the consolidated financial statements. Except as otherwise indicated in this Management's Analysis of Results, James Hardie Industries plc is referred to as "JHI plc." JHI plc, together with its direct and indirect wholly-owned subsidiaries, are collectively referred to as "James Hardie," the "Company," "we," "our," or "us." Definitions for certain capitalized terms used in this Management's Analysis of Results can be found in the section titled "Non-GAAP Financial Measures."

This Management's Analysis of Results includes financial measures that are not considered a measure of financial performance under generally accepted accounting principles in the United States ("US GAAP"). These non-GAAP financial measures should not be considered to be more meaningful than the equivalent US GAAP measures. Management has included such measures to provide investors with an alternative method for assessing its financial condition and operating results in a manner that is focused on the performance of its ongoing operations. These measures exclude the impact of certain legacy items, such as asbestos adjustments, or significant nonrecurring items, such as debt restructuring and acquisition costs, asset impairments, as well as adjustments to tax expense. In addition, management provides an adjusted effective tax rate, which excludes the tax impact of the pre-tax special items (items listed above) and tax special items. Management believes that this non-GAAP tax measure provides an ongoing effective rate which investors may find useful for historical comparisons and for forecasting and is an alternative method of assessing the economic impact of taxes on the Company, as it more closely approximates payments to taxing authorities. Management uses such non-GAAP financial measures for the same purposes. These non-GAAP measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with US GAAP. These non-GAAP financial measures are not prepared in accordance with US GAAP, may not be reported by all of the Company's competitors and may not be directly comparable to similarly titled measures of the Company's competitors due to potential differences in the exact method of calculation. For additional information regarding the non-GAAP financial measures presented in this Management's Analysis of Results, including a reconciliation of each non-GAAP financial measure to the equivalent US GAAP measure, see the section titled "Non-US GAAP Financial Measures." In addition, this Management's Analysis of Results includes financial measures and descriptions that are considered to not be in accordance with US GAAP, but which are consistent with financial measures reported by Australian companies. Since James Hardie prepares its consolidated financial statements in accordance with US GAAP, the Company provides investors with a table and definitions presenting cross-references between each US GAAP financial measure used in the Company's consolidated financial statements to the equivalent non-US GAAP financial measure used in this Management's Analysis of Results. See the section titled "Non-US **GAAP Financial Measures.**"

These documents, along with an audio webcast of the Management Presentation on 21 May 2019, are available from the Investor Relations area of our website at http://www.ir.jameshardie.com.au

NOTE TO THE READER:

As of 30 June 2018, the Company changed its reportable operating segments. Previously, the Company reported on four operating segments: (i) North America Fiber Cement, (ii) International Fiber Cement, (iii) Other Businesses, and (iv) Research and Development. As of 30 June 2018, the Company began reporting on five operating segments: (i) North America Fiber Cement, (ii) Asia Pacific Fiber Cement, (iii) Europe Building Products, (iv) Other Businesses, and (v) Research and Development. The significant changes to how certain businesses are reported in the new segment structure are as follows: (i) our European Fiber Cement business, as well as the newly acquired Fermacell business, are now reported as the Europe Building Products segment, and the remaining

Fiscal 2019 Fourth Quarter and Full Year Ended 31 March 2019



businesses that were historically reported in the International Fiber Cement segment are now reported in the Asia Pacific Fiber Cement segment. The Company has revised its historical segment information for the fourth quarter and full year ended 31 March 2018 to be consistent with the new reportable segment structure. The change in reportable segments had no effect on the Company's financial position, results of operations or cash flows for the periods presented. Readers are referred to Note 18 of our consolidated financial statements for further information on our segments.

Media/Analyst Enquiries:

Jason Miele Vice President, Investor and Media Relations

Telephone: +61 2 8845 3352

Email: media@jameshardie.com.au

GROUP RESULTS



James Hardie Industries plc Results for the 4th Quarter and Full Year Ended 31 March

US\$ Millions	Three Months and Full Year Ended 31 March					
	Q4 FY19	Q4 FY18	Change %	FY19	FY18	Change %
Net sales	\$ 624.8	\$ 525.9	19	\$ 2,506.6	\$ 2,054.5	22
Cost of goods sold	(414.2)	(334.8)	(24)	(1,675.6)	(1,324.3)	(27)
Gross profit	210.6	191.1	10	831.0	730.2	14
Selling, general and administrative expenses	(102.3)	(85.1)	(20)	(403.6)	(311.3)	(30)
Research and development expenses	(9.4)	(8.9)	(6)	(37.9)	(33.3)	(14)
Asset impairments	(2.8)	_		(15.9)	_	
Asbestos adjustments	(73.4)	(192.9)	62	(22.0)	(156.4)	86
EBIT	22.7	(95.8)		351.6	229.2	53
Net interest expense	(13.3)	(7.9)	(68)	(50.1)	(29.5)	(70)
Loss on early debt extinguishment ¹	_	_		(1.0)	(26.1)	96
Other income	_	0.5		0.1	0.7	(86)
Operating profit (loss) before income taxes	9.4	(103.2)		300.6	174.3	72
Income tax (expense) benefit	(8.6)	45.6		(71.8)	(28.2)	
Net operating profit (loss)	\$ 0.8	\$ (57.6)		\$ 228.8	\$ 146.1	57
Earnings per share - basic (US cents)	_	(13)		52	33	
Earnings per share - diluted (US cents)	_	(13)		52	33	
Volume (mmsf)	942.2	715.7	32	3,670.0	2,767.5	33

¹Readers are referred to Note 10 of our 31 March 2019 consolidated financial statements for further information related to long-term debt

Net sales for the quarter and full year increased 19% and 22%, respectively, from the prior corresponding periods to US\$624.8 million and US\$2,506.6 million, respectively. For both periods, net sales were favorably impacted by the acquisition of Fermacell in Europe and higher net sales in the North America Fiber Cement segment.

Gross profit of US\$210.6 million for the quarter and US\$831.0 million for the full year increased 10% and 14%, respectively, when compared to prior corresponding periods. Gross profit margin of 33.7% for the quarter and 33.2% for the full year, decreased 2.6 percentage points and 2.3 percentage points, respectively, when compared to the prior corresponding periods.

Selling, general and administrative ("SG&A") expenses for the quarter and full year increased 20% and 30%, respectively, when compared to the prior corresponding periods. The increase is primarily driven by the SG&A costs in the Europe Building Products segment, due to the acquisition of Fermacell on 3 April 2018 and the corresponding transaction and integration costs, as well as, higher labor and discretionary costs in the North America Fiber Cement segment.

Asset impairments for the full year reflects asset impairment charges of US\$12.9 million related to our decision to discontinue our windows business, and US\$3.0 million related to our decision to discontinue our Multiple Contour Trim ("MCT") product line.

Asbestos adjustments for the full year primarily reflects the unfavorable movement in the actuarial adjustment of US\$72.7 million recorded at year end in line with KPMGA's actuarial report partially offset by the effect of foreign exchange on Asbestos net liabilities.

Interest expense for the quarter and full year increased due to the higher average debt balance, primarily due to funding the acquisition of Fermacell.

Income tax expense for the quarter and full year increased when compared to the prior corresponding periods due to the movement in asbestos adjustments and a change in the accounting treatment of intangible assets which did not apply in the prior corresponding period, partially offset by a decrease in the US corporate income tax rate.

Net operating profit increased for the quarter and full year, primarily driven by the favorable movement in asbestos adjustments and higher gross profit, partially offset by higher income tax expense and SG&A expenses.



North America Fiber Cement Segment

Operating results for the North America Fiber Cement segment were as follows:

US\$ Millions	Three Months and Full Year Ended 31 March					
	Q4 FY19	Q4 FY18	Change	FY19	FY18	Change
Volume (mmsf)	593.3	586.8	1%	2,308.1	2,238.8	3%
Average net sales price per unit (per msf)	US\$704	US\$692	2%	US\$718	US\$698	3%
Fiber cement net sales	422.0	410.1	3%	1,676.9	1,578.1	6%
Gross profit			(4%)			3%
Gross margin (%)			(2.6 pts)			(0.9 pts)
EBIT	95.1	103.4	(8%)	382.5	381.9	_
EBIT margin (%)	22.5	25.2	(2.7 pts)	22.8	24.2	(1.4 pts)
EBIT excluding product line discontinuation ¹	95.1	103.4	(8%)	387.9	381.9	2%
EBIT margin excluding product line discontinuation (%)	22.5	25.2	(2.7 pts)	23.1	24.2	(1.1 pts)

¹ Excludes product line discontinuation expenses of nil for the quarter and US\$5.4 million for fiscal year 2019. These expenses include asset impairments of US\$3.0 million, and a one-time charge of US\$2.4 million to cost of goods sold associated with our decision to discontinue our MCT product line, as well as certain excess and obsolete ColorPlus[®] color palettes

Net sales for the quarter and full year were favorably impacted by higher sales volumes and a higher average net sales price compared to prior corresponding periods. The increase in volume includes growth in exteriors for the quarter and full year of 3% and 5%, respectively, compared to the prior corresponding periods, reflecting slight growth above the market index. This increase in volume was partially offset by a decrease in interiors volume for the quarter and full year of 10% and 4%, respectively. The increase in average net sales price of 2% for the quarter primarily reflects the annual change in our strategic pricing effective April 2018, partially offset by tactical pricing. For the full year, the increase in average net sales price of 3% primarily reflects the annual change in our strategic pricing effective April 2018.

We note that there are a number of data sources that measure US housing market growth. At the time of filing our results for the period ended 31 March 2019, only US Census Bureau data was available. According to the US Census Bureau, single family housing starts for the quarter were 184,500, or 5% below the prior corresponding period. For the full year ended 31 March 2019, single family housing starts were 865,400, or flat compared to the prior corresponding period. We note that the US Census Bureau's data can be different from other indices we use to measure US housing market growth, namely the McGraw-Hill Construction Residential Starts Data (also known as Dodge), the National Association of Home Builders and Fannie Mae.

Results Including Product Line Discontinuation Expenses

The change in gross margin for the quarter and full year can be attributed to the following components:

For the Three Months Ended 31 March 2019:

Higher average net sales price	1.1 pts
Higher production and other costs	(3.7 pts)
Total percentage point change in gross margin	(2.6 pts)



For the Full Year Ended 31 March 2019:

Higher average net sales price	2.0 pts
Higher start up costs	(0.1 pts)
Higher production and other costs	(2.8 pts)
Total percentage point change in gross margin	(0.9 pts)

Gross margin for the quarter decreased 2.6 percentage points compared to the prior corresponding period. This decrease was primarily due to higher production costs, partially offset by a higher average net sales price. Higher production costs were driven by higher input costs, primarily due to market rates for pulp and unfavorable plant performance.

Gross margin for the full year decreased 0.9 percentage points, compared to prior corresponding period. This decrease was primarily due to higher production costs, partially offset by a higher average net sales price. Higher production costs were driven by higher input costs, primarily due to market rates for pulp and freight. In addition, gross margin for the full year decreased as a result of a one-time charge of US\$2.4 million from our decision to discontinue the MCT product line and certain excess and obsolete ColorPlus[®] color palettes related to our win-with-color strategy.

For the full year of fiscal year 2019, we experienced significant inflationary trends across our key input costs, especially in pulp, and other raw materials. In addition, the freight market in the first half of fiscal year 2019 was in very tight supply, and as a result, market rates for freight exhibited significant inflationary pricing.

As a percentage of sales, SG&A expenses was flat for the quarter and increased 0.3 percentage points for the full year, when compared to the prior corresponding periods. SG&A expenses for the quarter and full year were higher compared to the prior corresponding periods, driven primarily by higher labor related costs and higher discretionary spend.

EBIT for the quarter decreased 8% compared to the prior corresponding period, primarily driven by a 4% decrease in gross profit and higher SG&A expenses. EBIT for the full year was flat compared to the prior corresponding period, primarily driven by a 3% increase in gross profit, offset by higher SG&A expenses and product line discontinuation expenses of US\$5.4 million.

EBIT margin for the quarter and full year decreased 2.7 percentage points and 1.4 percentage points to 22.5% and 22.8%, respectively, when compared to the prior corresponding periods, driven primarily by the decrease in gross margin. EBIT margin for the full year was additionally impacted by higher SG&A expenses as described above and product line discontinuation expenses.

Results Excluding Product Line Discontinuation Expenses

Gross margin for the full year, excluding product line discontinuation expenses, decreased compared to the prior corresponding period, primarily driven by higher production costs, partially offset by a higher average net sales price. Higher production costs were primarily due to higher input and freight costs.

EBIT for the full year, excluding product line discontinuation expenses, increased 2%, compared to the prior corresponding period, driven by an increase in gross profit, partially offset by higher SG&A expenses.

EBIT margin for the full year, excluding product line discontinuation expenses, decreased 1.1 percentage points to 23.1% when compared to the prior corresponding period, primarily driven by the decrease in gross margin and higher SG&A expenses.



Asia Pacific Fiber Cement Segment

The Asia Pacific Fiber Cement segment is comprised of the following businesses: (i) Australia Fiber Cement, (ii) New Zealand Fiber Cement, and (iii) Philippines Fiber Cement.

Operating results for the Asia Pacific Fiber Cement segment in US dollars were as follows:

US\$ Millions	Three Months and Full Year Ended 31 March					
	Q4 FY19	Q4 FY18	Change	FY19	FY18	Change
Volume (mmsf)	129.9	121.6	7%	546.1	494.7	10%
Average net sales price per unit (per msf)	US\$701	US\$767	(9%)	US\$724	US\$762	(5%)
Fiber cement net sales	102.3	105.1	(3%)	446.8	425.4	5%
Gross profit			(16%)			(6%)
Gross margin (%)			(4.9 pts)			(3.9 pts)
EBIT	20.5	26.3	(22%)	99.8	108.1	(8%)
EBIT margin (%)	20.0	25.0	(5.0 pts)	22.3	25.4	(3.1 pts)

The Asia Pacific Fiber Cement segment results in US dollars were unfavorably impacted by average foreign exchange rate movements for the quarter and full year as detailed in the table below:

		Q4 FY19			Full Year FY19	
	Results in AUD	Results in USD	Impact of FX	Results in AUD	Results in USD	Impact of FX
Average net sales price per unit (per msf)	+1%	-9%	-10%	+1%	-5%	-6%
Net sales	+7%	-3%	-10%	+11%	+5%	-6%
Gross profit	-7%	-16%	-9%	FLAT	-6%	-6%
EBIT	-14%	-22%	-8%	-2%	-8%	-6%

Operating results for the Asia Pacific Fiber Cement segment in Australian dollars were as follows:

A\$ Millions	Three Months and Full Year Ended 31 March					
	Q4 FY19	Q4 FY18	Change	FY19	FY18	Change
Volume (mmsf)	129.9	121.6	7%	546.1	494.7	10%
Average net sales price per unit (per msf)	A\$984	A\$976	1%	A\$992	A\$985	1%
Fiber cement net sales	143.6	133.8	7%	612.2	549.7	11%
Gross profit			(7%)			_
Gross margin (%)			(5.1 pts)			(4.0 pts)
EBIT	28.8	33.5	(14%)	136.5	139.8	(2%)
EBIT margin (%)	20.1	25.0	(4.9 pts)	22.3	25.4	(3.1 pts)

Volume for the quarter and full year increased 7% and 10%, respectively, compared to the prior corresponding periods, primarily driven by our Australian and Philippines businesses gaining volume growth above their underlying market growth. In Australia, volume growth was driven by market penetration and category share



gains. In the Philippines, volume growth was due to strategic distributor programs resulting in market penetration. Fiber cement net sales in Australian dollars for the quarter and full year increased 7% and 11%, respectively, compared to the prior corresponding periods, primarily driven by higher volume across all regions.

Gross profit in Australian dollars decreased 7% for the quarter compared to the prior corresponding period. The decrease for the quarter was primarily driven by higher input costs, partially offset by higher net sales. Gross profit was flat for the full year due to higher production costs driven by higher pulp and freight costs, as well as unfavorable plant performance in New Zealand, offset by higher net sales.

In Australian dollars, the change in gross margin for the quarter and full year can be attributed to the following components:

For the Three Months Ended 31 March 2019:

Higher average net sales price	0.4 pts
Higher production costs	(5.5 pts)
Total percentage point change in gross margin	(5.1 pts)

For the Full Year Ended 31 March 2019:

Higher average net sales price	0.3 pts
Higher production costs	(4.3 pts)
Total percentage point change in gross margin	(4.0 pts)

As a percentage of sales, SG&A expenses in Australian dollars was flat for the quarter and decreased 0.8 percentage points for the full year when compared to the prior corresponding periods. EBIT in Australian dollars decreased 14% and 2% for the quarter and full year, respectively, when compared to the prior corresponding periods to A\$28.8 million and A\$136.5 million, respectively.

Country Analysis

Australia Fiber Cement

Net sales in local currency for the quarter and full year increased 5% and 11%, respectively, from the prior corresponding periods, primarily due to an increase in volume and the favorable impact of our price increase. The key driver of volume growth was market penetration, as we gained market share compared to the prior corresponding periods, despite a continued, softening market. The market share gains were driven by the addition of several large customers, including one large customer in the first half of fiscal year 2018, and another large customer in the first quarter of fiscal year 2019. The volume growth during the quarter and full year was most prominent in the East Coast regions, and was realized in both the new construction and additions and alterations markets.

EBIT in local currency for the quarter and full year decreased 14% and increased 3%, respectively, when compared to the prior corresponding periods. The decrease in EBIT for the quarter was primarily due to higher pulp costs and SG&A expenses, partially offset by higher net sales. The increase in EBIT for the full year was primarily driven by higher net sales and favorable plant performance, partially offset by higher pulp, freight costs, and employment costs.

According to Australian Bureau of Statistics data, approvals for detached houses, a key driver of Australian business' sales volume, were 24,803 for the quarter, a decrease of 13% compared to the prior corresponding period. For the full year, approvals for detached houses were 115,373, a decrease of 4% compared to the prior



corresponding period. The other key driver of our sales volume, the alterations and additions market, was flat and increased 3% for the quarter and full year ended 31 March 2019, respectively, when compared to the prior corresponding periods.

New Zealand Fiber Cement

Net sales in local currency for the quarter and full year increased 4% and 8%, respectively, from the prior corresponding periods, primarily driven by higher volume. EBIT in local currency decreased for the quarter and full year, compared to the prior corresponding periods, primarily due to unfavorable plant performance and higher input costs.

Philippines Fiber Cement

Volume for the quarter and full year increased 14% and 15%, respectively, when compared to the prior corresponding periods, primarily as a result of market penetration during the current fiscal year. EBIT in local currency for the quarter and full year decreased compared to the prior corresponding periods, driven by higher input costs, one time inventory adjustments and start-up costs associated with our capacity expansion.

Europe Building Products Segment

The Europe Building Products segment is comprised of: (i) Europe Fiber Cement; and (ii) Fiber Gypsum. Operating results for the Europe Building Products segment in US dollars were as follows:

US\$ Millions	Three Months and Full Year Ended 31 March					
	Q4 FY19	Q4 FY18	Change	FY19	FY18	Change
Volume (mmsf)	219.0	7.3		815.8	34.0	
Average net sales price per unit (per msf)	US\$346	US\$878	(61%)	US\$354	US\$950	(63%)
Fiber cement net sales	8.8	7.4	19%	35.8	36.3	(1%)
Fiber gypsum net sales ¹	89.9	_		332.5	_	
Net sales	98.7	7.4		368.3	36.3	
Gross profit ²			NM			NM
Gross margin (%) ²			NM			NM
EBIT ³	7.1	(0.3)		10.0	0.3	
EBIT margin (%) ³	7.2	(4.1)	11.3 pts	2.7	0.8	1.9 pts

¹ Also includes cement bonded board net sales

Net sales for the quarter and full year increased compared to the prior corresponding period, driven by the increase in volume due to the Fermacell acquisition on 3 April 2018. Average net sales price in US dollars for the quarter and full year decreased compared to prior corresponding periods, primarily due to product mix, as most of the volume in the current period was from fiber gypsum products, which have a lower average net sales price than fiber cement.

² The change in gross profit and gross margin is not presented due to the impact from the acquisition of Fermacell during the first quarter of fiscal year 2019

³ Includes Fermacell transaction and integration costs of US\$4.1 million for the fourth quarter and US\$21.8 million for the full year, as well as, a US\$7.3 million inventory fair value adjustment during the full year resulting from acquisition accounting adjustments in Q1FY19



EBIT for the quarter increased US\$7.4 million, compared to the prior corresponding period, primarily due to additional earnings provided by Fermacell, partially offset by US\$4.1 million of Fermacell integration costs.

EBIT for the full year increased US\$9.7 million to US\$10.0 million, compared to the prior corresponding period, primarily due to additional earnings provided by Fermacell, partially offset by costs associated with the Fermacell acquisition. These costs for the full year include integration costs of US\$14.6 million, a one-time inventory fair value adjustment of US\$7.3 million, and transaction costs of US\$7.2 million.

Below, we have included Non-US GAAP measures, Europe Building Products segment Adjusted EBIT and Adjusted EBIT margin excluding costs associated with the acquisition. Note that the below reconciling items have not been excluded from Adjusted EBIT and Adjusted net operating profit as presented on pages 13 and 15, respectively.

US\$ Millions	Three Months and Ful	l Year Ended 31 March
	Q4 FY19	FY19
Europe Building Products segment EBIT	7.1	10.0
Inventory fair value adjustment 1	_	7.3
Transaction costs ²	_	7.2
Integration costs ³	4.1	14.6
Europe Building Products segment Adjusted EBIT excluding costs associated with the acquisition	11.2	39.1
Europe Building Products segment Adjusted EBIT margin excluding costs associated with the acquisition	11.3%	10.6%

¹ Under US GAAP, we are required to value the inventory acquired at fair market value, resulting in a preliminary total inventory fair value adjustment of US\$7.3 million. As this inventory was sold during the first quarter of FY19, the entire adjustment was recognized into cost of goods sold during that quarter

Net sales in the Europe Building Products segment for the quarter and full year of US\$98.7 million and US\$368.3 million, respectively, decreased 1% and increased 6%, respectively, from pro-forma net sales from the prior corresponding periods of US\$99.5 million and US\$348.8 million, respectively. In Euros, pro-forma net sales for the quarter and full year increased 7%.

² Transaction costs include certain non-recurring fees incurred in conjunction with the acquisition of Fermacell

³ Integration costs relate to professional, legal and other fees incurred in conjunction with the integration of Fermacell



Other Businesses Segment

US\$ Millions	Three Months and Full Year Ended 31 March					
	Q4 FY19	Q4 FY18	Change	FY19	FY18	Change
Net sales	1.8	3.3	(45%)	14.6	14.7	(1%)
Gross profit			NM			NM
Gross profit margin (%)			NM			NM
EBIT	(4.4)	(2.8)	(57%)	(30.9)	(8.6)	
Product line discontinuation	(3.5)	_		(24.1)	_	

The Other Businesses segment is comprised of our fiberglass windows business, which includes a fiberglass windows assembly facility as well as a fiberglass pultrusion business. In fiscal year 2019, we made the decision to shut down the fiberglass windows business and recorded product line discontinuation costs associated with the closure. In April 2019, we entered into a sale and purchase agreement for our fiberglass pultrusion portion of the business, which closed in the first quarter of fiscal year 2020.

EBIT loss for the quarter and full year was US\$4.4 million and US\$30.9 million, respectively. The EBIT loss for the quarter and full year was driven by product line discontinuation costs of US\$3.5 million and US\$24.1 million, respectively, as well as EBIT loss from operations of US\$0.9 million and US\$6.8 million, respectively. Product line discontinuation costs consist of impairment costs of US\$12.9 million, inventory adjustments of US\$8.5 million, and other related closure costs of US\$2.7 million.

Research and Development Segment

We record R&D expenses depending on whether they are core R&D projects that are designed to benefit all business units, which are recorded in our R&D segment, or commercialization projects for the benefit of a particular business unit, which are recorded in the individual business unit's segment results. The table below details the expenses of our R&D segment:

US\$ Millions		Three Months and Full Year Ended 31 March							
	Q,	4 FY19	Q4	4 FY18	Change %		FY19	FY18	Change %
Segment R&D expenses	\$	(6.1)	\$	(6.8)	10	\$	(26.7)	\$ (25.4)	(5)
Segment R&D SG&A expenses		(1.0)		(0.5)			(2.3)	(2.4)	4
Total R&D EBIT	\$	(7.1)	\$	(7.3)	3	\$	(29.0)	\$ (27.8)	(4)

The change in segment R&D expenses for the quarter and full year was due to normal variation among our research and development projects. The expense will fluctuate period to period depending on the nature and number of core R&D projects being worked on and the AUD/USD exchange rates during the period.

Other R&D expenses associated with commercialization projects in business units are recorded in the results of the respective business unit segment. Other R&D expenses associated with commercialization projects were US\$3.3 million for the quarter and US\$11.2 million for the full year, compared to US\$2.1 million and US\$7.9 million, respectively, for the prior corresponding periods. The increase was primarily driven by additional projects undertaken by the R&D team in our Europe Building Products segment.



General Corporate

Results for General Corporate were as follows:

US\$ Millions	Three Months and Full Year Ended 31 March					
	Q4 FY19	Q4 FY18	Change %	FY19	FY18	Change %
General Corporate SG&A expenses	\$ (14.7)	\$ (16.3)	10	\$ (57.3)	\$ (56.4)	(2)
Fermacell acquisition costs ¹	_	(5.3)		_	(10.0)	
Asbestos:						
Asbestos adjustments	(73.4)	(192.9)	62	(22.0)	(156.4)	86
AICF SG&A expenses ²	(0.4)	(0.6)	33	(1.5)	(1.9)	21
General Corporate EBIT	\$ (88.5)	\$ (215.1)	59	\$ (80.8)	\$ (224.7)	64

¹Relates to professional, legal and other fees incurred in FY2018 prior to the close of the Fermacell acquisition

For the quarter, General Corporate SG&A expenses decreased when compared with the prior corresponding period, primarily due to a favorable settlement related to New Zealand weathertightness claims of US\$1.1 million and favorable movements in recognized foreign exchange gains.

For the full year, General Corporate SG&A expenses increased US\$0.9 million, compared to the prior corresponding period. This increase was primarily due to a non-recurring US\$3.4 million gain in the prior year from the sale of a storage building located near our Fontana facility, as well as New Zealand weathertightness claims of US\$3.3 million, partially offset by lower stock compensation expenses and favorable movements in recognized foreign exchange gains.

Asbestos adjustments for both periods primarily reflect the unfavorable actuarial adjustment recorded at year end in line with KPMGA's actuarial report, as well as, the non-cash foreign exchange re-measurement impact on asbestos related balance sheet items, driven by the change in the AUD/USD spot exchange rate from the beginning balance sheet date to the ending balance sheet date, for each respective period.

The AUD/USD spot exchange rates are shown in the table below:

FY19		FY18	
31 March 2018	0.7681	31 March 2017	0.7644
31 March 2019	0.7096	31 March 2018	0.7681
Change (\$)	(0.0585)	Change (\$)	0.0037
Change (%)	(8)	Change (%)	_

²Relates to non-claims related operating costs incurred by AICF, which we consolidate into our financial results due to our pecuniary and contractual interests in AICF



For fiscal years 2019 and 2018, the asbestos adjustments recorded by the Company were made up of the following components:

US\$ Millions	Full	Year End	led 3	31 March
		FY19		FY18
Increase in actuarial estimate	\$	(72.7)	\$	(151.4)
Effect of foreign exchange rate movements		49.5		(5.3)
(Loss) gain on foreign currency forward contracts		(8.0)		1.4
Adjustments in insurance receivable		2.0		_
Asbestos research and education contribution		_		(1.1)
Asbestos adjustments	\$	(22.0)	\$	(156.4)

Per the KPMGA actuarial report, the undiscounted and uninflated central estimate net of insurance recoveries decreased to A\$1.400 billion at 31 March 2019 from A\$1.443 billion at 31 March 2018. The change in the undiscounted and uninflated central estimate of A\$43.1 million or 4% is primarily due to net cash outflows in the fiscal year 2019 of A\$142.8 million partially offset by an increase to the actuarial estimate. The increase in the KPMGA actuarial estimate is primarily due to the impact of increasing the undiscounted and uninflated central estimate to prevailing costs at 31 March 2019 from 31 March 2018 levels and additional costs associated with overseas exposures.

During fiscal year 2019, mesothelioma claims reporting activity was below actuarial expectations and the prior corresponding period. One of the more significant assumptions is the estimated peak period of mesothelioma disease claims, which was assumed to have occurred during the period 1 April 2014 through 31 March 2017. In fiscal year 2018, KPMGA formed the view that the increases in the mesothelioma claims reporting seen in recent years was a permanent effect, and therefore increased the projected number of future mesothelioma claims at 31 March 2018. The revised KPMGA modeling approach for mesothelioma claims considered the claimant's age which resulted in a higher number of projected claims, partially offset by a reduction in projected average claim size.

At 31 March 2019, KPMGA has formed the view that although the mix of claimants by age was slightly favorable relative to expectations, at this time it is too early to reflect changes to the valuation adjustments given that 2018/2019 was the first year of the new model. Changes to the assumptions may be necessary in future periods should mesothelioma claims reporting escalate or decline.

Potential variation in the estimated peak period of claims has an impact much greater than the other assumptions used to derive the discounted central estimate. In performing the sensitivity assessment of the estimated incidence pattern reporting for mesothelioma, if the pattern of incidence was shifted by two years, the central estimate could increase by approximately 19% on a discounted basis.

Asbestos gross cash outflows of A\$154.4 million for fiscal year 2019 were slightly higher than the actuarial expectation of A\$151.8 million.

Readers are referred to Note 12 of our 31 March 2019 consolidated financial statements for further information on asbestos adjustments.

OPERATING RESULTS - OTHER



EBIT

The table below summarizes EBIT results as discussed above:

US\$ Millions		Three Months and Full Year Ended 31 March						
	Q4 FY19	Q4 FY18	Change %	FY19	FY18	Change %		
North America Fiber Cement ¹	\$ 95.1	\$ 103.4	(8)	\$ 387.9	\$ 381.9	2		
Asia Pacific Fiber Cement	20.5	26.3	(22)	99.8	108.1	(8)		
Europe Building Products	7.1	(0.3)		10.0	0.3			
Other Businesses ²	(0.9)	(2.8)	68	(6.8)	(8.6)	21		
Research and Development	(7.1)	(7.3)	3	(29.0)	(27.8)	(4)		
General Corporate ³	(14.7)	(16.3)	10	(57.3)	(56.4)	(2)		
Adjusted EBIT	100.0	103.0	(3)	404.6	397.5	2		
Asbestos:								
Asbestos adjustments	(73.4)	(192.9)	62	(22.0)	(156.4)	86		
AICF SG&A expenses	(0.4)	(0.6)	33	(1.5)	(1.9)	21		
Fermacell acquisition costs ⁴	_	(5.3)		_	(10.0)			
Product line discontinuation ⁵	(3.5)	_		(29.5)	_			
EBIT	\$ 22.7	\$ (95.8)		\$ 351.6	\$ 229.2	53		

¹ Excludes product line discontinuation expenses of US\$5.4 million for the full year 2019, as a result of our decision to discontinue our MCT product line, as well as, certain excess and obsolete ColorPlus® color palettes

Net Interest Expense

US\$ Millions	Three Months and Full Year Ended 31 March					
	Q4 FY19	Q4 FY18	Change %	FY19	FY18	Change %
Gross interest expense	\$ (16.2)	\$ (11.2)	(45)	\$ (59.6)	\$ (37.7)	(58)
Capitalized interest	1.7	1.7	_	5.4	4.8	13
Interest income	0.7	0.7	_	2.1	1.5	40
Net AICF interest income	0.5	0.9	(44)	2.0	1.9	5
Net interest expense	\$ (13.3)	\$ (7.9)	(68)	\$ (50.1)	\$ (29.5)	(70)

Gross interest expense for the quarter and full year increased US\$5.0 million and US\$21.9 million, respectively, when compared to the prior corresponding periods, primarily due to the higher outstanding balance of our senior unsecured notes, which includes the financing of the Fermacell acquisition.

² Excludes product line discontinuation expenses of US\$3.5 million and US\$24.1 million for the quarter and full year 2019, respectively, as a result of our decision to discontinue our Windows business

³ Excludes Asbestos-related expenses and adjustments, and acquisition costs incurred prior to the close of Fermacell

⁴ Relates to professional, legal and other fees incurred in FY2018 prior to the close of the Fermacell acquisition

⁵ Product line discontinuation expenses include asset impairments and other charges as a result of our decision to discontinue product lines in both our North America Fiber Cement segment and our Other Businesses segment

OPERATING RESULTS - OTHER



Other Income

During the quarter, other income decreased from US\$0.5 million in the prior corresponding period to nil. For the full year, other income decreased from US\$0.7 million in the prior corresponding period to US\$0.1 million. The movement in other income is primarily driven by the valuation of our interest rate swaps.

Income Tax

	Three Months and Full Year Ended 31 March					
	Q4 FY19	Q4 FY18	FY19	FY18		
Income tax (expense) benefit (US\$ Millions)	(8.6)	45.6	(71.8)	(28.2)		
Effective tax rate (%)	91.5	44.2	23.9	16.2		
Adjusted income tax expense ¹ (US\$ Millions)	(12.4)	(13.6)	(52.1)	(75.5)		
Adjusted effective tax rate ¹ (%)	14.4	14.4	14.8	20.6		

¹ Includes tax adjustments related to the amortization benefit of certain US intangible assets, asbestos, product line discontinuation, loss on early debt extinguishment, and other tax adjustments

Total income tax expense for the quarter increased US\$54.2 million when compared to the prior corresponding period. The increase in income tax expense was primarily due to the change in the asbestos actuarial adjustment, when compared to the prior corresponding period.

Total income tax expense for the full year increased US\$43.6 million, when compared to the prior corresponding period. The increase was primarily due to the change in the accounting treatment of the amortization of intangible assets which did not apply in the prior corresponding period and the change in the asbestos actuarial adjustment, partially offset by the decrease in the US corporate income tax rate.

Total Adjusted income tax expense for the quarter and full year decreased US\$1.2 million and US\$23.4 million, respectively, compared to the prior corresponding periods. The decrease in Adjusted income tax expense for the quarter and full year was driven by adjustments from the ongoing accounting treatment of amortization of intangible assets and a reduction in the US statutory corporate tax rate.

Readers are referred to Note 15 of our 31 March 2019 consolidated financial statements for further information related to income tax.

OPERATING RESULTS - OTHER



Net Operating Profit

US\$ Millions		Three Mo	onths and Ful	Year Ended	d 31 March	
	Q4 FY19	Q4 FY18	Change %	FY19	FY18	Change %
EBIT	\$ 22.7	\$ (95.8)		\$ 351.6	\$ 229.2	53
Net interest expense	(13.3)	(7.9)	(68)	(50.1)	(29.5)	(70)
Loss on early debt extinguishment ¹	_	_		(1.0)	(26.1)	96
Other income	_	0.5		0.1	0.7	(86)
Income tax (expense) benefit	(8.6)	45.6		(71.8)	(28.2)	
Net operating profit (loss)	0.8	(57.6)	101	228.8	146.1	57
			'			
Excluding:						
Asbestos:						
Asbestos adjustments	73.4	192.9	(62)	22.0	156.4	(86)
AICF SG&A expenses	0.4	0.6	(33)	1.5	1.9	(21)
AICF interest income, net	(0.5)	(0.9)	44	(2.0)	(1.9)	5
Fermacell acquisition costs ²	_	5.3		_	10.0	
Product line discontinuation ³	3.5	_		29.5	_	
Loss on early debt extinguishment ¹	_	_		1.0	26.1	(96)
Tax adjustments ⁴	(3.8)	(59.2)	94	19.7	(47.3)	
Adjusted net operating profit	73.8	81.1	(9)	300.5	291.3	3
Adjusted diluted earnings per share (US cents)	17	18		68	66	

¹ In December 2017, we redeemed our 5.875% senior notes due 2023 and recorded a loss on early debt extinguishment in connection with this redemption of US\$26.1 million, including call redemption premiums and unamortized financing costs. In October 2018, we repaid our outstanding 364-day term loan facility and incurred a loss of US\$1.0 million, associated with unamortized financing costs. Readers are referred to Note 10 of our 31 March 2019 consolidated financial statements for further information related to long-term debt.

Adjusted net operating profit of US\$73.8 million for the quarter decreased US\$7.3 million, or 9%, compared to the prior corresponding period, primarily due to higher net interest expense of US\$5.4 million and a US\$3.0 million decrease in Adjusted EBIT, partially offset by lower Adjusted income tax expense of US\$1.2 million. The decrease in Adjusted EBIT was driven by the underlying performance of the operating business units when compared to the prior corresponding period, primarily due to the US\$8.3 million and US\$5.8 million decrease in Adjusted EBIT in the North America Fiber Cement and Asia Pacific Fiber Cement segments, respectively. The decrease was partially offset by the US\$7.4 million increase in EBIT in the Europe Building Products segment, compared to the prior corresponding period.

Adjusted net operating profit of US\$300.5 million for the full year increased US\$9.2 million, or 3%, compared to the prior corresponding period, primarily due to lower Adjusted income tax expense of US\$23.4 million and a US\$7.1 million increase in Adjusted EBIT, partially offset by higher net interest expense of US\$20.6 million. The increase in Adjusted EBIT was primarily driven by the favorable underlying performance of the operating business units when compared to the prior corresponding period.

²Relates to professional, legal and other fees incurred in FY2018 in conjunction with the acquisition of Fermacell

³ Product line discontinuation expenses incurred in FY2019 include asset impairments and other charges as a result of our decision to discontinue product lines in both our North America Fiber Cement and Other Businesses segments

⁴ Includes tax adjustments related to the amortization benefit of certain US intangible assets, asbestos, product line discontinuation, loss on early debt extinguishment, and other tax adjustments



Cash Flow

Operating Activities

Cash provided by operating activities decreased US\$14.4 million to US\$287.6 million. The decrease in cash provided by operating activities was primarily driven by changes in other operating assets and liabilities of US\$56.2 million and net cash outflows in working capital of US\$20.1 million, partially offset by a US\$61.9 million increase in net income adjusted for non-cash items. The primary driver of the change in other operating assets and liabilities was due to changes in income taxes payable and other normal variations in the course of our business. The net cash outflow in working capital was primarily due to the timing of payments in accounts payable and the timing of collections in accounts receivable, partially offset by the buildup of inventories in the North America Fiber Cement segment in the prior year, related to our then capacity constraint.

Investing Activities

Cash used in investing activities increased US\$609.0 million to US\$848.0 million. The increase in cash used in investing activities was primarily due to the US\$558.7 million acquisition of Fermacell, as well as an increase in purchases in property, plant and equipment of US\$97.4 million. The increase in capital expenditures was primarily related to the greenfield expansion projects in Prattville and Tacoma. This was partially offset by higher net proceeds from AICF's short-term investments of US\$66.2 million.

Financing Activities

Cash provided by financing activities increased US\$303.6 million to US\$364.2 million. The increase in cash provided by financing activities was primarily driven by higher net proceeds from credit facilities and senior notes of US\$125.0 million and US\$102.0 million, respectively, as well as AICF's repayment of its NSW loan in the prior year of US\$51.9 million, compared to nil in the current year.

Capacity Expansion

We continually evaluate the capacity required to service the housing markets in which we operate to ensure we meet demand and achieve our market penetration objectives. During the current quarter:

In North America we:

- Continued the start-up of our Tacoma greenfield expansion project, which is expected to be completed in the first half of fiscal year 2020;
- Continued the construction of a greenfield expansion project in Prattville, Alabama, which is expected to be commissioned in the first half of fiscal year 2021 at an estimated total cost of US\$240.0 million; and
- Continued the planning and design of an expansion project within our ColorPlus[®] product line, including projects at our Peru and Pulaski facilities, and a greenfield project in Massachusetts.

In Asia Pacific we:

- · Completed the start-up of the additional capacity expansion in the Philippines; and
- Continued the planning and design of a brownfield expansion project at our existing Carole Park facility in Australia with an estimated total cost of A\$28.5 million. The brownfield expansion project is expected to be commissioned by the first quarter of fiscal year 2021.



Liquidity and Capital Allocation

Our cash position decreased from US\$281.6 million at 31 March 2018 to US\$78.7 million at 31 March 2019.

At 31 March 2019, we held two forms of debt: an unsecured revolving credit facility and senior unsecured notes. The effective weighted average interest rate on our total debt was 4.4% and 4.7% at 31 March 2019 and 31 March 2018, respectively. The weighted average term of all debt, including undrawn facilities, was 6.3 years and 6.9 years at 31 March 2019 and 31 March 2018, respectively.

At 31 March 2019, we had a US\$500.0 million unsecured revolving credit facility. At 31 March 2019, a total of US\$150.0 million was drawn from the unsecured revolving facility, compared to US\$100.0 million at 31 March 2018. The unsecured revolving credit facility's expiration date is December 2022 and the size of the facility may be increased by up to US\$250.0 million.

On 3 April 2018, we drew €400.0 million (US\$492.4 million based on the exchange rate at 3 April 2018) from the 364-day term loan facility, and used these funds to complete the Fermacell acquisition. In October 2018, we completed the sale of €400.0 million (US\$458.8 million, based on the exchange rate at 3 October 2018) aggregate principal amount of 3.625% senior unsecured notes due 2026. The proceeds from the offering were used to repay our outstanding 364-day term loan facility.

Based on our existing cash balances, together with anticipated operating cash flows arising during the year and unutilized committed credit facilities, we anticipate that we will have sufficient funds to meet our planned working capital and other expected cash requirements for the next twelve months.

We have historically met our working capital needs and capital expenditure requirements from a combination of cash flows from operations and credit facilities. Seasonal fluctuations in working capital generally have not had a significant impact on our short or long term liquidity.

Capital Management and Dividends

The following table summarizes the dividends declared or paid in respect of fiscal years 2019, 2018 and 2017:

US\$ Millions	US Cents/ Security	Total US\$ (Millions)	Announcement Date	Record Date	Payment Date
FY 2019 second half dividend	0.26	115.0	21 May 2019	6 June 2019	2 August 2019
FY 2019 first half dividend	0.10	43.6	8 November 2018	12 December 2018	22 February 2019
FY 2018 second half dividend	0.30	128.5	22 May 2018	7 June 2018	3 August 2018
FY 2018 first half dividend	0.10	46.2	9 November 2017	13 December 2017	23 February 2018
FY 2017 second half dividend	0.28	131.3	18 May 2017	8 June 2017	4 August 2017
FY 2017 first half dividend	0.10	46.6	17 November 2016	21 December 2016	24 February 2017
FY 2016 second half dividend	0.29	130.2	19 May 2016	9 June 2016	5 August 2016



We periodically review our capital structure and capital allocation objectives and expect the following prioritization to remain:

- invest in R&D and capacity expansion to support organic growth;
- provide ordinary dividend payments within the payout ratio of 50-70% of net operating profit, excluding asbestos:
- maintain flexibility to manage through market cycles; and
- consider flexibility for accretive and strategic inorganic growth and/or other shareholder returns when appropriate.

Other Asbestos Information

Claims Data

	Three Months and Full Year Ended 31 March					
	Q4 FY19	Q4 FY18	Change %	FY19	FY18	Change %
Claims received	133	129	(3)	568	562	(1)
Actuarial estimate for the period	144	144	_	576	576	_
Difference in claims received to actuarial estimate	11	15		8	14	
Average claim settlement ¹ (A\$)	219,000	231,000	5	262,000	253,000	(4)
Actuarial estimate for the period ²	290,000	283,000	(2)	290,000	283,000	(2)
Difference in claims paid to actuarial estimate	71,000	52,000		28,000	30,000	

¹ Average claim settlement is derived as the total amount paid divided by the number of non-nil claim settlements

For the period ended 31 March 2019, we noted the following related to asbestos-related claims:

- Claims received during the full year were 1% below actuarial estimates and 1% higher than the prior corresponding period;
- Mesothelioma claims reported for the full year were 4% lower than actuarial expectations and 5% lower than the prior corresponding period;
- The average claim settlement for the quarter and full year was 24% and 10% below actuarial expectations, respectively;
- Average claim settlement sizes were lower for most disease types, including mesothelioma claims for most age groups, compared to actuarial expectations for fiscal year 2019; and
- The decrease in the average claim settlement for the full year versus actuarial estimates was largely attributable to lower average claim settlement for non-mesothelioma claims.

AICF Funding

On 2 July 2018, we made a payment of A\$138.4 million (US\$103.0 million) to AICF, representing 35% of our free cash flow for fiscal year 2018. Free cash flow, as defined in the AFFA, was equivalent to our fiscal year 2018 operating cash flow of US\$295.0 million less an adjustment of US\$0.8 million, resulting in free cash flow of US\$294.2 million for fiscal year 2018, as defined by the AFFA.

² This actuarial estimate is a function of the assumed experience by disease type and the relative mix of settlements assumed by disease type. Any variances in the assumed mix of settlements by disease type will have an impact on the average claim settlement experience



We anticipate that we will make a contribution of approximately US\$100.9 million to AICF on 1 July 2019. This amount represents 35% of our free cash flows of US\$288.4 million. Our free cash flow as defined by the AFFA, is our operating cash flow per US GAAP in effect in December 2004. To reconcile our current year operating cash flow of US\$287.6 million to 2004 US GAAP, a US\$0.8 million adjustment is required.

From the time AICF was established in February 2007 through the date of this Report, we have contributed approximately A\$1,193.4 million to the fund.

Readers are referred to Notes 2 and 12 of our 31 March 2019 consolidated financial statements for further information on asbestos.



Financial Measures - US GAAP equivalents

This document contains financial statement line item descriptions that are considered to be non-US GAAP, but are consistent with those used by Australian companies. Because we prepare our consolidated financial statements under US GAAP, the following table cross-references each non-US GAAP line item description, as used in Management's Analysis of Results and Media Release, to the equivalent US GAAP financial statement line item description used in our consolidated financial statements:

Management's Analysis of Results and Media Release	Consolidated Statements of Operations and Other Comprehensive Income (Loss) (US GAAP)
Net sales	Net sales
Cost of goods sold	Cost of goods sold
Gross profit	Gross profit
Selling, general and administrative expenses	Selling, general and administrative expenses
Research and development expenses	Research and development expenses
Asbestos adjustments	Asbestos adjustments
EBIT*	Operating income (loss)
Net interest income (expense)*	Sum of interest expense and interest income
Other income (expense)	Other income (expense)
Operating profit (loss) before income taxes*	Income (loss) before income taxes
Income tax (expense) benefit	Income tax (expense) benefit
Net operating profit (loss)*	Net income (loss)
*- Represents non-US GAAP descriptions used by Au	ustralian companies.

EBIT – Earnings before interest and tax.

EBIT margin – EBIT margin is defined as EBIT as a percentage of net sales.

Sales Volume

<u>mmsf</u> – million square feet, where a square foot is defined as a standard square foot of 5/16" thickness.

msf – thousand square feet, where a square foot is defined as a standard square foot of 5/16" thickness.

NON-US GAAP FINANCIAL TERMS



This Management's Analysis of Results includes certain financial information to supplement the Company's consolidated financial statements which are prepared in accordance with accounting principles generally accepted in the United States ("US GAAP"). These financial measures are designed to provide investors with an alternative method for assessing our performance from on-going operations, capital efficiency and profit generation. Management uses these financial measure for the same purposes. These financial measures include:

- Adjusted EBIT;
- North America Fiber Cement Segment Adjusted EBIT excluding product line discontinuation;
- Europe Building Products Segment Adjusted EBIT excluding costs associated with the acquisition;
- Adjusted EBIT margin;
- North America Fiber Cement Segment Adjusted EBIT margin excluding product line discontinuation;
- Europe Building Products Segment Adjusted EBIT margin excluding costs associated with the acquisition;
- Adjusted net operating profit;
- Adjusted diluted earnings per share;
- Adjusted operating profit before income taxes;
- Adjusted income tax expense;
- Adjusted effective tax rate;
- Adjusted EBITDA;
- Adjusted EBITDA excluding Asbestos;
- Adjusted selling, general and administrative expenses ("Adjusted SG&A"); and
- Adjusted return on capital employed ("Adjusted ROCE").

These financial measures are or may be non-US GAAP financial measures as defined in the rules of the U.S. Securities and Exchange Commission and may exclude or include amounts that are included or excluded, as applicable, in the calculation of the most directly comparable financial measures calculated in accordance with US GAAP. These financial measures are not meant to be considered in isolation or as a substitute for comparable US GAAP financial measures and should be read only in conjunction with the Company's consolidated financial statements prepared in accordance with US GAAP. In evaluating these financial measures, investors should note that other companies reporting or describing similarly titled financial measures may calculate them differently and investors should exercise caution in comparing the Company's financial measures to similar titled measures by other companies.

Non-financial Terms

AFFA – Amended and Restated Final Funding Agreement

AICF - Asbestos Injuries Compensation Fund Ltd

<u>Legacy New Zealand weathertightness claims ("New Zealand weathertightness")</u> – Expenses arising from defending and resolving claims in New Zealand that allege poor building design, inadequate certification of plans, inadequate construction review and compliance certification and deficient work by sub-contractors

New South Wales Ioan facility ("NSW Loan") – AICF has access to a secured loan facility made available by the New South Wales Government, which can be used by AICF to fund the payment of asbestos claims and certain operating and legal costs



Financial Measures - US GAAP equivalents

Adjusted EBIT

US\$ Millions		Three Months and Full Year Ended 31 March								
	Q	Q4 FY19 Q4 FY18		FY19		Y19 F				
EBIT	\$	22.7	\$ (95.8)	\$	351.6	\$	229.2			
Asbestos:										
Asbestos adjustments		73.4	192.9		22.0		156.4			
AICF SG&A expenses		0.4	0.6		1.5		1.9			
Fermacell acquisition costs		_	5.3		_		10.0			
Product line discontinuation		3.5	_		29.5		_			
Adjusted EBIT	\$	100.0	\$ 103.0	\$	404.6	\$	397.5			
Net sales		624.8	525.9		2,506.6		2,054.5			
Adjusted EBIT margin		16.0%	19.6%		16.1%		19.3%			

North America Fiber Cement Segment Adjusted EBIT excluding product line discontinuation

US\$ Millions	Three Months and Full Year Ended 31 March			
	Q4 FY19 F			FY19
North America Fiber Cement Segment EBIT	\$	95.1	\$	382.5
Product line discontinuation		_		5.4
North America Fiber Cement Segment Adjusted EBIT excluding product line discontinuation	\$	95.1	\$	387.9
North America Fiber Cement segment net sales	<u> </u>	422.0	Ψ	1.676.9
· ·	_	422.0		1,070.9
North America Fiber Cement Segment Adjusted EBIT margin excluding product line discontinuation		22.5%		23.1%

Europe Building Products Segment Adjusted EBIT excluding costs associated with the acquisition

US\$ Millions	Three Months and Full Year Ended 31 March			
	Q	Q4 FY19 F		
Europe Building Products Segment EBIT	\$	7.1	\$	10.0
Inventory fair value adjustment		_		7.3
Transaction costs		_		7.2
Integration costs		4.1		14.6
Europe Building Products Segment Adjusted EBIT excluding costs associated with the acquisition	\$	11.2	\$	39.1
Europe Building Products segment net sales		98.7		368.3
Europe Building Products Segment Adjusted EBIT margin excluding costs associated with the acquisition		11.3%		10.6%



Adjusted net operating profit

US\$ Millions	Three Months and Full Year Ended 31 March							
	Q4 FY19	Q4 FY18	FY19	FY18				
Net operating profit (loss)	\$ 0.8	\$ (57.6)	\$ 228.8	\$ 146.1				
Asbestos:								
Asbestos adjustments	73.4	192.9	22.0	156.4				
AICF SG&A expenses	0.4	0.6	1.5	1.9				
AICF interest income, net	(0.5)	(0.9)	(2.0)	(1.9)				
Loss on early debt extinguishment	_	_	1.0	26.1				
Fermacell acquisition costs	l –	5.3	_	10.0				
Product line discontinuation	3.5	_	29.5	_				
Tax adjustments ¹	(3.8)	(59.2)	19.7	(47.3)				
Adjusted net operating profit	\$ 73.8	\$ 81.1	\$ 300.5	\$ 291.3				

¹ Includes tax adjustments related to the amortization benefit of certain US intangible assets, asbestos, product line discontinuation, loss on early debt extinguishment and other tax adjustments

Adjusted diluted earnings per share

Adjusted net operating profit (US\$ millions)

Weighted average common shares outstanding - Diluted (millions)

Adjusted diluted earnings per share (US cents)

	Three Months and Full Year Ended 31 March										
Q4 FY19 Q4 FY18			FY19	FY18							
	\$ 73.8	\$	81.1	\$	300.5	\$	291.3				
	443.4		443.0		443.0		442.3				
	17		18		68		66				

Adjusted effective tax rate

US\$ Millions	Three Months and Full Year Ended 31 March							
	Q4	FY19	G	Q4 FY18	FY19			FY18
Operating profit (loss) before income taxes	\$	9.4	\$	(103.2)	\$	300.6	\$	174.3
Asbestos:								
Asbestos adjustments		73.4		192.9		22.0		156.4
AICF SG&A expenses		0.4		0.6		1.5		1.9
AICF interest income, net		(0.5)		(0.9)		(2.0)		(1.9)
Loss on early debt extinguishment		_		_		1.0		26.1
Fermacell acquisition costs		_		5.3		_		10.0
Product line discontinuation		3.5		_		29.5		_
Adjusted operating profit before income taxes	\$	86.2	\$	94.7	\$	352.6	\$	366.8
Income tax (expense) benefit		(8.6)		45.6		(71.8)		(28.2)
Tax adjustments ¹		(3.8)		(59.2)		19.7		(47.3)
Adjusted income tax expense	\$	(12.4)	\$	(13.6)	\$	(52.1)	\$	(75.5)
Effective tax rate		91.5%		44.2%		23.9%		16.2%
Adjusted effective tax rate		14.4%		14.4%		14.8%		20.6%

¹ Includes tax adjustments related to the amortization benefit of certain US intangible assets, asbestos, product line discontinuation, loss on early debt extinguishment and other tax adjustments



Adjusted EBITDA excluding Asbestos

US\$ Millions	Three Months and Full Year Ended 31 March							
	Q4 FY19 Q4 FY18		4 FY18		FY19		FY18	
EBIT	\$	22.7		(95.8)	\$	351.6	\$	229.2
Depreciation and amortization		30.7		23.4		119.4		92.0
Adjusted EBITDA	\$	53.4	\$	(72.4)	\$	471.0	\$	321.2
Asbestos:								
Asbestos adjustments		73.4		192.9		22.0		156.4
AICF SG&A expenses		0.4		0.6		1.5		1.9
Adjusted EBITDA excluding Asbestos	\$	127.2	\$	121.1	\$	494.5	\$	479.5

Adjusted selling, general and administrative expenses ("Adjusted SG&A")

US\$ Millions	Three Months and Full Year Ended 31 March							
	Q4 FY19 Q4 FY18		FY19			FY18		
SG&A expenses	\$	102.3	\$	85.1	\$	403.6	\$	311.3
Excluding:								
AICF SG&A expenses		(0.4)		(0.6)		(1.5)		(1.9)
Fermacell acquisition costs		_		(5.3)		_		(10.0)
Product line discontinuation		(0.7)		_		(2.1)		_
Adjusted SG&A expenses	\$	101.2	\$	79.2	\$	400.0	\$	299.4
Net sales		624.8		525.9		2,506.6		2,054.5
SG&A expenses as a percentage of net sales		16.4%		16.2%		16.1%		15.2%
Adjusted SG&A expenses as a percentage of net sales		16.2%		15.1%		16.0%		14.6%



Adjusted return on capital employed ("Adjusted ROCE")

US\$ Millions	Full Year Ended 31 March ¹			
	l	FY19		FY18
Numerator				
Adjusted EBIT	\$	404.6	\$	397.5
Adjustments to EBIT ²		(7.3)		_
Adjusted EBIT for ROCE		397.3		397.5
Denominator				
Gross capital employed (GCE)		1,492.7		1,272.0
Adjustments to GCE ³		(77.4)		(24.3)
Adjusted gross capital employed ³	1,415.3 1,2		1,247.7	
Adjusted ROCE		28.1%		31.9%

¹ Adjusted ROCE is used to assess annual financial results and therefore is not presented for the three months ended 31 March 2019

² Adjustments as calculated according to ROCE stock compensation plan documents

³ Calculated as Total Assets minus Current Liabilities as reported in our financial results; adjusted by (i) excluding balance sheet items related to legacy issues (such as asbestos adjustments) dividends payables and deferred taxes; (ii) adding back asset impairment charges in the relevant period, unless otherwise determined by the renumeration committee; (iii) adding back leasehold assets for manufacturing facilities and other material leased assets; and (iv) deducting all greenfield construction-in-progress, and any brownfield construction-in-progress projects involving capacity expansion that are individually greater than US\$20 million, until such assets reach commercial production and are transferred to the fixed asset register

SUPPLEMENTAL FINANCIAL INFORMATION



As set forth in Note 12 of the consolidated financial statements, the net AFFA liability, while recurring, is based on periodic actuarial determinations, claims experience and currency fluctuations. The Company's management measures its financial position, operating performance and year-over-year changes in operating results with and without the effect of the net AFFA liability.

Further, the Company's annual payment to AICF is determined by reference to the free cash flow as defined in the AFFA. Free cash flow for these purposes is defined as the Company's operating cash flow, based on US GAAP as of 21 December 2004. As there have been changes to US GAAP since the AFFA was entered into, the annual payment is no longer based upon the current US GAAP operating cash flow statement.

Accordingly, management believes that the following non-GAAP information is useful to it and investors in evaluating the company's financial position and ongoing operating financial performance, as well as estimating the annual payment due to AICF. The following non-GAAP tables should be read in conjunction with the consolidated financial statements and related notes contained therein.

James Hardie Industries plc Supplementary Financial Information 31 March 2019 (Unaudited)

US\$ Millions	Total Excluding Asbestos Compensation	Asbestos Compensation	As Reported (US GAAP)
Restricted cash and cash equivalents – Asbestos	\$ —	\$ 39.8	39.8
Restricted short term investments – Asbestos	_	17.7	17.7
Insurance receivable – Asbestos ¹	_	51.2	51.2
Workers compensation asset – Asbestos ¹	_	27.8	27.8
Deferred income taxes – Asbestos	_	349.3	349.3
Asbestos liability ¹	_	1,089.6	1,089.6
Workers compensation liability – Asbestos ¹	_	27.8	27.8
Income taxes payable ¹	63.9	(25.3)	38.6
Asbestos adjustments	_	(22.0)	(22.0)
Selling, general and administrative expenses	(402.1)	(1.5)	(403.6)
Net interest (expense) income	(52.1)	2.0	(50.1)
Income tax (expense) benefit	(93.0)	21.2	(71.8)

¹ The amounts shown on these lines are a summation of both the current and non-current portion of the respective asset or liability as presented on our consolidated balance sheets.

SUPPLEMENTAL FINANCIAL INFORMATION



James Hardie Industries plc Supplementary Statements of Cash Flows For the Full Year Ended 31 March 2019 (Unaudited)

US\$ Millions		US GAAP as of ecember 2004	ing Items to	As	Reported
Cash Flows From Operating Activities				1	
Net income	\$	228.8	\$ _	\$	228.8
Adjustments to reconcile net income to net cash provided by operating activities					
Depreciation and amortization		119.4	_		119.4
Deferred income taxes		12.7	_		12.7
Stock-based compensation		12.5	_		12.5
Asbestos adjustments		22.0	_		22.0
Asset impairments		15.9	_		15.9
Loss on early debt extinguishment		1.0	_		1.0
Other, net		16.3	_		16.3
Changes in operating assets and liabilities:					
Restricted cash and cash equivalents - Asbestos		103.8	(103.8)		_
Payment to AICF		(103.0)	103.0		_
Accounts and other receivables		(18.1)	_		(18.1)
Inventories		(28.6)	_		(28.6)
Prepaid expenses and other assets		(1.7)	_		(1.7)
Insurance receivable - Asbestos		4.8	_		4.8
Accounts payable and accrued liabilities		(12.9)	_		(12.9)
Asbestos liability		(108.8)	108.8		
Claims and handling costs paid - Asbestos		_	(108.8)		(108.8)
Income taxes payable		8.8	. –		8.8
Other accrued liabilities		15.5	_		15.5
Net cash provided by operating activities	\$	288.4	\$ (0.8)	\$	287.6
Cash Flows From Investing Activities			, ,		
Purchases of property, plant and equipment	\$	(301.1)	\$ _	\$	(301.1)
Capitalized interest		(5.4)	_		(5.4)
Acquisition of business, net of cash acquired		(558.7)	_		(558.7)
Purchase of restricted short-term investments - Asbestos		` _	(89.1)		(89.1)
Proceeds from restricted short-term investments - Asbestos		_	106.3		106.3
Net cash used in investing activities	\$	(865.2)	\$ 17.2	\$	(848.0)
Cash Flows From Financing Activities					
Proceeds from credit facilities	\$	230.0	\$ _	\$	230.0
Repayments of credit facilities		(180.0)	_		(180.0)
Proceeds from 364-day term loan facility		492.4	_		492.4
Repayment of 364-day term loan facility		(458.8)	_		(458.8)
Proceeds from senior unsecured notes		458.8	_		458.8
Debt issuance costs		(6.1)	_		(6.1)
Dividends paid		(172.1)	_		(172.1)
Net cash provided by financing activities	\$	364.2	\$ _	\$	364.2
Effects of exchange rate changes on cash and cash equivalents, restricted cash and restricted cash - Asbestos		9.7	(3.1)	•	6.6
Net decrease in cash and cash equivalents, restricted cash and restricted cash Asbestos	h - \$	(202.9)	\$ 13.3	\$	(189.6)

FORWARD-LOOKING STATEMENTS



This Management's Analysis of Results contains forward-looking statements. James Hardie Industries plc (the "Company") may from time to time make forward-looking statements in its periodic reports filed with or furnished to the Securities and Exchange Commission, on Forms 20-F and 6-K, in its annual reports to shareholders, in offering circulars, invitation memoranda and prospectuses, in media releases and other written materials and in oral statements made by the Company's officers, directors or employees to analysts, institutional investors, existing and potential lenders, representatives of the media and others. Statements that are not historical facts are forward-looking statements and such forward-looking statements are statements made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.

Examples of forward-looking statements include:

- statements about the Company's future performance;
- projections of the Company's results of operations or financial condition;
- statements regarding the Company's plans, objectives or goals, including those relating to strategies, initiatives, competition, acquisitions, dispositions and/or its products;
- expectations concerning the costs associated with the suspension or closure of operations at any of the Company's plants and future plans with respect to any such plants;
- expectations concerning the costs associated with the significant capital expenditure projects at any of the Company's plants and future plans with respect to any such projects;
- expectations regarding the extension or renewal of the Company's credit facilities including changes to terms, covenants or ratios;
- expectations concerning dividend payments and share buy-backs;
- statements concerning the Company's corporate and tax domiciles and structures and potential changes to them, including potential tax charges;
- statements regarding tax liabilities and related audits, reviews and proceedings;
- statements regarding the possible consequences and/or potential outcome of legal proceedings brought against us and the potential liabilities, if any, associated with such proceedings;
- expectations about the timing and amount of contributions to AICF, a special purpose fund for the compensation of proven Australian asbestos-related personal injury and death claims;
- expectations concerning the adequacy of the Company's warranty provisions and estimates for future warranty-related costs;
- statements regarding the Company's ability to manage legal and regulatory matters (including but not limited to product liability, environmental, intellectual property and competition law matters) and to resolve any such pending legal and regulatory matters within current estimates and in anticipation of certain third-party recoveries; and
- statements about economic conditions, such as changes in the US economic or housing market conditions or changes in the market conditions in the Asia Pacific region, the levels of new home construction and home renovations, unemployment levels, changes in consumer income, changes or stability in housing values, the availability of mortgages and other financing, mortgage and other interest rates, housing affordability and supply, the levels of foreclosures and home resales, currency exchange rates, and builder and consumer confidence.

Words such as "believe," "anticipate," "plan," "expect," "intend," "target," "estimate," "project," "predict," "forecast," "guideline," "aim," "will," "should," "likely," "continue," "may," "objective," "outlook" and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. Readers are cautioned not to place undue reliance on these forward-looking statements and all such forward-looking statements are qualified in their entirety by reference to the following cautionary statements.

Forward-looking statements are based on the Company's current expectations, estimates and assumptions and because forward-looking statements address future results, events and conditions, they, by their very nature, involve inherent risks and uncertainties, many of which are unforeseeable and beyond the Company's control. Such known and unknown risks, uncertainties and other factors may cause actual results, performance or other achievements to differ materially from the anticipated results, performance or achievements expressed, projected or implied by these forwardlooking statements. These factors, some of which are discussed under "Risk Factors" in Section 3 of the Form 20-F filed with the Securities and Exchange Commission on 21 May 2019, include, but are not limited to: all matters relating to or arising out of the prior manufacture of products that contained asbestos by current and former Company subsidiaries; required contributions to AICF, any shortfall in AICF and the effect of currency exchange rate movements on the amount recorded in the Company's financial statements as an asbestos liability; the continuation or termination of the governmental loan facility to AICF; compliance with and changes in tax laws and treatments; competition and product pricing in the markets in which the Company operates; the consequences of product failures or defects; exposure to environmental, asbestos, putative consumer class action or other legal proceedings; general economic and market conditions; the supply and cost of raw materials; possible increases in competition and the potential that competitors could copy the Company's products; reliance on a small number of customers; a customer's inability to pay; compliance with and changes in environmental and health and safety laws; risks of conducting business internationally; compliance with and changes in laws and regulations; currency exchange risks; dependence on customer preference and the concentration of the Company's customer base on large format retail customers, distributors and dealers; dependence on residential and commercial construction markets; the effect of adverse changes in climate or weather patterns; possible inability to renew credit facilities on terms favorable to the Company, or at all; acquisition or sale of businesses and business segments; changes in the Company's key management personnel; inherent limitations on internal controls; use of accounting estimates; the integration of Fermacell into our business; and all other risks identified in the Company's reports filed with Australian, Irish and US securities regulatory agencies and exchanges (as appropriate). The Company cautions you that the foregoing list of factors is not exhaustive and that other risks and uncertainties may cause actual results to differ materially from those referenced in the Company's forwardlooking statements. Forward-looking statements speak only as of the date they are made and are statements of the Company's current expectations concerning future results, events and conditions. The Company assumes no obligation to update any forward-looking statements or information except as required by law.



Q4 FY19 MANAGEMENT PRESENTATION 21 May 2019



CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS

This Management Presentation contains forward-looking statements. James Hardie Industries plc (the "Company") may from time to time make forward-looking statements in its periodic reports filed with or furnished to the Securities and Exchange Commission, on Forms 20-F and 6-K, in its annual reports to shareholders, in offering circulars, invitation memoranda and prospectuses, in media releases and other written materials and in oral statements made by the Company's officers, directors or employees to analysts, institutional investors, existing and potential lenders, representatives of the media and others. Statements that are not historical facts are forward-looking statements and such forward-looking statements made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.

Examples of forward-looking statements include:

- statements about the Company's future performance;
- projections of the Company's results of operations or financial condition;
- statements regarding the Company's plans, objectives or goals, including those relating to strategies, initiatives, competition, acquisitions, dispositions and/or its products;
- expectations concerning the costs associated with the suspension or closure of operations at any of the Company's plants and future plans with respect to any such plants;
- expectations concerning the costs associated with the significant capital expenditure projects at any of the Company's plants and future plans with respect to any such projects;
- expectations regarding the extension or renewal of the Company's credit facilities including changes to terms, covenants or ratios;
- expectations concerning dividend payments and share buy-backs;
- statements concerning the Company's corporate and tax domiciles and structures and potential changes to them, including potential tax charges;
- statements regarding tax liabilities and related audits, reviews and proceedings;
- statements regarding the possible consequences and/or potential outcome of legal proceedings brought against us and the potential liabilities, if any, associated with such proceedings;
- expectations about the timing and amount of contributions to Asbestos Injuries Compensation Fund (AICF), a special purpose fund for the compensation of proven Australian asbestos-related personal injury and death claims;
- expectations concerning the adequacy of the Company's warranty provisions and estimates for future warranty-related costs;
- statements regarding the Company's ability to manage legal and regulatory matters (including but not limited to product liability, environmental, intellectual property and competition law matters) and to resolve any such pending legal and regulatory matters within current estimates and in anticipation of certain third-party recoveries; and
- statements about economic conditions, such as changes in the US economic or housing recovery or changes in the market conditions in the Asia Pacific region, the levels of new home construction and home renovations, unemployment levels, changes in consumer income, changes or stability in housing values, the availability of mortgages and other financing, mortgage and other interest rates, housing affordability and supply, the levels of foreclosures and home resales, currency exchange rates, and builder and consumer confidence.



CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS (continued)

Words such as "believe," "anticipate," "plan," "expect," "intend," "target," "estimate," "project," "predict," "forecast," "guideline," "aim," "will," "should," "likely," "continue," "may," "objective," "outlook" and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. Readers are cautioned not to place undue reliance on these forward-looking statements and all such forward-looking statements are qualified in their entirety by reference to the following cautionary statements.

Forward-looking statements are based on the Company's current expectations, estimates and assumptions and because forward-looking statements address future results, events and conditions, they, by their very nature, involve inherent risks and uncertainties, many of which are unforeseeable and beyond the Company's control. Such known and unknown risks, uncertainties and other factors may cause actual results, performance or other achievements to differ materially from the anticipated results, performance or achievements expressed, projected or implied by these forward-looking statements. These factors, some of which are discussed under "Risk Factors" in Section 3 of the Form 20-F filed with the Securities and Exchange Commission on 21 May 2019, include, but are not limited to: all matters relating to or arising out of the prior manufacture of products that contained asbestos by current and former Company subsidiaries; required contributions to AICF, any shortfall in AICF and the effect of currency exchange rate movements on the amount recorded in the Company's financial statements as an asbestos liability; the continuation or termination of the governmental loan facility to AICF; compliance with and changes in tax laws and treatments; competition and product pricing in the markets in which the Company operates; the consequences of product failures or defects; exposure to environmental, asbestos, putative consumer class action or other legal proceedings; general economic and market conditions; the supply and cost of raw materials; possible increases in competition and the potential that competitors could copy the Company's products; reliance on a small number of customers; a customer's inability to pay; compliance with and changes in environmental and health and safety laws; risks of conducting business internationally; compliance with and changes in laws and regulations; currency exchange risks; dependence on customer preference and the concentration of the Company's customer base on large format retail customers, distributors and dealers; dependence on residential and commercial construction markets; the effect of adverse changes in climate or weather patterns; possible inability to renew credit facilities on terms favorable to the Company, or at all; acquisition or sale of businesses and business segments; changes in the Company's key management personnel; inherent limitations on internal controls; use of accounting estimates; the integration of Fermacell into our business; and all other risks identified in the Company's reports filed with Australian, Irish and US securities regulatory agencies and exchanges (as appropriate). The Company cautions you that the foregoing list of factors is not exhaustive and that other risks and uncertainties may cause actual results to differ materially from those referenced in the Company's forward-looking statements. Forward-looking statements speak only as of the date they are made and are statements of the Company's current expectations concerning future results, events and conditions. The Company assumes no obligation to update any forward-looking statements or information except as required by law.



NOTE TO THE READER

As of 30 June 2018, the Company changed its reportable operating segments. Previously, the Company reported on four operating segments: (i) North America Fiber Cement, (iii) Other Businesses, and (iv) Research and Development. As of 30 June 2018, the Company began reporting on five operating segments: (i) North America Fiber Cement, (ii) Asia Pacific Fiber Cement, (iii) Europe Building Products, (iv) Other Businesses, and (v) Research and Development. The significant changes to how certain businesses are reported in the new segment structure are as follows: (i) our European Fiber Cement business, as well as the newly acquired Fermacell business, are now reported as the Europe Building Products segment, and the remaining businesses that were historically reported in the International Fiber Cement segment are now reported in the Asia Pacific Fiber Cement segment. The Company has revised its historical segment information for the fourth quarter and full year ended 31 March 2018 to be consistent with the new reportable segment structure. The change in reportable segments had no effect on the Company's financial position, results of operations or cash flows for the periods presented. Readers are referred to Note 18 of our consolidated financial statements for further information on our segments.



USE OF NON-GAAP FINANCIAL INFORMATION; AUSTRALIAN EQUIVALENT TERMINOLOGY

This Management Presentation includes financial measures that are not considered a measure of financial performance under generally accepted accounting principles in the United States (US GAAP). These financial measures are designed to provide investors with an alternative method for assessing our performance from on-going operations, capital efficiency and profit generation. Management uses these financial measures for the same purposes. These financial measures include:

- Adjusted EBIT;
- North America Fiber Cement Segment Adjusted EBIT excluding product line discontinuation;
- Europe Building Products Segment Adjusted EBIT excluding costs associated with the acquisition;
- Adjusted EBIT margin;
- North America Fiber Cement Segment Adjusted EBIT margin excluding product line discontinuation;
- Europe Building Products Segment Adjusted EBIT margin excluding costs associated with the acquisition;
- Adjusted net operating profit;
- Adjusted diluted earnings per share;
- Adjusted operating profit before income taxes;
- Adjusted income tax expense;
- Adjusted effective tax rate;
- Adjusted EBITDA;
- Adjusted EBITDA excluding Asbestos;
- Adjusted selling, general and administrative expenses ("Adjusted SG&A"); and
- Adjusted return on capital employed ("Adjusted ROCE").

These financial measures are or may be non-US GAAP financial measures as defined in the rules of the U.S. Securities and Exchange Commission and may exclude or include amounts that are included or excluded, as applicable, in the calculation of the most directly comparable financial measures calculated in accordance with US GAAP. These non-GAAP financial measures should not be considered to be more meaningful than the equivalent US GAAP measure. Management has included such measures to provide investors with an alternative method for assessing its operating results in a manner that is focused on the performance of its ongoing operations and excludes the impact of certain legacy items, such as asbestos adjustments. Additionally, management uses such non-GAAP financial measures for the same purposes. However, these non-GAAP financial measures are not prepared in accordance with US GAAP, may not be reported by all of the Company's competitors and may not be directly comparable to similarly titled measures of the Company's competitors due to potential differences in the exact method of calculation. For additional information regarding the non-GAAP financial measures presented in this Management Presentation, including a reconciliation of each non-GAAP financial measure to the equivalent US GAAP measure, see the slide titled "Non-US GAAP Financial Measures" included in the Appendix to this Management Presentation.

In addition, this Management Presentation includes financial measures and descriptions that are considered to not be in accordance with US GAAP, but which are consistent with financial measures reported by Australian companies, such as operating profit, EBIT and EBIT margin. Since the Company prepares its Consolidated Financial Statements in accordance with US GAAP, the Company provides investors with a table and definitions presenting cross-references between each US GAAP financial measure used in the Company's Consolidated Financial Statements to the equivalent non-US GAAP financial measure used in this Management Presentation. See the section titled "Non-US GAAP Financial Measures" included in the Appendix to this Management Presentation.



AGENDA







Group Operating Review

Dr Jack Truong, CEO

Financial Review

Matt Marsh, EVP and CFO

Strategy Update

Dr Jack Truong, CEO

Questions and Answers



GROUP OPERATING REVIEW – DR JACK TRUONG, CEO



FY19 GROUP RESULTS OVERVIEW

	Q4'19	FY19
Sales Volume	942.2 mmsf 32%	3,670.0 mmsf 33%
Net Sales	US\$624.8M	US\$2,506.6M
Adjusted EBIT ¹	US\$100.0M 3%	US\$404.6M 2%
Adjusted Net Operating Profit ²	US\$73.8 M	US\$300.5M
Operating Cash Flow		US\$287.6M

- North America delivered improved PDG, albeit below our expectations
- Australia and Philippines continue to lead the way in gaining growth above market
- European segment met our expectations
- Input cost environment remained challenging, and we are focused on lean manufacturing
- Disciplined capital allocation
- Windows business shut-down



¹ Excludes product line discontinuation expenses, asbestos related expenses and adjustments, and acquisition costs incurred prior to the close of Fermacell

² Excludes product line discontinuation expenses, asbestos related expenses and adjustments, tax adjustments, loss on early debt extinguishment, and acquisition costs incurred prior to the close of Fermacell

FY19 NORTH AMERICA SUMMARY

	Q4'19	FY19
Sales Volume	593.3 mmsf 1%	2,308.1 mmsf 3%
	US\$422.0 M	US\$1,676.9 M
Net Sales	3%	6%
EBIT Excluding ¹	US\$95.1 M → 8%	US\$387.9M 2%
EBIT Margin Excluding ¹	22.5 % 2.7 pts	23.1%

¹ Excludes product line discontinuation expenses

- Housing market demand was soft in 2H of the fiscal year
- Exteriors business grew above market, showing improvement from prior year (volume up 4.7% in FY19)
- Continued soft performance in Interiors (volume down 4.4% in FY19)
- EBIT Margin Excluding¹ within our target range despite significant inflationary trends across key input costs
- Commercial transformation and implementation of lean manufacturing underway







FY19 APAC SUMMARY

	Q4'19	FY19
Sales Volume	129.9 mmsf	546.1 mmsf 10%
Net Sales	A\$143.6 M	A\$612.2 M
Net Sales	1 7%	11%
CDIT	A\$28.8 M	A\$136.5 M
EBIT	- 14%	- 2%
EDIT Manain	20.1%	22.3%
EBIT Margin	4.9 pts	3.1 pts

- Continued to deliver excellent top line results in a softening market
- Particularly strong volume growth in Australia and the Philippines
- Continued gains in market and category share
- EBIT and EBIT Margin significantly impacted by input cost inflation











FY19 EUROPE SUMMARY

	Q4'19	FY19
Net Sales	€86.9 M	€318.0 M
EBIT Excluding ²	€9.8M ↑23% ¹	€33.7M 136% ¹
EBIT Margin Excluding ²	11.3%	10.6%

- Good top line growth; up 7% in Euros
- Integration on track
- Good traction repositioning fiber cement for growth
- EBIT Margin Excluding² in line with expectations

² Excludes transaction & integration costs and inventory fair value adjustment in FY19







¹ The unaudited pro forma information presents the results of operations of the Company as if the Fermacell acquisition and related financing was completed on 1 April 2017



FINANCIAL REVIEW – MATT MARSH, EVP AND CFO



KEY FINANCIAL MESSAGES

- Good and disciplined financial performance in an inflationary market
 - North America Fiber Cement exteriors business continued to grow above our addressable market
 - Market penetration and category share gains in Asia Pacific Fiber Cement segment
 - Fermacell included in financial results for the full year and performing as expected
 - Exited Windows business
- FY19 Adjusted NOPAT of US\$300.5 million
- Capital expenditure of US\$301.1 million primarily consisting of capacity expansion
- Second half dividend declared of 26 cents per share

RESULTS – 4TH QUARTER FY19

Three Months Ended 31 March								
US\$ Millions	Q4'19	Q4'18	% Change					
Net sales	624.8	525.9	19					
Gross profit	210.6	191.1	10					
EBIT	22.7	(95.8)						
Net operating profit (loss)	0.8	(57.6)						
Adjusted EBIT ¹	100.0	103.0	(3)					
Adjusted Net Operating Profit ²	73.8	81.1	(9)					

Net sales increased 19%, US\$98.9 million

- The acquired Fermacell business in Europe contributed net sales of US\$89.9 million
- Higher average net sales price and volumes in the North America Fiber Cement segment
- Higher volumes in the Asia Pacific Fiber Cement segment

Gross profit increased 10%, gross margin % down 260bps

Adjusted net operating profit² decreased 9%

 North America Fiber Cement and Asia Pacific Fiber Cement segments EBIT decreased 8% and 22%, respectively



¹ Excludes product line discontinuation expenses, asbestos related expenses and adjustments, and acquisition costs incurred prior to the close of Fermacell

² Excludes product line discontinuation expenses, asbestos related expenses and adjustments, tax adjustments, loss on early debt extinguishment, and acquisition costs incurred prior to the close of Fermacell

RESULTS – FULL YEAR FY19

Full Year Ended 31 March							
US\$ Millions	FY19	FY18	% Change				
Net sales	2,506.6	2,054.5	22				
Gross profit	831.0	730.2	14				
ЕВІТ	351.6	229.2	53				
Net operating profit	228.8	146.1	57				
Adjusted EBIT ¹	404.6	397.5	2				
Adjusted net operating profit ²	300.5	291.3	3				

Net sales increased 22%, US\$452.1 million

- The acquired Fermacell business in Europe contributed net sales of US\$332.5 million
- Higher average net sales price and volumes in the North America Fiber Cement segment
- Higher volumes in the Asia Pacific Fiber Cement segment

Gross profit increased 14%, gross margin down 230bps

Adjusted net operating profit² increased US\$9.2 million

Europe Building Products EBIT and North America
 Fiber Cement segment EBIT Excluding³ increased

¹ Excludes product line discontinuation expenses, asbestos related expenses and adjustments, and acquisition costs incurred prior to the close of Fermacell

² Excludes product line discontinuation expenses, asbestos related expenses and adjustments, tax adjustments, loss on early debt extinguishment, and acquisition costs incurred prior to the close of Fermacell

³ Excludes product line discontinuation expenses

NORTH AMERICA FIBER CEMENT SUMMARY

	Q4'19	FY19
Sales Volume	593.3 mmsf 1%	2,308.1 mmsf 3%
Net Sales	US\$422.0M	US\$1,676.9M
Average Price	US\$704 per msf 2%	US\$718 per msf 3%
ЕВІТ	US\$95.1 M	US\$382.5 M FLAT
EBIT Excluding ¹	US\$95.1 M	US\$387.9 M

 $^{^{1}}$ Excludes product line discontinuation expenses of US\$5.4 million for the full year FY19

Volume

- Slightly positive PDG in exteriors, but below our expectations
 - Exteriors volumes +3.5% for Q4 and +4.7% for FY19
- Decline in interiors
 - Interiors volumes -9.6% for Q4 and -4.4% for FY19

Price

- Favorably impacted by annual change in strategic pricing
- Quarter price partially offset by tactical pricing


EBIT Excluding¹

- Q4 FY19 decrease driven by:
 - Higher input costs and unfavorable plant performance
 - Partially offset by a higher average net sales price
- Full year increase driven by:
 - Higher volume and average net sales price
 - Partially offset by higher input costs, higher freight costs and higher SG&A expenses




NORTH AMERICA FIBER CEMENT






FY19 EBIT Margin Excluding¹ % remains within our target range, but down 110 bps to 23.1% compared to pcp



¹ Excludes product line discontinuation expenses of US\$5.4 million in Q2 FY19

NORTH AMERICA INPUT COSTS

Quarterly US Input Costs



- The price of NBSK pulp up 12% compared to pcp
- Gas prices up 5% compared to pcp
- Cement prices up 3% compared to pcp
- Electric prices *flat* compared to pcp
- Freight prices down 3% compared to pcp

The information underlying the table above is sourced as follows:

- Pulp Cost per ton from RISI
- Gas Cost per thousand cubic feet for industrial users from US Energy Information Administration
- Electric Cost per thousand kilowatt hour for industrial users from US Energy Information Administration
- · Cement Relative index from the Bureau of Labor Statistics
- Freight Cost per mile from Dial-a-Truck Solutions
- Gas and Electric prices for current quarter are based on prior quarter actuals



ASIA PACIFIC FIBER CEMENT SUMMARY

	Q4'19	FY19
Sales Volume	129.9 mmsf 7%	546.1 mmsf 10%
Net Sales	A\$143.6 M 7%	A\$612.2 M 11%
Average Price	A\$984 per msf 1%	A\$992 per msf 1%
US\$ EBIT	US\$20.5M 22%	US\$99.8 M 8%
А\$ ЕВІТ	A\$28.8 M	A\$136.5 M 2%

Volume

- Strong volume growth above market index in Australia and Philippines
- Market penetration and category share gains, despite a softening market

EBIT

- Higher net sales and strong volume performance
- Inflationary input cost environment
- Segment results in US dollars impacted by unfavorable foreign exchange rate movements



ASIA PACIFIC FIBER CEMENT (LOCAL CURRENCY)




	Q4'19		FY19			
Australia			Australia			
Volume	Net Sales	EBIT	Volume	Net Sales	EBIT	

Australia

- Market penetration and category share gains
- EBIT for the full year favorably impacted by higher net sales and favorable plant performance, partially offset by higher input costs






New Zealand

- · Favorably impacted by higher sales volume
- EBIT compressed by unfavorable plant performance and higher input costs





Philippines

- Volume increase driven by market penetration
- EBIT unfavorably impacted by higher input costs, non-recurring operating costs, and start up costs.



EUROPE BUILDING PRODUCTS SUMMARY¹

	Q4'19	FY19
Net Sales	€86.9M 👚	€318.0M 👚
Sales Volume	219.0 mmsf 👕	815.8 mmsf 👚
Average Price	€305 per msf 👢	€306 per msf 👢
EBIT	€6.3M 👚	€9.1M 👚
EBIT Excluding ²	€9.8M 👚	€33.7M 👚
EBIT Margin Excluding ²	11.3% 👚	10.6% 👚





¹ Includes European Fiber Cement business, as well as Fermacell

Volume

Increase driven by acquisition of Fermacell

Price

- Decrease due to product mix
- Fiber gypsum has a lower average net sales price compared to Fiber Cement

Net Sales


 Net sales in Euros increased 7% for the quarter and full year, on a pro-forma basis

EBIT

- EBIT includes:
 - €3.5 million and €18.4 million of transaction and integration costs for Q4 FY19 and FY19, respectively
 - €6.2 million inventory fair value adjustment in FY19
- EBIT Margin Excluding² of 11.3% and 10.6% for the quarter and full year, respectively

² Excludes transaction & integration costs and inventory fair value adjustment

OTHER BUSINESSES SEGMENT EBIT



Decision made to exit Windows business

- Shutdown fiberglass windows business
- Sold our fiberglass pultrusion portion of the business in the first quarter of fiscal year 2020
- Product line discontinuation expenses totaling US\$3.5
 million and US\$24.1 million for Q4 FY19 and FY19,
 respectively
 - Impairment costs of US\$12.9 million for FY19
 - Inventory adjustments of US\$8.5 million for FY19
 - Other related closure costs of US\$2.7 million for FY19



PRODUCT LINE DISCONTINUATION EXPENSES¹

US\$ Millions	Q1'19	Q2'19	Q3'19	Q4'19	Fu	ıll Year FY19
North America Fiber Cement segment:						
Discontinuation of MCT	\$ -	\$ 3.6	\$ -	\$ -	\$	3.6
Discontinuation of certain ColorPlus® color palettes	-	1.8	-	-		1.8
Other Businesses segment:						
Discontinuation of Windows Business	-	15.8	4.8	3.5		24.1
Total product line discontinuation expenses	\$ -	\$ 21.2	\$ 4.8	\$ 3.5	\$	29.5

North America Fiber Cement Segment

• In Q2'FY19 we made the decision to discontinue our MCT product line and certain ColorPlus® color palettes

Other Businesses Segment


- In Q2'FY19 we decided to exit our Windows business
 - Fiberglass pultrusion business; and
 - Fiberglass windows assembly business
- In Q3'FY19 we shutdown fiberglass windows assembly business; production ceased
- In Q1'FY20 we sold our fiberglass pultrusion portion of the business




¹ Excluded from Adjusted EBIT and Adjusted net operating profit

SEGMENT EBIT – 4TH QUARTER FY19

Research and Development



General Corporate Costs¹



Excludes asbestos related expenses and adjustments, and acquisition costs incurred prior to the close of Fermacell

R&D

On strategy to invest ~2-3% of net sales

General Corporate Costs

- Quarter decrease driven by a favorable settlement related to New Zealand weathertightness claims
- Full year increase driven by:
 - Non-recurring gain of US\$3.4 million in the prior year from the sale of a storage building near our Fontana facility
 - New Zealand weathertightness claims of US\$3.3 million
 - Partially offset by lower stock compensation expenses and favorable movements in recognized foreign exchange gains



INCOME TAX

Three Months and Full Year Ended 31 March								
US\$ Millions	Q4'19	Q4'18	FY19	FY18				
Operating profit (loss) before taxes	9.4	(103.2)	300.6	174.3				
Asbestos adjustments ¹	73.3	192.6	21.5	156.4				
Fermacell acquisition costs	-	5.3	-	10.0				
Product line discontinuation	3.5	-	29.5	-				
Loss on early debt extinguishment	-	-	1.0	26.1				
Adjusted operating profit before income taxes	86.2	94.7	352.6	366.8				
Adjusted income tax expense ²	(12.4)	(13.6)	(52.1)	(75.5)				
Adjusted effective tax rate	14.4%	14.4%	14.8%	20.6%				
Income tax (expense) benefit	(8.6)	45.6	(71.8)	(28.2)				
Income taxes paid			26.3	49.1				
Income taxes payable ³			38.6	29.1				

14.8% adjusted effective tax rate for the full year

- Decrease in adjusted income tax expense driven by adjustments related to the ongoing accounting treatment of amortization of intangible assets, and a reduction in the US statutory corporate tax rate
- Income taxes are not currently paid or payable in Australia due to tax losses. Australian tax losses primarily result from deductions relating to contributions to AICF



¹ Includes asbestos adjustments, AICF SG&A expenses and net AICF interest income

² Includes tax adjustments related to asbestos, the amortization benefit of certain US intangible assets and other tax adjustments

³ Includes non-current US income taxes payable of US\$25.2 million as of 31 March 2019 related to the deemed repatriation promulgated by the US Tax Cuts and Jobs Act and will be paid in annual installments through FY25

CASH FLOWS¹

US\$ Millions	FY19	FY18	Change (%)
Net Income	228.8	146.2	56
Adjustment for non-cash items	199.8	219.7	(9)
Annual AICF contribution	(103.0)	(102.2)	(1)
Operating working capital ²	(59.6)	(42.7)	(40)
Other net operating activities	22.6	75.2	(70)
AICF cash flow, net	(0.2)	(1.9)	89
Cash Flow from Operations	288.4	294.3	(2)
Purchases of property, plant and equipment ³	(306.5)	(208.5)	(47)
Proceeds from sale of property, plant and equipment	-	7.9	
Acqusition of business, net of cash acquired	(558.7)	-	
Free Cash Flow ⁴	(576.8)	93.7	
Dividends paid	(172.1)	(177.5)	3
Net repayments to credit facilities	50.0	(75.0)	
Proceeds from 364-day term loan facility	492.4	-	
Repayment on 364-day term loan facility	(458.8)	-	
Proceeds from unsecured notes, net	452.7	384.3	18
Repayment of NSW loan - Asbestos	-	(51.9)	
Other financing activities	-	(18.5)	
Free Cash Flow after Financing Activities	(212.6)	155.1	

¹ Derived from supplementary statement of cash flow

Decrease in net operating cash flow

- Decrease in other assets and liabilities as well as income tax payable
- Net cash outflow due to working capital
- Increase in net income adjusted for non-cash items

Higher investing activities

- Acquisition of Fermacell in Europe
- Increase in capacity expansion related capital expenditures

Cash provided by financing activities

- Driven by higher proceeds from unsecured notes and senior notes
- No NSW loan repayment by AICF in the current year




² Excludes AP related to capital expenditures

³ Includes capitalized interest

⁴ Distinct from the term defined by the AFFA for purposes of calculating our annual contribution to AICF

CAPITAL EXPENDITURES



YTD CAPEX spend of US\$301.1 million increased US\$97.4 million compared to pcp

North America capacity projects

- Continued start-up of Tacoma greenfield expansion
- Continued construction of our Prattville facility
- Continued expansion within our ColorPlus® product line

Asia Pacific capacity projects

- Completed start-up of additional Philippines capacity
- Continued Carole Park brownfield expansion project

FINANCIAL MANAGEMENT FRAMEWORK

Strong Financial Management

- Strong margins and operating cash flows
- Strong governance and transparency
- Investment-grade financial management

Moody's S&P Fitch Ba1 BB BB affirmed Sept'18 affirmed Mar'19 affirmed Mar'19 outlook stable outlook stable

Disciplined Capital Allocation


- Invest in R&D and capacity expansion to support organic growth
- Maintain ordinary dividends within the defined payout ratio
- Flexibility for:
 - Cyclical market volatility
 - Accretive and strategic inorganic opportunities or further shareholder returns, when appropriate

Liquidity and Funding

- Conservative leveraging of balance sheet at a target within 1-2 times Adjusted EBITDA excluding asbestos.
 - US\$500 million unsecured revolving credit facility;
 - US\$800m senior unsecured notes at Q4 FY19;
 - €400m (US\$449.4m) senior unsecured notes at Q4 FY19;
 - At Q4 FY19, total debt had a weighted average maturity of 6.3 years and weighted average rate of 4.4%

Financial management consistent with investment grade credit Ability to withstand market cycles and other unanticipated events

LIQUIDITY PROFILE AT 31 MARCH 2019



¹ Incremental liquidity of up to US\$250 million may be accessed via an accordion feature, which is provided for under the terms of the syndicated revolving credit facility agreement, but not credit approved

Strong balance sheet

- US\$78.7 million cash
- US\$1,301.6 million net debt³
- US\$340.5 million available on revolving credit facility

Corporate debt structure

- US\$400 million 4.75% senior unsecured notes maturing 2025
- US\$400 million 5.00% senior unsecured notes maturing 2028
- €400 million (US\$457.2)² 3.625 % senior unsecured notes, maturing 2026
- US\$500 million unsecured revolving credit facility, maturing 2022

Leverage strategy

 ~2.4x net debt to Adjusted EBITDA excluding asbestos; temporarily outside of the 1-2x leverage target range



² Based on exchange rate as of 31 March 2019

³ Includes debt issuance costs (US\$19.1 million)


ASBESTOS COMPENSATION


KEY POINTS

- Updated actuarial report completed as at 31 March 2019
- Undiscounted and uninflated estimate decreased to A\$1,400 million from A\$1,443 million
- Decrease in central estimate of A\$43.1 million
 - Decrease due to net cash outflows of A\$142.8 million
 - Partially offset by an increase in the actuarial estimate
- Total contributions of A\$138.4 million (US\$103.0 million) were made during FY2019 from our
 FY2018 free cash flow
- From the time AICF was established in February 2007, we have contributed approximately A\$1,193 million to the fund
- We anticipate that we will make a further contribution of approximately US\$100.9 million to
 AICF on 1 July 2019
 - This amount represents 35% of our free cash flows for fiscal year 2019, as defined by the AFFA




ASBESTOS CLAIMS DATA





- Full year claims received were 1% higher, compared to pcp
- Claims reporting during the full year for mesothelioma:
 - 4% lower than actuarial estimates
 - 5% lower than pcp




- Average claim settlement for the full year was 24% below actuarial estimates:
 - Average claim settlement sizes for most disease types, including mesothelioma for most age groups
 - Largely attributable to lower average claim settlement for non-mesothelioma claims

¹ Average claim settlement is derived as the total amount paid divided by the number of non-nil claims



SUMMARY



- Good and disciplined financial performance in an inflationary market
 - Higher net sales in North America Fiber Cement and Asia Pacific Fiber Cement segments
 - Market penetration and category share gains in our Asia Pacific Fiber Cement segment
 - Positive first year results from our Europe Building Products segment
 - Disciplined capital allocation within a strong financial management framework



¹ Excludes product line discontinuation costs, asbestos adjustments, tax adjustments, loss on early debt extinguishment, and acquisition costs incurred prior to the close of Fermacell

² Excludes product line discontinuation costs, asbestos adjustments and acquisition costs incurred prior to the close of Fermacell



STRATEGY UPDATE – DR JACK TRUONG, CEO



LONG TERM VALUE CREATION

North America

• 35/90 with strong returns (20-25% EBIT margin)

Europe

• €1 billion business with 20+% EBIT margin

APAC

 Deliver growth above market with strong returns (20-25% EBIT margin)







STRATEGIC PRIORITIES: FY20 - FY22

North America

Europe

Asia Pacific

1 Accelerate Exteriors Growth

Drive Lean Transformation

Re-establish Interiors as a

across all ten plants

Growth Business

- 1 Gain market traction
 - · current fiber cement
 - new, for Europe, fiber cement
- 2 Continue to drive fiber gypsum market penetration
- 3 Continue to unlock existing manufacturing capacity in all five plants

- 1 Continue to drive growth above market
- Continue to drive Lean manufacturing across all four plants






NA: LEAN TRANSFORMATION - UPDATE

- Lean transformation is off to a strong start
- Employee Engagement is high
- Standards implemented across all plants
- Hardie Manufacturing Operating System (HMOS) implemented in three plants
- Drive lean culture throughout manufacturing organization
- Key Focus areas
 - Roll Throughput Yield
 - Net available hours
 - Lower cost per square foot

US\$100 Million in Cost Out Savings Over Three Years FY20 – FY22

North America - Cost to Manufacture per msf¹



¹ Excludes fixed costs and outbound freight



NA: ACCELERATE EXTERIORS GROWTH - UPDATE

Win With Color

Statement & Dream Collections launched

Manufacturing scaling up

Partnering with channel to ensure Statement stocking positions are in place

Cost optimization underway



Statement Collection and Dream Collection homes in Nashville, Tennessee

Commercial Transformation

Pull & Push are both required to deliver PDG growth targets, consistently

Easier to do business with

Sales team structure in place

Key leaders and talent added



Statement Collection of homes in Boston, Massachusetts



EUROPE: TOP LINE GROWTH - UPDATE

Sales synergy of Fiber Cement Exteriors with Fiber Gypsum Interiors

Launch of Hardie Windbreaker, our first new Fiber Cement product introduction for Europe

- New Zealand original product innovation
- Europe market development
- US R&D product innovation and adaptation specific to European market
- US manufacturing



James Hardie Cladding



HardiePanel fiber cement - exterior of Kindergarten in Brittany, France



Fermacell fiber gypsum - interior of Kindergarten in Brittany, France



FY20 KEY ASSUMPTIONS & MARKET OUTLOOK

North America

Europe

Asia Pacific

Modest growth in the US housing market in FY20

US Residential Housing starts forecast between 1.2 and 1.3 million

EBIT Margin in the top half of our stated range of 20 to 25%¹

Exteriors volume: 3-5% PDG

Slight housing market growth across addressable market

Introduction of new fiber cement products for Europe

EBIT Margin accretion²

Addressable housing market in Australia to decrease in FY20

APAC volume: 3-5% growth above the market

EBIT Margin in the top half of our stated range of 20 to 25%³



¹ Expectation is based upon the Company continuing to improve operating performance in our plants, higher net average sales price and mix, continued inflation for input costs and modest underlying housing growth.

² Expectation is based upon the Company continuing to improve operating performance in our plants and slight underlying housing growth.

³ Expectation is based upon the Company continuing to improve operating performance in our plants, higher net average sales price and mix, continued inflation for input costs and volume growth above a decreasing addressable housing market.



QUESTIONS





APPENDIX




NORTH AMERICA FIBER CEMENT VOLUME




- **Exteriors**
- Interiors

- Volume increased 3.5% and 4.7% for the quarter and full year, respectively, compared to pcp
- Focus is on transforming our commercial strategy and delivering higher PDG
- Volume decreased 9.6% and 4.4% for the quarter and full year, respectively, compared to pcp

NORTH AMERICA FIBER CEMENT






- FY19 strategic price increase effective April 2018
- Overall, satisfied with price positioning

Softer market conditions remain across most geographies and customer segments



 $^{^{\,1}}$ Rolling 12 month average of seasonally adjusted estimate of housing starts by US Census Bureau

TRANSLATION IMPACT ON CONSOLIDATED RESULTS



	As Re	ported	_	Translation act ¹		
% Change	Q4 FY19	FY19	Q4 FY19	FY19		
Net Sales	1 9%	22 %	22 %	23 %		
Gross Profit	1 0%	1 4%	12 %	15%		
Adjusted EBIT	~ 3%	2 %	▼ 3%	2 %		
Adjusted net operating profit	y 9%	^ 3%	▼ 9%	3 %		

Trai	nslation	Impac	et ²
Q4 I	FY19	FY	′19
•	3%	•	1%
~	2%	•	1%
	-	•	-
	-		-

¹ As reported Q4 FY19 and full year FY19 figures converted using Q4 FY18 and full year FY18 average exchange rates, respectively

² Reflects the difference between Q4 FY19 As Reported and Q4 FY19 using Q4 FY18 average exchange rates, as well as the difference between full year FY19 As Reported and full year FY19 using full year FY18 average exchange rates

ASIA PACIFIC FIBER CEMENT RESULTS AUD vs USD

	Three Mon	ths and Full	Year Ended	d 31 March				
		Q4'19	F	Full Year FY19				
	Results in AUD	Results in USD	Impact of FX	Results in AUD	Results in USD	Impact of FX		
Averge net sales price per unit (per msf)	+1%	-9%	-10%	+1%	-5%	-6%		
Net sales	+7%	-3%	-10%	+11%	+5%	-6%		
Gross profit	-7%	-16%	-9%	FLAT	-6%	-6%		
ЕВІТ	-14%	-22%	-8%	-2%	-8%	-6%		



EUROPE BUILDING PRODUCTS PRO FORMA¹

	Q4'19	Full Year FY19
Net Sales	US\$98.7 M	US\$368.3 M 6% ¹
EBIT Excluding ²	US\$11.2 M 15%	US\$39.1 M 35%
EBIT Margin Excluding ²	11.3%	10.6%





Net sales decreased 1% and increased 6% for the quarter and full year, respectively, on a pro-forma basis compared to pcp



¹ The unaudited pro forma information presents the results of operations of the Company as if the Fermacell acquisition and related financing was completed on 1 April 2017. The unaudited pro forma excludes transaction and integration costs of US\$4.1 million and US\$21.8 million for the quarter and full year, respectively, and the US\$7.3 million inventory fair value adjustment in full year FY19

² Excludes transaction and integration costs and inventory fair value adjustment

FINANCIAL SUMMARY

	Three Months and Full Year Ended 31 March										
US\$ Millions	Q4'19			Q4'18	% Change		FY19		FY18	% Change	
Net Sales											
North America Fiber Cement	\$	422.0	\$	410.1	3	\$	1,676.9	\$	1,578.1	6	
Asia Pacific Fiber Cement		102.3		105.1	(3)		446.8		425.4	5	
Europe Building Products		98.7		7.4			368.3		36.3		
Other Businesses		1.8		3.3	(45)		14.6		14.7	(1)	
Total Net Sales	\$	624.8	\$	525.9	19	\$	2,506.6	\$	2,054.5	22	
EBIT											
North America Fiber Cement ¹	\$	95.1	\$	103.4	(8)	\$	387.9	\$	381.9	2	
Asia Pacific Fiber Cement		20.5		26.3	(22)		99.8		108.1	(8)	
Europe Building Products ²		7.1		(0.3)			10.0		0.3		
Other Businesses ¹		(0.9)		(2.8)	68		(6.8)		(8.6)	21	
Research & Development		(7.1)		(7.3)	3		(29.0)		(27.8)	(4)	
General Corporate ³		(14.7)		(16.3)	10		(57.3)		(56.4)	(2)	
Adjusted EBIT	\$	100.0	\$	103.0	(3)	\$	404.6	\$	397.5	2	
Net interest expense ⁴	\$	(13.8)	\$	(8.8)	(57)	\$	(52.1)	\$	(31.4)	(66)	
Other income		-		0.5			0.1		0.7		
Adjusted income tax expense		(12.4)		(13.6)	9		(52.1)		(75.5)	31	
Adjusted net operating profit	\$	73.8	\$	81.1	(9)	\$	300.5	\$	291.3	3	

¹ Excludes product line discontinuation expenses

⁴ Excludes AICF interest income



² Includes Europe transaction and integration costs and inventory fair value adjustment

³ Excludes Asbestos related expenses and adjustments, and acquisition costs incurred prior to the close of Fermacell

NET POST-TAX UNFUNDED ASBESTOS LIABILITY

A\$ millions (except where stated)												
		FY19		FY18								
Central Estimate - Undiscounted and Uninflated	\$	1,399.8	\$	1,442.9								
Provision for claims handling costs of AICF		28.5		30.1								
Cross claims and other		35.1		33.8								
Net assets of AICF		(78.2)		(81.9)								
Effect of tax		(528.0)		(526.0)								
Net post-tax unfunded liability in A\$ millions	\$	857.2	\$	898.9								
Exchange rate A\$ to US\$		0.7096		0.7681								
Net post-tax unfunded liability in US\$ millions	\$	608.4	\$	690.4								




ASBESTOS CASH MOVEMENTS FOR FULL YEAR

A\$ millions	
AICF cash and investments - 31 March 2018	\$ 84.6
Contributions to AFFA by James Hardie	138.4
Insurance recoveries	6.6
Interest income, net	2.7
Claims paid	(147.5)
Operating costs	(3.7)
AICF cash and investments - 31 March 2019	\$ 81.1



UPDATED ACTUARIAL ESTIMATE





DEPRECIATION AND AMORTIZATION

US\$ Millions	Three Months and Full Year Ended 31 March									
	Q4'19		Q4'18		FY19			FY18		
Depreciation and amortization										
North America Fiber Cement	\$	21.7	\$	18.4	\$	80.2	\$	72.5		
Asia Pacific Fiber Cement		3.0		3.2		12.8		12.6		
Europe Building Products		4.5		-		18.7		0.1		
Other Businesses		0.6		0.5		2.3		2.1		
Research and Development		0.3		1.0		1.1		1.4		
General Corporate		0.6		0.3		4.3		3.3		
Total depreciation and amortization	\$	30.7	\$	23.4	\$	119.4	\$	92.0		



INCOME TAXES

- How ETR is calculated under US GAAP changed in FY19
 - Recorded a net deferred tax asset of US\$1,160.3 million arising from all previous intragroup transfers, including an internal restructuring which took place in Q4 FY18 to align certain intangible assets with our US business
 - Effective 1 April 2018, amortization of these intangible assets reduces the deferred tax asset instead of reducing income tax expense
- Economic (cash taxes paid) impact of tax expected to remain constant or improve
 - Future Adjusted ETR may be more volatile because of:
 - New US GAAP standards
 - Ongoing impacts of US Tax Reform



NON-US GAAP FINANCIAL MEASURES AND TERMS

This Management Presentation forms part of a package of information about the company's results. It should be read in conjunction with the other parts of this package, including the Management's Analysis of Results, Media Release and Consolidated Financial Statements

Definitions

EBIT – Earnings before interest and taxes

EBIT margin – EBIT margin is defined as EBIT as a percentage of net sales

Sales Volumes

mmsf – million square feet, where a square foot is defined as a standard square foot of 5/16" thickness

msf – thousand square feet, where a square foot is defined as a standard square foot of 5/16" thickness

Non-financial Terms

AFFA – Amended and Restated Final Funding Agreement

AICF – Asbestos Injuries Compensation Fund Ltd

<u>Legacy New Zealand weathertightness claims ("New Zealand weathertightness")</u> – Expenses arising from defending and resolving claims in New Zealand that allege poor building design, inadequate certification of plans, inadequate construction review and compliance certification and deficient work by sub-contractors

<u>New South Wales loan facility ("NSW Loan")</u> – AICF has access to a secured loan facility made available by the New South Wales Government, which can be used by AICF to fund the payment of asbestos claims and certain operating and legal costs



Financial Measures – US GAAP equivalents

This document contains financial statement line item descriptions that are considered to be non-US GAAP, but are consistent with those used by Australian companies. Because the company prepares its Consolidated Financial Statements under US GAAP, the following table cross-references each non-US GAAP line item description, as used in Management's Analysis of Results and Media Release, to the equivalent US GAAP financial statement line item description used in the company's Consolidated Financial Statements:

Management's Analysis of Results and	Consolidated Statements of Operations
Media Release	and Other Comprehensive Income (Loss)
	(US GAAP)

Net sales Net sales

Cost of goods sold
Gross profit
Gross profit
Gross profit

Selling, general and administrative expenses

Selling, general and administrative expenses

Research and development expenses Research and development expenses

Asbestos adjustments Asbestos adjustments

EBIT* Operating income (loss)

Net interest income (expense)* Sum of interest expense and interest income

Other income (expense) Other income (expense)

Operating profit (loss) before income taxes* Income (loss) before income taxes

Net operating profit (loss)* Net income (loss)

*- Represents non-US GAAP descriptions used by Australian companies.



Financial Measures – US GAAP equivalents

Adjusted EBIT

US\$ Millions	Three Months and Full Year Ended 31 March								
		Q4'19		Q4'18		FY19		FY18	
EBIT	\$	22.7	\$	(95.8)	\$	351.6	\$	229.2	
Asbestos:									
Asbestos adjustments		73.4		192.9		22.0		156.4	
AICF SG&A expenses		0.4		0.6		1.5		1.9	
Fermacell acquisition costs		-		5.3		-		10.0	
Product line discontinuation		3.5		-		29.5		-	
Adjusted EBIT	\$	100.0	\$	103.0	\$	404.6	\$	397.5	
Net sales		624.8		525.9		2,506.6		2,054.5	
Adjusted EBIT margin		16.0%		19.6%		16.1%		19.3%	

Adjusted net operating profit

US\$ Millions	Three Months and Full Year Ended 31 March									
		Q4'19		Q4'18		FY19		FY18		
Net operating profit	\$	0.8	\$	(57.6)	\$	228.8	\$	146.1		
Asbestos:										
Asbestos adjustments		73.4		192.9		22.0		156.4		
AICF SG&A expenses		0.4		0.6		1.5		1.9		
AICF interest income, net		(0.5)		(0.9)		(2.0)		(1.9)		
Loss on early debt extinguishment		-		-		1.0		26.1		
Fermacell acquisition costs		-		5.3		-		10.0		
Product line discontinuation		3.5		-		29.5		-		
Tax adjustments ¹		(3.8)		(59.2)		19.7		(47.3)		
Adjusted net operating profit	\$	73.8	\$	81.1	\$	300.5	\$	291.3		

¹ Includes tax adjustments related to the amortization benefit of certain US intangible assets, asbestos, product line discontinuation, loss on early debt extinguishment, and other tax adjustments



North America Fiber Cement Segment Adjusted EBIT excluding product line discontinuation

US\$ Millions	Three Months and Full Year Ende				
		Q4'19		FY19	
EBIT	\$	95.1	\$	382.5	
Product line discontinuation		-		5.4	
North America Fiber Cement Segment Adjusted EBIT excluding					
product line discontinuation	\$	95.1	\$	387.9	
North America Fiber Cement Segment net sales		422.0		1,676.9	
North America Fiber Cement Segment Adjusted EBIT margin excluding product line discontinuation		22.5%		23.1%	

Europe Building Products Segment Adjusted EBIT excluding costs associated with the acquisition

US\$ Millions	Thr	ee Months and 31 M	ll Year Ended า
		Q4'19	FY19
EBIT	\$	7.1	\$ 10.0
Inventory fair value adjustment		-	7.3
Transaction costs		-	7.2
Integration costs		4.1	14.6
Europe Building Products Segment Adjusted EBIT excluding costs			
associated with the acquisition	\$	11.2	\$ 39.1
Europe Building Products Segment net sales		98.7	368.3
Europe Building Products Segment Adjusted EBIT margin excluding			
costs associated with the acquisition		11.3%	10.6%



Adjusted diluted earnings per share

	Three Months and Full Year Ended 31 March									
	Q4'19 Q4'18 FY19 FY18									
Adjusted net operating profit (US\$ Millions)	\$ 73.8	\$ 81.1	\$ 300.5	\$ 291.3						
Weighted average common shares outstanding - Diluted (millions)	443.4	443.0	443.0	442.3						
Adjusted diluted earnings per share (US cents)	17	18	68	66						

Adjusted effective tax rate

US\$ Millions	Three Months and Full Year Ended 31 March								
		Q4'19		Q4'18	FY19			FY18	
Operating profit before income taxes	\$	9.4	\$	(103.2)	\$	300.6	\$	174.3	
Asbestos:									
Asbestos adjustments		73.4		192.9		22.0		156.4	
AICF SG&A expenses		0.4		0.6		1.5		1.9	
AICF interest income, net		(0.5)		(0.9)		(2.0)		(1.9)	
Fermacell acquisition costs		-		5.3		-		10.0	
Product line discontinuation		3.5		-		29.5		-	
Loss on early debt extinguishment		-		-		1.0		26.1	
Adjusted operating profit before income taxes	\$	86.2	\$	94.7	\$	352.6	\$	366.8	
Income tax expense		(8.6)		45.6		(71.8)		(28.2)	
Tax adjustments ¹		(3.8)		(59.2)		19.7		(47.3)	
Adjusted income tax expense	\$	(12.4)	\$	(13.6)	\$	(52.1)	\$	(75.5)	
Effective tax rate		91.5%		44.2%		23.9%		16.2%	
Adjusted effective tax rate		14.4%		14.4%		14.8%		20.6%	

¹ Includes tax adjustments related to the amortization benefit of certain US intangible assets, asbestos, product line discontinuation, loss on early debt extinguishment, and other tax adjustments



Adjusted EBITDA excluding Asbestos

US\$ Millions	Three Months and Full Year Ended 31 March									
	Q4'19			Q4'18		FY19		FY18		
EBIT	\$	22.7	\$	(95.8)	\$	351.6	\$	229.2		
Depreciation and amortization		30.7		23.4		119.4		92.0		
Adjusted EBITDA	\$	53.4	\$	(72.4)	\$	471.0	\$	321.2		
Asbestos:										
Asbestos adjustments		73.4		192.9		22.0		156.4		
AICF SG&A expenses		0.4		0.6		1.5		1.9		
Adjusted EBITDA excluding Asbestos	\$	127.2	\$	121.1	\$	494.5	\$	479.5		

Adjusted selling, general and administrative expenses ("Adjusted SG&A")

US\$ Millions	Three Months and Full Year Ended 31 March									
	Q4'19			Q4'18		FY19	FY18			
SG&A expenses	\$	102.3	\$	85.1	\$	403.6	\$	311.3		
Excluding:										
AICF SG&A expenses		(0.4)		(0.6)		(1.5)		(1.9)		
Fermacell acquisition costs		-		(5.3)		-		(10.0)		
Product line discontinuation		(0.7)		-		(2.1)		-		
Adjusted SG&A expenses	\$	101.2	\$	79.2	\$	400.0	\$	299.4		
Net sales		624.8		525.9		2,506.6		2,054.5		
SG&A expenses as a percentage of net sales		16.4%		16.2%		16.1%		15.2%		
Adjusted SG&A expenses as a percentage of net sales		16.2%		15.1%		16.0%		14.6%		



Adjusted Return on Capital Employed ("Adjusted ROCE")

US\$ Millions	Full Year Ended 31 March ¹						
		FY19		FY18			
Numerator							
Adjusted EBIT	\$	404.6	\$	397.5			
Denominator							
Gross capital employed (GCE)		1,492.7		1,272.0			
Adjustment to GCE		(77.4)		(24.3)			
Adjusted gross capital employed	\$	1,415.3	\$	1,247.7			
Adjusted Return on Capital Employed		28.6%		31.9%			





Q4 FY19 MANAGEMENT PRESENTATION 21 May 2019



James Hardie Industries plc Consolidated Financial Statements

as of and for the Period Ended 31 March 2019

James Hardie Industries plc Index

	Page
Report of Independent Registered Public Accounting Firm	<u>F-3</u>
Consolidated Balance Sheets as of 31 March 2019 and 2018	F-4
Consolidated Statements of Operations and Comprehensive Income for the Years Ended 31	Γ.
March 2019, 2018 and 2017	<u>F-5</u>
Consolidated Statements of Cash Flows for the Years Ended 31 March 2019, 2018 and 2017	F-6
Consolidated Statements of Changes in Shareholders' Equity (Deficit) for the Years Ended 31	Г 7
March 2019, 2018 and 2017	<u>F-7</u>
Notes to Consolidated Financial Statements	F-8

Report of Independent Registered Public Accounting Firm

To the Shareholders and the Board of Directors of James Hardie Industries plc

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of James Hardie Industries plc (the Company) as of 31 March 2019 and 2018, and the related consolidated statements of operations and comprehensive income, changes in shareholders' equity (deficit), and cash flows for each of the three years in the period ended 31 March 2019, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at 31 March 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended 31 March 2019, in conformity with U.S. generally accepted accounting principles.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ Ernst & Young LLP

We have served as the Company's auditor since 2008. Irvine, California 21 May 2019

James Hardie Industries plc Consolidated Balance Sheets

(Millions of US dollars)	3	31 March 2019		31 March 2018
Assets	,			
Current assets:				
Cash and cash equivalents	\$	78.7	\$	281.6
Restricted cash and cash equivalents		5.1		5.0
Restricted cash and cash equivalents - Asbestos		39.8		26.6
Restricted short-term investments - Asbestos		17.7		38.4
Accounts and other receivables, net of provision for doubtful trade debts of US\$2.9 million and US \$1.3 million as of 31 March 2019 and 31 March 2018		254.6		202.7
Inventories		317.4		255.7
Prepaid expenses and other current assets		31.3		25.4
Insurance receivable - Asbestos		7.5		5.
Workers' compensation - Asbestos		2.0		2.
Total current assets		754.1		842.6
Property, plant and equipment, net		1,388.4		992.
Goodwill		201.1		4.9
Intangible assets, net		174.4		12.3
Insurance receivable - Asbestos		43.7		52.8
Workers' compensation - Asbestos		25.8		28.8
Deferred income taxes		1,092.9		29.9
Deferred income taxes - Asbestos		349.3		382.9
Other assets		2.9		4.
Total assets	\$	4,032.6	\$	2,351.
Liabilities and Shareholders' Equity (Deficit)		4,002.0		2,001.0
Current liabilities:				
Accounts payable and accrued liabilities	\$	255.5	\$	193.0
Accrued payroll and employee benefits	<u> </u>	84.9	*	61.8
Accrued product warranties		6.8		7.3
Income taxes payable		13.4		3.2
Asbestos liability		110.5		114.
Workers' compensation - Asbestos		2.0		2.
Other liabilities		9.9		12.8
Total current liabilities		483.0		394.6
Long-term debt				884.4
		1,380.3		
Deferred income taxes		80.4		66.4
Accrued product warranties		39.8		45.5
Income taxes payable		25.2		25.9
Asbestos liability		979.1		1,101.0
Workers' compensation - Asbestos		25.8		28.8
Other liabilities		44.6		25.9
Total liabilities		3,058.2		2,572.5
Commitments and contingencies (Note 14)				
Shareholders' equity (deficit):				
Common stock, Euro 0.59 par value, 2.0 billion shares authorized; 442,269,905 shares issued and outstanding at 31 March 2019 and 441,524,118 shares issued and outstanding at 31 March 2018		230.0		229.
Additional paid-in capital		197.6		185.0
Accumulated equity (deficit)		577.1		(635.3
Accumulated other comprehensive loss		(30.3)		(1.3
Total shareholders' equity (deficit)		974.4		(221.5
Total liabilities and shareholders' equity (deficit)	\$	4,032.6	\$	2,351.0

James Hardie Industries plc Consolidated Statements of Operations and Comprehensive Income

(Millions of US dollars, except per share data) Net sales Cost of goods sold Gross profit Selling, general and administrative expenses Research and development expenses	2,506.6 (1,675.6)	2018 \$ 2,054.5	2017 \$ 1,921.6
Cost of goods sold Gross profit Selling, general and administrative expenses	(1,675.6)	•	\$ 1 921 6
Gross profit Selling, general and administrative expenses			Ψ 1,021.0
Selling, general and administrative expenses		(1,324.3)	(1,246.9)
	831.0	730.2	674.7
Research and develonment expenses	(403.6)	(311.3)	(291.6)
Noodardi ana advolopinoni oxpondos	(37.9)	(33.3)	(30.3)
Asset impairments	(15.9)	_	_
Asbestos adjustments	(22.0)	(156.4)	40.4
Operating income	351.6	229.2	393.2
Interest expense, net of capitalized interest	(54.2)	(32.9)	(28.5)
Interest income	4.1	3.4	1.0
Loss on early debt extinguishment	(1.0)	(26.1)	_
Other income	0.1	0.7	1.3
Income before income taxes	300.6	174.3	367.0
Income tax expense	(71.8)	(28.2)	(90.5)
Net income \$	228.8	\$ 146.1	\$ 276.5
Income per share:			
Basic \$	0.52	\$ 0.33	\$ 0.62
Diluted \$	0.52	\$ 0.33	\$ 0.62
Weighted average common shares outstanding (Millions):			
Basic	441.9	441.2	442.7
Diluted	443.0	442.3	443.9
Comprehensive income, net of tax:			
Net income \$	228.8	\$ 146.1	\$ 276.5
Cash flow hedges	(0.1)	_	_
Currency translation adjustments	(28.9)	0.9	(3.0)
Comprehensive income \$	199.8	\$ 147.0	\$ 273.5

James Hardie Industries plc Consolidated Statements of Cash Flows

Dispreciation and amortization in come to not can't provided by operating activities 1927 176.8	(Milliana of LO dellara)			rears	s Ended 31 March		004=
Net income	,		2019		2018		2017
Depreciation and amortization 1914 82.0 1915 191			200.0	•	440.4	•	070.5
Dependention and amortization 1914 92.0 1915 191		\$	228.8	\$	146.1	\$	276.5
Deference in come taxes			440.4		02.0		83.2
Stock-based compensation	·						26.0
Ecces ta benefits from share-based awards							9.3
Cases tax benefits from share-based awards							
Asset impairments	•		22.0				(40.4
Distance namy debit extinguishment 10			15.0		(0.8)		
Charry and other receivables in operating assets and labilities: Coccurries and other receivables (18.1) (2.0) Inventories (28.6) (3.1) (2.0) Inventories (28.6) (3.1) (2.0) Inventories (28.6) (3.1) (2.0) Insurance receivable - Asbestos (1.1) (2.8) Insurance receivable - Asbestos (1.9) (1.2) Insurance receivable - Asbestos (2.9) (1.2) Insurance receivable - Asbestos (2.9) (1.2) Insurance receivable - Asbestos (2.9) (1.2) Insurance receivable - Asbestos (1.0) (1.0) Insurance receivable - Asbestos	·				26.1		_
Case							15.0
Accounts and other receivebiles (2,8)			10.5		12.0		13.0
Prepaid expenses and other assets			(18.1)		(2.0)		(28.4
Proposition connector and other assets of the state insurance receivable - Astestics (1,12) (1,2)			• •				(9.7
Net cash used in investing activities 4,8 7,3 7,5							(2.1
Accounts payable and accrued liabilities			• • •		, ,		93.3
Claims and handling costs paid - Asbestos 100 km 10							39.6
Display Content Cont							(91.8
Other acorued liabilities 15.5 47.8 47.8 20.0 <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td>(2.7</td></th<>							(2.7
Net cash provided by operating activities \$ 287.6 \$ 300.00 \$ 100.00 Cash Flows From Investing Activities \$ (301.1) \$ (203.1) \$ (20	• •						17.7
Cash Flows From Investing Activities S 301.11 \$ 20.03.7 \$ 0 Purchases of property, plant and equipment - 7.9 -		•		Φ.		•	382.5
Purchases of property, plant and equipment \$ (301.1) \$ (203.7) \$ (203.7) Proceeds from sale of property, plant and equipment - 7.9 - Capitalized interest (558.7) (48.8) - Acquisition of business, net of cash acquired (558.7) - - Acquisition of business, net of cash acquired (558.7) - - Acquisition of business, net of cash acquired (89.1) - - Acquisition of business, net of cash acquired (89.1) - - Acquisition of business, net of cash acquired (89.1) - - Acquisition of business, net of cash acquired in the cash sections of the cash section of the cash section of restricted short-term investments. Asbestos (89.1) - - Proceeds from restricted short-term investments. Asbestos 8 (28.0) - </td <td></td> <td><u> </u></td> <td>207.0</td> <td>Ψ</td> <td>302.0</td> <td>Ψ_</td> <td>302.3</td>		<u> </u>	207.0	Ψ	302.0	Ψ_	302.3
Proceeds from sale of property, plant and equipment — 7.9 Capitalized interest (56.4) (4.8) Acquisition of business, net of cash acquired (58.7) — Acquisition of business, net of cash acquired — — Proceeds from restricted short-term investments - Asbestos (88.1) (78.2) Proceeds from restricted short-term investments - Asbestos (88.1) (80.2) * Proceeds from restricted short-term investments - Asbestos (80.8) (80.80) * (30.0) * Proceeds from from credit facilities \$ 20.0 \$ 38.0 \$<	•	¢	(301.1)	\$	(203.7)	¢	(101.9)
Acquisition of business, net of cash acquired (558.7) ————————————————————————————————————		Ψ	(301.1)	Ψ		Ψ	(101.5)
Acquisition of business, net of cash acquired (558.7) ————————————————————————————————————			(5.4)				(2.0)
Acquisition of assets G G G Purchase of restricted short-term investments - Asbestos (86.3) (76.4) Proceads from restricted short-term investments - Asbestos (86.4) (80.00) 40.00 Net cash used in investing activities (86.40) (80.40) (80.00) (80.00) Cash Flows From Financing Activities 80.00 (80.00) <td< td=""><td></td><td></td><td>• • •</td><td></td><td>(4.0)</td><td></td><td>(2.0)</td></td<>			• • •		(4.0)		(2.0)
Purchase of restricted short-term investments - Asbestos (89.1) (78.4) 70.00 70.00 10.00 20.00 3.00<			(000.1)				(5.1)
Proceeds from restricted short-term investing activities 106.3 40.0 2 </td <td>•</td> <td></td> <td>(89.1)</td> <td></td> <td>(78.4)</td> <td></td> <td>(0.1)</td>	•		(89.1)		(78.4)		(0.1)
Net cash used in investing activities \$ (848.0) \$ (230.0) <							_
Cash Flows From Financing Activities Proceeds from credit facilities \$ 230.0 \$ 380.0 \$ Repayments of credit facilities (180.0) (455.0) (65.0) Proceeds from 364-day term loan facility 492.4 — Proceeds from senior unsecured notes 458.8 800.0 Proceeds from senior unsecured notes (6.1) (15.7) Repayment of senior unsecured notes (6.1) (15.7) Repayment of senior unsecured notes — (400.0) Call redemption premium paid to note holders — (400.0) Call redemption premium paid to note holders — — Proceeds from issuance of shares — — Call redemption premium paid to note holders — — Proceeds from issuance of shares — — — Call redemption premium paid to note holders — — — Proceeds from issuance of shares — — — Call redemption share-based awards — — — Dividence is from issuance of shares — — <td></td> <td>•</td> <td></td> <td>\$</td> <td></td> <td>\$</td> <td>(109.0)</td>		•		\$		\$	(109.0)
Proceeds from credit facilities \$ 230.0 \$ 380.0 \$ 200.0 Repayments of credit facilities (180.0) (455.0) (7.00) Proceeds from 364-day term loan facility 492.4 — — Repayments of 364-day term loan facility 495.8 800.0 — Proceeds from senior unsecured notes 458.8 800.0 — Proceeds from senior unsecured notes — (400.0) — Repayment of senior unsecured notes — (400.0) — Call redemption premium paid to note holders — (19.5) — Proceeds from issuance of shares —	-		(040.0)		(255.0)	<u> </u>	(103.0
Repayments of credit facilities (1800) (455.0) Common Control Contro	•	\$	230.0	\$	380.0	\$	395.0
Proceeds from 364-day term loan facility 492.4 — <td></td> <td>•</td> <td></td> <td>Ψ</td> <td></td> <td>Ψ</td> <td>(410.0)</td>		•		Ψ		Ψ	(410.0)
Repayments of 364-day term loan facility (458.8) — Proceeds from senior unsecured notes 458.8 800.0 Debt issuance costs (6.1) (15.7) Repayment of senior unsecured notes — (400.0) Call redemption premium paid to note holders — (19.5) Proceeds from issuance of shares — — 0.2 Excess tax benefits from share-based awards — — — Common stock repurchased and retired — — — Common stock repurchased and retired (172.1) (177.5) — Proceeds from NSW Loan - Asbestos — — — Repayments of NSW Loan - Asbestos — — — Repayments of NSW Loan - Asbestos — — — Net cash provided by (used in) financing activities \$ 364.2 \$ 60.6 \$ Effects of exchange rate changes on cash and cash equivalents, restricted cash and restricted cash - Asbestos (189.6) 120.2 Net (decrease) increase in cash and cash equivalents, restricted cash - Asbestos at beginning of period 313.2 192.8 <tr< td=""><td></td><td></td><td></td><td></td><td>(400.0)</td><td></td><td>(410.0</td></tr<>					(400.0)		(410.0
Proceeds from senior unsecured notes 458.8 800.0 Debt issuance costs (6.1) (15.7) Repayment of senior unsecured notes — (400.0) Call redemption premium paid to note holders — (19.5) Proceeds from issuance of shares — 0 0.2 Excess tax benefits from share-based awards — — — Common stock repurchased and retired — (172.1) (177.5) — Common stock repurchased and retired — — — — Proceeds from NSW Loan - Asbestos — <td></td> <td></td> <td></td> <td></td> <td><u>_</u></td> <td></td> <td>_</td>					<u>_</u>		_
Debt issuance costs (6.1) (15.7) Repayment of senior unsecured notes — (400.0) Call redemption premium paid to note holders — (19.5) Proceeds from issuance of shares — 0.2 Excess tax benefits from share-based awards — — Common stock repurchased and retired — — Proceeds from NSW Loan - Asbestos — — Repayments of NSW Loan - Asbestos — (51.9) Net cash provided by (used in) financing activities \$ 364.2 \$ 60.6 \$ (5.2) Effects of exchange rate changes on cash and cash equivalents, restricted cash and restricted cash - Asbestos (189.6) 120.4 Asbestos \$ 6.6 \$ (3.2) \$ (3.2) Net (decrease) increase in cash and cash equivalents, restricted cash and restricted cash - Asbestos (189.6) 120.4 Cash and cash equivalents, restricted cash - Asbestos at beginning of period 313.2 192.8 Supplemental Disclosure of Cash Flow Activities \$ 57.0 \$ 26.3 \$ (3.2) Cash paid during the year for interest \$ 57.0 \$ 26.3 \$ 49.1							77.3
Repayment of senior unsecured notes — (400.0) Call redemption premium paid to note holders — (19.5) Proceeds from issuance of shares — 0.2 Excess tax benefits from share-based awards — — — — — — — — — — — — — — — — — — —							(1.7)
Call redemption premium paid to note holders Proceeds from issuance of shares Common stock repurchased awards Common stock repurchased and retired (172.1) (177.5)			(0.1)				(
Proceeds from issuance of shares — 0.2 Excess tax benefits from share-based awards — — Common stock repurchased and retired — — Dividends paid (172.4) (177.5) — Proceeds from NSW Loan - Asbestos — — — Repayments of NSW Loan - Asbestos — — — — Net cash provided by (used in) financing activities \$ 364.2 \$ 60.6 <t< td=""><td>• •</td><td></td><td>_</td><td></td><td></td><td></td><td></td></t<>	• •		_				
Excess tax benefits from share-based awards Common stock repurchased and retired Common stock repurchased in (172.1) Common stock repurchas			_				0.3
Common stock repurchased and retired			_		-		3.0
Dividends paid (172.1) (177.5)			_		_		(99.8)
Proceeds from NSW Loan - Asbestos Repayments of NSW Loan - Asbestos Net cash provided by (used in) financing activities Effects of exchange rate changes on cash and cash equivalents, restricted cash and restricted cash - Asbestos Net (decrease) increase in cash and cash equivalents, restricted cash and restricted cash - Asbestos Cash and cash equivalents, restricted cash - Asbestos at beginning of period Cash and cash equivalents, restricted cash and restricted cash - Asbestos at beginning of period Cash and cash equivalents, restricted cash and restricted cash - Asbestos at end of period Supplemental Disclosure of Cash Flow Activities Cash paid during the year for interest \$ 57.0 \$ 26.3 \$ Cash paid during the year for income taxes, net	·		(172.1)		(177.5)		(176.8)
Repayments of NSW Loan - Asbestos Net cash provided by (used in) financing activities Effects of exchange rate changes on cash and cash equivalents, restricted cash and restricted cash - Asbestos Net (decrease) increase in cash and cash equivalents, restricted cash and restricted cash - Asbestos Net (decrease) increase in cash and cash equivalents, restricted cash and restricted cash - Asbestos Cash and cash equivalents, restricted cash - Asbestos at beginning of period Cash and cash equivalents, restricted cash and restricted cash - Asbestos at end of period Supplemental Disclosure of Cash Flow Activities Cash paid during the year for interest \$ 57.0 \$ 26.3 \$ Cash paid during the year for income taxes, net			(,				77.0
Net cash provided by (used in) financing activities Effects of exchange rate changes on cash and cash equivalents, restricted cash and restricted cash - Asbestos Net (decrease) increase in cash and cash equivalents, restricted cash and restricted cash - Asbestos Cash and cash equivalents, restricted cash - Asbestos at beginning of period Cash and cash equivalents, restricted cash and restricted cash - Asbestos at end of period Cash and cash equivalents, restricted cash and restricted cash - Asbestos at end of period Supplemental Disclosure of Cash Flow Activities Cash paid during the year for interest \$ 57.0 \$ 26.3 \$ Cash paid during the year for income taxes, net			_		(51.9)		(74.3
Effects of exchange rate changes on cash and cash equivalents, restricted cash and restricted cash - Asbestos Net (decrease) increase in cash and cash equivalents, restricted cash and restricted cash - Asbestos Cash and cash equivalents, restricted cash - Asbestos at beginning of period Cash and cash equivalents, restricted cash and restricted cash - Asbestos at end of period Supplemental Disclosure of Cash Flow Activities Cash paid during the year for interest \$ 57.0 \$ 26.3 \$ Cash paid during the year for income taxes, net		\$	364.2	\$		\$	(210.0
Asbestos \$ 6.6 \$ (3.2) \$ Net (decrease) increase in cash and cash equivalents, restricted cash and restricted cash - Asbestos Cash and cash equivalents, restricted cash - Asbestos at beginning of period Cash and cash equivalents, restricted cash and restricted cash - Asbestos at end of period Cash and cash equivalents, restricted cash and restricted cash - Asbestos at end of period Supplemental Disclosure of Cash Flow Activities Cash paid during the year for interest \$ 57.0 \$ 26.3 \$ Cash paid during the year for income taxes, net		<u> </u>		Ť	00.0	Ť	(210.0
Cash and cash equivalents, restricted cash and restricted cash - Asbestos at beginning of period Cash and cash equivalents, restricted cash and restricted cash - Asbestos at end of period Supplemental Disclosure of Cash Flow Activities Cash paid during the year for interest Cash paid during the year for income taxes, net 192.8 313.2 \$ Supplemental Disclosure of Cash Flow Activities Cash paid during the year for income taxes, net \$ 57.0 \$ 26.3 \$ 49.1	Asbestos	\$	6.6	\$	(3.2)	\$	0.2
Cash and cash equivalents, restricted cash and restricted cash - Asbestos at end of period Supplemental Disclosure of Cash Flow Activities Cash paid during the year for interest \$ 57.0 \$ 26.3 \$ Cash paid during the year for income taxes, net \$ 26.3 \$ 49.1 \$	Net (decrease) increase in cash and cash equivalents, restricted cash and restricted cash - Asbestos		(189.6)		120.4		63.7
period\$ 123.6\$ 313.2\$Supplemental Disclosure of Cash Flow ActivitiesCash paid during the year for interest\$ 57.0\$ 26.3\$Cash paid during the year for income taxes, net\$ 26.3\$ 49.1\$	Cash and cash equivalents, restricted cash and restricted cash - Asbestos at beginning of period		313.2		192.8		129.1
Cash paid during the year for interest \$ 57.0 \$ 26.3 \$ Cash paid during the year for income taxes, net \$ 26.3 \$ 49.1 \$		\$	123.6	\$	313.2	\$	192.8
Cash paid during the year for income taxes, net \$ 26.3 \$ 49.1 \$	Supplemental Disclosure of Cash Flow Activities						
	Cash paid during the year for interest	\$	57.0	\$	26.3	\$	26.2
Cash paid to AICF \$ 103.0 \$ 102.2 \$	Cash paid during the year for income taxes, net	\$	26.3	\$	49.1	\$	51.5
	Cash paid to AICF	\$	103.0	\$	102.2	\$	91.1

James Hardie Industries plc Consolidated Statements of Changes in Shareholders' Equity (Deficit)

(Millions of US dollars)	nmon tock	Pa	litional aid-in apital	1)	umulated Deficit) Equity	Treasury Stock	Со	occumulated Other Imprehensive come (Loss)	Total
Balances as of 31 March 2016	\$ 231.4	\$	164.4	\$	(621.8)	\$ 	\$	0.8	\$ (225.2)
Net income	_		_		276.5	_		_	276.5
Other comprehensive loss	_		_		_	_		(3.0)	(3.0)
Stock-based compensation	0.9		8.4		_	_		_	9.3
Tax benefit from stock options exercised	_		3.0		_	_		_	3.0
Equity awards exercised	_		0.3		_	_		_	0.3
Dividends declared	_		_		(173.3)	_		_	(173.3)
Treasury stock purchased	_		_		_	(99.8)		_	(99.8)
Treasury stock retired	(3.2)		(2.3)		(94.3)	99.8		_	_
Balances as of 31 March 2017	\$ 229.1	\$	173.8	\$	(612.9)	\$ _	\$	(2.2)	\$ (212.2)
Net income					146.1	_			146.1
Other comprehensive income	_		_		_	_		0.9	0.9
Stock-based compensation	0.4		11.6		(0.9)	_		_	11.1
Equity awards exercised	_		0.2		_	_		_	0.2
Dividends declared	 		<u> </u>		(167.6)				 (167.6)
Balances as of 31 March 2018	\$ 229.5	\$	185.6	\$	(635.3)	\$ 	\$	(1.3)	\$ (221.5)
Net income	_				228.8	_		_	228.8
Other comprehensive loss	_		_		_	_		(29.0)	(29.0)
Stock-based compensation	0.5		12.0		_	_		_	12.5
Adoption of ASU 2016-16	_		_		1,160.3	_		_	1,160.3
Dividends declared					(176.7)	_			(176.7)
Balances as of 31 March 2019	\$ 230.0	\$	197.6	\$	577.1	\$ 	\$	(30.3)	\$ 974.4

1. Background and Basis of Presentation

Nature of Operations

James Hardie Industries plc ("JHI plc") manufactures and sells fiber cement, fiber gypsum and cement-bonded building products for interior and exterior building construction applications, primarily in the United States, Australia, Europe, New Zealand, the Philippines and Canada. On 3 April 2018, JHI plc completed the acquisition of German-based XI (DL) Holdings GmbH (n/k/a James Hardie Europe Holdings 2) and its subsidiaries (including, but not limited to, Fermacell GmbH (n/k/a James Hardie Europe GmbH)) (collectively, "Fermacell"). Fermacell manufactures and sells fiber gypsum and cement-bonded building products primarily in continental Europe.

Basis of Presentation

The consolidated financial statements represent the financial position, results of operations and cash flows of JHI plc and its wholly-owned subsidiaries and variable interest entity ("VIE"). Unless the context indicates otherwise, JHI plc and its direct and indirect wholly-owned subsidiaries and VIE (as of the time relevant to the applicable reference) are collectively referred to as "James Hardie", the "James Hardie Group" or the "Company". The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP"). The US dollar is used as the reporting currency.

Reporting Segments

During the first quarter of fiscal year 2019, the Company changed its reportable operating segments in conjunction with how information is evaluated by the Chief Operating Decision Maker ("CODM") for the purpose of assessing segment performance and allocation of resources. The Company has revised its historical segment information at 31 March 2018 and for the years ended 31 March 2018 and 2017 to be consistent with the current reportable segment structure. The change in reportable segments had no effect on the Company's financial position, results of operations or cash flows for the periods presented. See Note 18 for further details on segment reporting.

2. Summary of Significant Accounting Policies

Reclassifications

Within the consolidated balance sheet at 31 March 2018, the Company reclassified the *Intangible Assets, Net* and *Goodwill* balances of US\$12.3 million and US\$4.9 million, respectively, which were previously included in *Other Assets*, to conform to the current presentation.

Within the operating activities section of the consolidated statement of cash flows for the year ended 31 March 2017, the Company reclassified the change in the *Income Tax Payable* balance of US\$2.7 million which was previously included within a change in *Other Accrued Liabilities*, and separated these costs in the change in *Income Tax Payable* line item, to conform to the current presentation.

The Company adopted Accounting Standards Update ("ASU") No. 2016-18 starting with the fiscal year beginning 1 April 2018, which required *Restricted Cash and Restricted Cash - Asbestos* to be included in the starting and ending cash balances on the consolidated statements of cash flows. See Recent Accounting Pronouncements later in this footnote for further details on this accounting standard update, including all reclassifications made to the consolidated statements of cash flows for the years ended 31 March 2018 and 2017.

Principles of Consolidation

The consolidated financial statements of the Company include the accounts of JHI plc, its wholly-owned subsidiaries and VIE. All intercompany balances and transactions have been eliminated in consolidation.

A VIE is an entity that is evaluated for consolidation using more than a simple analysis of voting control. The analysis is based on: (i) what party has the power to direct the most significant activities of the VIE that impact its economic performance; and (ii) what party has rights to receive benefits or is obligated to absorb losses that are significant to the VIE. The analysis of the party that consolidates a VIE is a continual assessment.

In February 2007, the Company's shareholders approved the Amended and Restated Final Funding Agreement (the "AFFA"), an agreement pursuant to which the Company provides long-term funding to Asbestos Injuries Compensation Fund ("AICF"), a special purpose fund that provides compensation for the Australian-related personal injuries for which certain former subsidiary companies of James Hardie in Australia (being Amaca Pty Ltd ("Amaca"), Amaba Pty Ltd ("Amaba") and ABN 60 Pty Limited ("ABN 60") (collectively, the "Former James Hardie Companies")) are found liable. JHI plc owns 100% of James Hardie 117 Pty Ltd (the "Performing Subsidiary"), which, under the terms of the AFFA, has an obligation to make payments to AICF on an annual basis subject to the provisions of the AFFA. JHI plc guarantees the Performing Subsidiary's obligation. Additionally, the Company appoints three AICF directors and the New South Wales ("NSW") Government appoints two AICF directors.

Although the Company has no ownership interest in AICF, for financial reporting purposes, the Company consolidates AICF, which is a VIE as defined under US GAAP, due to its pecuniary and contractual interests in AICF as a result of the funding arrangements outlined in the AFFA. The Company's consolidation of AICF results in AICF's assets and liabilities being recorded on its consolidated balance sheets and AICF's income and expense transactions being recorded in the consolidated statements of operations and comprehensive income. These items are Australian dollar-denominated and are subject to remeasurement into US dollars at each reporting date.

For the fiscal years ended 31 March 2019, 2018 and 2017, the Company did not provide financial or other support to AICF that it was not previously contractually required to provide.

Use of Estimates

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

Foreign Currency Translation/Remeasurement

All assets and liabilities are translated or remeasured into US dollars at current exchange rates while revenues and expenses are translated or remeasured at average exchange rates in effect for the period. The effects of foreign currency translation adjustments are included directly in other comprehensive income in shareholders' equity (deficit). Gains and losses arising from foreign currency transactions are recognized in income currently.

The Company has recorded on its balance sheet certain foreign assets and liabilities, including asbestosrelated assets and liabilities under the terms of the AFFA, that are denominated in foreign currencies and

James Hardie Industries plc

Notes to Consolidated Financial Statements (continued)

subject to translation (foreign entities) or remeasurement (AICF entity and Euro denominated debt) into US dollars at each reporting date. Unless otherwise noted, the Company converts foreign currency denominated assets and liabilities into US dollars at the spot rate at the end of the reporting period; while revenues and expenses are converted using an average exchange rate for the period. Gains or losses resulting from transactions denominated in foreign currencies are included in *Selling, general and administrative expenses* in the consolidated statements of operations and comprehensive income, and may be offset by other transactions. The Company recorded a foreign exchange gain relating to its Euro denominated debt which was economically offset by a foreign exchange loss on loans between subsidiaries, resulting in a net translation gain of US\$2.9 million for the year ended 31 March 2019, which was recorded in *Selling, general and administrative expenses* in the consolidated statements of operations and comprehensive income.

Restricted Cash and Cash Equivalents

Restricted cash and cash equivalents generally relate to amounts subject to letters of credit with insurance companies, which restrict the cash from use for general corporate purposes.

Inventories

Inventories are valued at the lower of cost or net realizable value. Cost is generally determined under the first-in, first-out method, except that the cost of raw materials and supplies is determined using actual or average costs. Cost includes the costs of materials, labor and applied factory overhead. On a regular basis, the Company evaluates its inventory balances for excess quantities and obsolescence by analyzing demand, inventory on hand, sales levels and other information. Based on these evaluations, inventory costs are adjusted to net realizable value, if necessary.

Property, Plant and Equipment

Property, plant and equipment are stated at cost. Property, plant and equipment of businesses acquired are recorded at their estimated fair value at the date of acquisition. Depreciation of property, plant and equipment is computed using the straight-line method over the following estimated useful lives:

	Years
Buildings	10 to 50
Buildings Improvements	3 to 25
Leasehold Improvements	5 to 40
Machinery and Equipment	1 to 30

During the year ended 31 March 2019, the Company recorded impairment charges to Property, Plant and Equipment of US\$9.1 million.

See Note 8 for additional information.

Depreciation and Amortization

The Company records depreciation and amortization under both *Cost of goods sold* and *Selling, general* and administrative expenses, depending on the asset's business use. All depreciation and amortization related to plant building, machinery and equipment is recorded in *Cost of goods sold*.

Goodwill and Other Intangible Assets

Goodwill is the excess of purchase price over the fair value of tangible and identifiable intangible net assets acquired in various business combinations. Goodwill is not amortized but is tested at the reporting unit level for impairment annually, or more often if indicators of impairment exist. Factors that could cause an impairment in the future could include, but are not limited to, adverse macroeconomic conditions, deterioration in industry or market conditions, decline in revenue and cash flows or increases in costs and capital expenditures compared to projected results. A goodwill impairment charge is recorded for the amount by which the carrying value of the reporting unit exceeds the fair value of the reporting unit. During the year ended 31 March 2019, the Company recorded a goodwill impairment charge of US\$4.6 million in the Other Businesses segment due to the Company's decision to cease production of its fiberglass windows business. The Company did not record any goodwill impairment charges for the years ended 31 March 2018 and 2017.

Intangible assets from acquired businesses are recognized at their estimated fair values at the date of acquisition and consist of trademarks, customer relationships and other intangible assets. Finite-lived intangibles are amortized to expense over the applicable useful lives, ranging from 2 to 13 years, based on the nature of the asset and the underlying pattern of economic benefit as reflected by future net cash inflows. The Company performs an impairment test of intangibles annually, or whenever events or changes in circumstances indicate their carrying value may be impaired. During the year ended 31 March 2019, the Company recorded total impairment charges on amortizable intangible assets of US\$2.6 million. The Company did not record any intangible asset impairment charges for the years ended 31 March 2018 and 2017.

See Note 7 for additional information.

Impairment of Long-Lived Assets

Long-lived assets, such as property, plant and equipment, are evaluated each quarter for events or changes in circumstances that indicate that an asset might be impaired because the carrying amount of the asset may not be recoverable. These include, without limitation, a significant adverse change in the extent or manner in which a long-lived asset or asset group is being used, a current period operating or cash flow loss combined with a history of operating or cash flow losses, a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset or asset group and/or a current expectation that it is more likely than not that a long lived asset or asset group will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.

When such indicators of potential impairment are identified, recoverability is tested by grouping long-lived assets that are used together and represent the lowest level for which cash flows are identifiable and distinct from the cash flows of other long-lived assets, which is typically at the production line or plant facility level, depending on the type of long-lived asset subject to an impairment review.

Recoverability is measured by a comparison of the carrying amount of the asset group to the estimated undiscounted future cash flows expected to be generated by the asset group. If the carrying amount exceeds the estimated undiscounted future cash flows, an impairment charge is recognized at the amount by which the carrying amount exceeds the estimated fair value of the asset group.

The methodology used to estimate the fair value of the asset group is based on a discounted cash flow analysis that considers the asset group's highest and best use that would maximize the value of the asset group. In addition, the estimated fair value of an asset group also considers, to the extent practicable, a market participant's expectations and assumptions in estimating the fair value of the asset group. If the estimated fair value of the asset group is less than the carrying value, an impairment loss is recognized at an amount equal to the excess of the carrying value over the estimated fair value of the asset group.

See Notes 7 and 8 for additional information.

Accrued Product Warranties

An accrual for estimated future warranty costs is recorded based on an analysis by the Company, which includes the historical relationship of warranty costs to installed product at an estimated remediation cost per standard foot. Based on this analysis and other factors, the adequacy of the Company's warranty provision is adjusted as necessary.

Debt

The Company's debt consists of an unsecured revolving credit facility and senior unsecured notes. Each of the Company's debt instruments is recorded at cost, net of any original issue discount or premium, where applicable. The related original issue discount, premium and debt issuance costs are amortized over the term of each respective borrowing using the effective interest method. Debt is presented as current if the liability is due to be settled within 12 months after the balance sheet date, unless the Company has the ability and intention to refinance on a long term basis in accordance with US GAAP. Readers are referred to the discussion later in this footnote under Fair Value Measurements and Note 10 for the Company's fair value considerations.

In addition, the Company consolidates AICF which has a loan facility. Readers are referred to the discussion later in this footnote under Asbestos-related Accounting Policies.

Revenue Recognition

The Company recognizes revenues when the requisite performance obligation has been met, that is, when the Company transfers control of its products to customers, which depending on the terms of the underlying contract, is generally upon delivery. The Company records estimated reductions in sales for customer rebates and discounts including volume, promotional, cash and other discounts. Rebates and discounts are recorded based on management's best estimate when products are sold. The estimates are based on historical experience for similar programs and products. Management reviews these rebates and discounts on an ongoing basis and the related accruals are adjusted, if necessary, as additional information becomes available.

A portion of the Company's revenue is made through distributors under a vendor managed inventory agreement whereby revenue is recognized upon the transfer of title and risk of loss to the distributors.

See Note 3 for additional information.

Income Taxes

The Company accounts for income taxes under the asset and liability method. Under this method, deferred income taxes are recognized by applying enacted statutory rates applicable to future years to differences between the tax bases and financial reporting amounts of existing assets and liabilities. The effect on deferred taxes of a change in tax rates is recognized in income in the period that includes the enactment date. The realization of the US deferred tax assets is affected primarily by the continued profitability of the US business. A valuation allowance is provided when it is more likely than not that all or some portion of deferred tax assets will not be realized. Interest and penalties related to uncertain tax positions are recognized in Income tax expense on the consolidated statements of operations and comprehensive income. Readers are referred to Note 15 for further discussion of income taxes.

Financial Instruments

The Company calculates the fair value of financial instruments and includes this additional information in the notes to the consolidated financial statements. The estimated fair value amounts have been determined by the Company using available market information and appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop the estimates of fair value. Accordingly, the estimates presented herein are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts.

Periodically, interest rate swaps, commodity swaps and forward exchange contracts are used to manage market risks and reduce exposure resulting from fluctuations in interest rates, commodity prices and foreign currency exchange rates. Changes in the fair value of financial instruments that are not designated as hedges are recorded in earnings within *Other income* at each measurement date. The Company does not use derivatives for trading purposes. Readers are referred to Note 13 for further discussion on financial instruments.

Fair Value Measurements

Assets and liabilities of the Company that are carried or disclosed at fair value are classified in one of the following three categories:

- Level 1 Quoted market prices in active markets for identical assets and liabilities that the Company has the ability to access at the measurement date;
- Level 2 Observable market-based inputs or unobservable inputs that are corroborated by market data for the asset or liability at the measurement date;
- Level 3 Unobservable inputs that are not corroborated by market data used when there is minimal market activity for the asset or liability at the measurement date.

Fair value measurements of assets and liabilities are assigned a level within the fair value hierarchy based on the lowest level of any input that is significant to the fair value measurement in its entirety.

The carrying amounts of Cash and Cash Equivalents, Restricted cash and cash equivalents, Trade receivables, Trade payables and the Revolving Credit Facility approximates their respective fair values due to the short-term nature of these instruments.

Stock-based Compensation

Stock-based compensation expense represents the estimated fair value of equity-based and liability-classified awards granted to employees and is recognized as an expense over the vesting period. Stock-based compensation expense is included in the line item *Selling, general and administrative* expenses on the consolidated statements of operations and comprehensive income.

Equity awards with vesting based solely on a service condition are typically subject to graded vesting, in that the awards primarily vest 25% after the first year, 25% after the second year and 50% after the third year. For equity awards subject to graded vesting, the Company has elected to use the accelerated recognition method. Accordingly, each vesting tranche is valued separately, and the recognition of stock-based compensation expense is more heavily weighted earlier in the vesting period. Stock-based compensation expense for equity awards that are subject to performance or market vesting conditions are based upon an estimate of the number of awards that are expected to vest and typically recognized ratably over the vesting period. The Company issues new shares to award recipients when the vesting condition for restricted stock units ("RSU's") has been satisfied.

For RSU's subject to a service vesting condition, the fair value is equal to the market value of the Company's common stock on the date of grant, adjusted for the fair value of estimated dividends as the restricted stock holder is not entitled to dividends over the vesting period. For RSU's subject to a scorecard performance vesting condition, the fair value is adjusted for changes in JHI plc's common stock price at each balance sheet date until the end of the performance period. For RSU's subject to a market vesting condition, the fair value is estimated using a Monte Carlo Simulation.

Compensation expense recognized for liability-classified awards is based upon an estimate of the number of awards that are expected to vest and on the fair market value of JHI plc's common stock on the date of the grant. A corresponding liability is recorded and adjusted for subsequent changes in JHI plc's common stock price at each balance sheet date.

Earnings Per Share

The Company discloses basic and diluted earnings per share ("EPS"). Basic EPS is calculated using net income divided by the weighted average number of common shares outstanding during the period. Diluted EPS is similar to basic EPS except that the weighted average number of common shares outstanding is increased to include the number of additional common shares calculated using the treasury method that would have been outstanding if the dilutive potential common shares, such as stock options and RSUs, had been issued.

Basic and dilutive common shares outstanding used in determining net income per share are as follows:

	Years Ended 31 March		
(Millions of shares)	2019	2018	2017
Basic common shares outstanding	441.9	441.2	442.7
Dilutive effect of stock awards	1.1	1.1	1.2
Diluted common shares outstanding	443.0	442.3	443.9
(US dollars)	2019	2018	2017
Net income per share - basic	0.52	0.33	0.62
Net income per share - diluted	0.52	0.33	0.62

There were no potential common shares which would be considered anti-dilutive for the years ended 31 March 2019, 2018 and 2017.

Unless they are anti-dilutive, RSU's which vest solely based on continued employment are considered to be outstanding as of their issuance date for purposes of computing diluted EPS and are included in the calculation of diluted EPS using the Treasury Method. Once these RSU's vest, they are included in the basic EPS calculation on a weighted-average basis.

RSU's which vest based on performance or market conditions are considered contingent shares. At each reporting date prior to the end of the contingency period, the Company determines the number of contingently issuable shares to include in the diluted EPS calculation, as the number of shares that would be issuable under the terms of the RSU arrangement, if the end of the reporting period were the end of the contingency period. Once these RSU's vest, they are included in the basic EPS calculation on a weighted-average basis.

Potential common shares of 2.2 million, 1.6 million and 1.8 million for the years ended 31 March 2019, 2018 and 2017, respectively, have been excluded from the calculation of diluted common shares outstanding as they are considered contingent shares which are not expected to vest.

Asbestos-related Accounting Policies

Asbestos Liability

The amount of the asbestos liability has been recognized by reference to (but not exclusively based upon) the most recent actuarial estimate of projected future cash flows as calculated by KPMG Actuarial ("KPMGA"), who are engaged and appointed by AICF under the terms of the AFFA. Based on their assumptions, KPMGA arrived at a range of possible total future cash flows and calculated a central estimate, which is intended to reflect a probability-weighted expected outcome of those actuarially estimated future cash flows projected by KPMGA to occur through 2072.

The Company recognizes the asbestos liability in the consolidated financial statements by reference to (but not exclusively based upon) the undiscounted and uninflated central estimate. The Company considered discounting when determining the best estimate under US GAAP. The Company has recognized the asbestos liability by reference to (but not exclusively based upon) the central estimate as undiscounted on the basis that the timing and amounts of such cash flows are not fixed or readily determinable. The Company considered inflation when determining the best estimate under US GAAP. It is the Company's view that there are material uncertainties in estimating an appropriate rate of inflation over the extended period of the AFFA. The Company views the undiscounted and uninflated central estimate as the best estimate under US GAAP.

Adjustments in the asbestos liability due to changes in the actuarial estimate of projected future cash flows and changes in the estimate of future operating costs of AICF are reflected in the consolidated statements of operations and comprehensive income during the period in which they occur. Claims paid by AICF and claims-handling costs incurred by AICF are treated as reductions in the Asbestos liability balances.

Insurance Receivable

The insurance receivable recorded by the Company has been recognized by reference to (but not exclusively based upon) the most recent actuarial estimate of recoveries expected from insurance policies and insurance companies with exposure to the asbestos claims, as calculated by KPMGA. The assessment of recoveries is based on the expected pattern of claims against such policies less an allowance for credit risk based on credit agency ratings. The insurance receivable generally includes these cash flows as undiscounted and uninflated, however, where the timing of recoveries has been agreed with the insurer, the receivables are

recorded on a discounted basis. The Company records insurance receivables that are deemed probable of being realized.

Adjustments in the insurance receivable due to changes in the actuarial estimate, or changes in the Company's assessment of recoverability are reflected in the consolidated statements of operations and comprehensive income during the period in which they occur. Insurance recoveries are treated as a reduction in the insurance receivable balance.

Workers' Compensation

An estimate of the liability related to workers' compensation claims is prepared by KPMGA as part of the annual actuarial assessment. This estimate contains two components - amounts that will be met by a workers' compensation scheme or policy, and amounts that will be met by the Former James Hardie Companies.

The estimated liability is included as part of the asbestos liability and adjustments to the estimate are reflected in the consolidated statements of operations and comprehensive income during the period in which they occur. Amounts that are expected to be paid by the workers' compensation schemes or policies are recorded as workers' compensation receivable. Adjustments to the workers' compensation liability result in an equal adjustment in the workers' compensation receivable recorded by the Company and have no effect on the consolidated statements of operations and comprehensive income.

Restricted Cash and Cash Equivalents

Cash and cash equivalents of AICF are reflected as restricted assets, as the use of these assets is restricted to the settlement of asbestos claims and payment of the operating costs of AICF. Since cash and cash equivalents are highly liquid, the Company classifies these amounts as a current asset on the consolidated balance sheets.

Restricted Short-Term Investments

Short-term investments of AICF consist of highly liquid investments held in the custody of major financial institutions. All short-term investments are classified as available for sale and are recorded in the financial statements at fair value. The fair value of restricted short-term investments is based on quoted market prices using the specific identification method. Unrealized gains and losses on the fair value of these investments are included as a separate component of *Accumulated other comprehensive loss*. Realized gains and losses on short-term investments are recognized in *Other income* on the consolidated statements of operations and comprehensive income.

Short-Term Debt

AICF has access to a secured loan facility (the "AICF Loan Facility") made available by the NSW Government, which can be used by AICF to fund the payment of asbestos claims and certain operating and legal costs of AICF and Former James Hardie Companies (together, the "Obligors").

Interest accrues daily on amounts outstanding, is calculated based on a 365-day year and is payable monthly. AICF may, at its discretion, elect to accrue interest payable on amounts outstanding under the AICF Loan Facility on the date interest becomes due and payable.

Deferred Income Taxes

The Performing Subsidiary is able to claim a tax deduction for its contributions to AICF over a five-year period commencing in the year the contribution is incurred. Consequently, a deferred tax asset has been recognized equivalent to the anticipated tax benefit over the life of the AFFA.

Adjustments are made to the deferred income tax asset as adjustments to the asbestos-related assets and liabilities are recorded.

Asbestos Adjustments

The Asbestos adjustments reflected in the consolidated statements of operations and comprehensive income reflect the net change in the actuarial estimate of the asbestos liability and insurance receivables, and the change in the estimate of AICF claims handling costs. Additionally, as the asbestos-related assets and liabilities are denominated in Australian dollars, the reported values of these asbestos-related assets and liabilities in the Company's consolidated balance sheets in US dollars are subject to adjustment depending on the closing exchange rate between the two currencies at the balance sheet dates, the effect of which is also included in Asbestos adjustments in the consolidated statements of operations and comprehensive income.

Asbestos Impact on Statement of Cash Flows

Restricted cash and cash equivalents - Asbestos

The Restricted cash and cash equivalents held by AICF as recorded on the consolidated balance sheets was included in the total beginning and ending cash balance in the consolidated statements of cash flows. The movement in Restricted cash and cash equivalents - Asbestos was reflected in either the cash flows from operating activities, cash flows from investing activities or cash flows from financing activities sections of the consolidated statements of cash flows as described in detail below.

Asbestos Adjustments

The Asbestos adjustments as recorded on the consolidated statements of operations and comprehensive income (as described above) is presented as a reconciling item from net income to cash flows from operating activities in the consolidated statements of cash flows.

Asbestos Insurance Receivable

Proceeds from insurance claims by AICF are reflected in the cash flows from operating activities section of the consolidated statements of cash flows.

Asbestos Claims Paid

Asbestos claims paid by AICF are reflected in the cash flows from operating activities section of the consolidated statements of cash flows.

Restricted Short-Term Investments

Purchases or proceeds from short-term investments, made by AICF, are reflected in the cash flows from investing activities section of the consolidated statements of cash flows.

AICF Loan Facility

Any drawings, repayments, or payments of accrued interest under the AICF Loan Facility, made by AICF, are reflected in the cash flows from financing activities section of the consolidated statements of cash flows.

Business combinations

The Company accounts for acquired businesses using the acquisition method of accounting. This method requires that the purchase price be allocated to the identifiable assets acquired and liabilities assumed at their estimated fair values at the date of acquisition. The excess of the purchase price over the identifiable assets acquired and liabilities assumed is recorded as goodwill.

The fair values are determined by management, taking into consideration information supplied by management of the acquired entities, and other relevant information. Such information typically includes valuations obtained from independent appraisal experts, which management reviews and considers in its estimates of fair values. The valuations are generally based upon future cash flow projections for the acquired assets, discounted to present value. The determination of fair values requires significant judgment by management, particularly with respect to the value of identifiable intangible assets. This judgment could result in either a higher or lower value assigned to amortizable or depreciable assets. The impact could result in either higher or lower amortization and/or depreciation expense. Management's estimates of fair value are based upon assumptions believed to be reasonable, but due to the inherent uncertainty during the measurement period, which may be up to one year from the acquisition date, the Company records adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU No. 2014-09, which provides guidance requiring companies to recognize revenue depicting the transfer of goods or services to customers in amounts that reflect the payment to which a company expects to be entitled in exchange for those goods or services. ASU No. 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU No. 2014-09 was effective for annual reporting periods beginning after 15 December 2017, and interim periods within those years, with early adoption permitted for annual reporting periods beginning after 15 December 2016. The Company adopted ASU No. 2014-09 (and related clarifying guidance issued by the FASB) starting with the fiscal year beginning 1 April 2018 using a modified retrospective approach. As a result of adopting ASU No. 2014-09, the Company recorded no adjustment to the opening retained earnings as of 1 April 2018. The impact to revenues and related deferred revenue balances as a result of applying ASU No. 2014-09 was not material as of and for the year ended 31 March 2019. See Note 3 for further details.

In February 2016, the FASB issued ASU No. 2016-02, which provides guidance on the amount, timing, and uncertainty of cash flows arising from leases. The standard requires lessees to recognize lease assets and lease liabilities on the balance sheet and requires expanded disclosures about leasing arrangements. Lessor accounting will remain largely unchanged from current guidance, however ASU No. 2016-02 will provide improvements that are intended to align lessor accounting with the lessee model and with updated revenue recognition guidance. The amendments in ASU No. 2016-02 shall be applied on a modified retrospective basis, and are effective for fiscal years and interim periods within those years, beginning after 15 December 2018, with early adoption permitted. In July 2018, the FASB issued ASU No. 2018-11, which provided a second accepted transition method, which would allow companies to adopt the new lease standard as a cumulative-effect adjustment to the opening balance of retained earnings as of the beginning of the period of adoption, rather than at the beginning of the earliest period presented. The Company is in process implementing this guidance, including obtaining copies of all active leases, extracting and documenting key components of each lease, educating and training key stakeholders on this new accounting guidance and performing steps to ensure the population of leases is complete. The Company will adopt ASU No. 2016-02 (and related clarifying guidance issued by the FASB) starting with the fiscal year beginning 1 April 2019, using the second modified retrospective transition method outlined in ASU No. 2018-11, and is currently evaluating the impact of the guidance on its consolidated financial statements.

In October 2016, the FASB issued ASU No. 2016-16, which requires entities to recognize the income tax consequences of intra-entity transfers of assets other than inventory when the transfer occurs. The amendments in ASU No. 2016-16 are effective for fiscal years and interim periods within those years, beginning after 15 December 2017, with early adoption permitted. The amendments in ASU No. 2016-16 shall be applied on a modified retrospective basis, wherein the beginning retained earnings in the period in which the guidance is adopted should include a cumulative-effect adjustment to reflect the effects of applying the new guidance. The Company adopted ASU No. 2016-16 starting with the fiscal year beginning 1 April 2018, and recorded an increase in gross deferred income tax assets of US\$1,313.0 million, a valuation allowance of US\$148.2 million, a decrease in other assets of US\$4.5 million and a corresponding cumulative retained earnings adjustment of US\$1,160.3 million, resulting from the internal restructuring transaction implemented during the year ended 31 March 2018 relating to the alignment of certain intangible assets with its US business and from other internal restructuring transactions undertaken in prior years. The internal restructuring implemented during the year ended 31 March 2018 resulted in the establishment of US ownership of certain of the Company's fiber cement related trademarks, tradenames, patents, product and manufacturing technology and know-how, and other related intellectual property rights (collectively, intellectual property), owned and predominantly developed by one of the Company's Irish subsidiaries, and represent the primary fiber cement business value drivers of which the Company's US fiber cement business is a majority economic beneficiary. As a result of this internal restructure, the tax basis of this intellectual property was recognized at fair market value and is subject to amortization for US income tax purposes. The Company established a valuation allowance against the deferred tax asset for the intellectual property that has an indefinite life for US income tax purposes and is not subject to tax amortization.

In November 2016, the FASB issued ASU No. 2016-18, which requires the statement of cash flows to explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The Company adopted ASU No. 2016-18 starting with the fiscal year beginning 1 April 2018 and the amendments in ASU No. 2016-18 were applied on a retrospective basis for each period presented. In accordance with disclosure requirements of this new accounting standard, the impact of adoption on the consolidated statements of cash flows was as follows:

(Millions of US dollars)	As reported	ASU 2016-18 Adjustment	As adjusted
Cash and cash equivalents at the beginning of the period	\$ 78.9	\$ 113.9	\$ 192.8
Cash and cash equivalents at the end of the period	281.6	31.6	313.2
Restricted cash - Asbestos	95.2	(95.2)	_
Payment to AICF	(102.2)	102.2	
Asbestos liability	(104.4)	104.4	_
Asbestos claims paid	_	(104.4)	(104.4)
Net cash provided by operating activities	295.0	7.0	302.0
Purchase of investments - Asbestos		(78.4)	(78.4)
Proceeds from investments - Asbestos	_	40.0	40.0
Net cash used in investing activities	(200.6)	(38.4)	(239.0)
Repayments of NSW Loan - Asbestos		(51.9)	(51.9)
Net cash used in financing activities	112.5	(51.9)	60.6
Effects of exchange rate changes on cash	(4.2)	1.0	(3.2)

Year ended 31 March 2017

(Millions of US dollars)	As reported	ASU 2016-18 Adjustment	As adjusted
Cash and cash equivalents at the beginning of the period	\$ 107.1	\$ 22.0	\$ 129.1
Cash and cash equivalents at the end of the period	78.9	113.9	192.8
Restricted cash - Asbestos	0.9	(0.9)	_
Payment to AICF	(91.1)	91.1	<u>—</u>
Asbestos liability	(92.0)	92.0	_
Asbestos claims paid	_	(91.8)	(91.8)
Net cash provided by operating activities	292.1	90.4	382.5
Proceeds from NSW Loan - Asbestos		77.0	77.0
Repayments of NSW Loan - Asbestos	_	(74.3)	(74.3)
Net cash used in financing activities	(212.7)	2.7	(210.0)
Effects of exchange rate changes on cash	1.4	(1.2)	0.2

In January 2017, the FASB issued ASU No. 2017-01, which clarifies the definition of a business to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of either assets or of businesses. The Company adopted ASU No. 2017-01 starting with the fiscal year beginning 1 April 2018 and the adoption of this standard did not have a material impact on the consolidated financial statements.

In January 2017, the FASB issued ASU No. 2017-04, which removes step 2 from the goodwill impairment test. Under the new guidance, if a reporting unit's carrying amount exceeds it fair value, an entity will record an impairment charge based on that difference. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. The Company adopted ASU No. 2017-04 prospectively on 1 April 2018, and the adoption of this standard did not have a material impact on the consolidated financial statements.

In March 2018, the FASB issued ASU No. 2018-05, which provides the U.S. Securities and Exchange Commission Staff's guidance when preparing the initial accounting for the income tax effects of the US Tax Cuts and Jobs Act ("TCJ Act"), which was enacted on 22 December 2017. The staff guidance addresses the specific situation in which the initial accounting for certain income tax effects of the TCJ Act will not be complete at the time that financial statements are issued. ASU No. 2018-05 is effective for financial statements that include the reporting period in which the TCJ Act was enacted. Therefore, the Company implemented the guidance in ASU No. 2018-05 in its financial statements for the fiscal year ending 31 March 2018. The Company finalized the accounting for the effects of the TCJ Act during the quarter ended 31 December 2018, and recognized a discrete tax benefit of US\$1.8 million as a result of additional guidance provided by the Internal Revenue Service in respect to the application of Internal Revenue Code Section 162 (m). The Company also recognized insignificant tax effects due to the finalization of the one-time transition tax, the re-measurement of deferred tax assets and liabilities, and other impacts of the TCJ Act. The Company is electing to account for Global Intangible Low Tax Income in the year the tax is incurred.

In June 2018, the FASB issued ASU No. 2018-07, which expands the scope of Topic 718, Compensation-Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. The amendments in this ASU are effective for fiscal years beginning after 15 December 2018, and interim periods within that fiscal year, with early adoption permitted. The Company adopted ASU No. 2018-07 prospectively on 1 January 2019, and the adoption of this standard did not have a material impact on the Company's consolidated financial statements.

In July 2018, the FASB issued ASU No. 2018-09, which clarifies, corrects errors in, and makes minor improvements to a wide variety of topics in the Accounting Standards Codification ("ASC"). The transition and effective date of this guidance is based on the facts and circumstances of each amendment. Some of the amendments in ASU No. 2018-09 do not require transition guidance and were effective upon issuance of ASU No. 2018-09. The Company adopted these specific amendments during the three months ended 30 June 2018 and noted no material impact on its consolidated financial statements. However, many of the amendments do have transition guidance with effective dates for annual periods beginning after 15 December 2018. For these specific amendments, the Company will follow the specific transition guidance for each relevant amendment, and does not expect the adoption of these amendments to have a material impact on its consolidated financial statements.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Change to the Disclosure Requirements for Fair Value Measurement. ASU No. 2018-13 modifies the disclosure requirements by adding, removing, and modifying certain required disclosures for fair value measurements for assets and liabilities disclosed within the fair value hierarchy. The amendments

in the ASU are effective for fiscal years, and interim periods within those fiscal years, beginning after 15 December 2019, with early adoption permitted. The Company adopted ASU No. 2018-13 starting with fiscal year beginning 1 April 2018 and the adoption of this standard did not have a material impact on the Company's consolidated financial statements.

In August 2018, the FASB issued ASU No. 2018-15, which clarifies the accounting treatment for implementation costs incurred in a cloud computing arrangement that is a service contract. ASU No. 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The guidance provides criteria for determining which implementation costs to capitalize as an asset related to the service contract and which costs to expense. The amendments in ASU No. 2018-15 should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption, and are effective for fiscal years and interim periods within those years, beginning after 15 December 2019, with early adoption permitted. The Company adopted ASU No. 2018-15 on 1 July 2018 based on the prospective transition method, and the adoption of the standard did not have a material impact on the consolidated financial statements.

3. Revenues

The following represents the Company's disaggregated revenues for the years ended 31 March 2019, 2018 and 2017:

				Yea	r En	ided 31 March 2	2019			
(Millions of US dollars)		h America er Cement		sia Pacific er Cement	Ει	urope Building Products	В	Other usinesses	Co	onsolidated
Fiber cement revenues	\$	1,676.9	\$	446.8	\$	35.8	\$		\$	2,159.5
Fiber gypsum revenues		_		_		332.5		_		332.5
Other revenues		_		_		_		14.6		14.6
Total revenues	\$	1,676.9	\$	446.8	\$	368.3	\$	14.6	\$	2,506.6
	Year Ended 31 March 2018									
(Millions of US dollars)		h America er Cement		sia Pacific er Cement	Ει	urope Building Products	В	Other usinesses	Co	onsolidated
Fiber cement revenues	\$	1,578.1	\$	425.4	\$	36.3	\$	_	\$	2,039.8
Fiber gypsum revenues		_		_		_		_		_
Other revenues		_				<u> </u>		14.7		14.7
Total revenues	\$	1,578.1	\$	425.4	\$	36.3	\$	14.7	\$	2,054.5
				Yea	r En	ided 31 March 2	2017			
(Millions of US dollars)		h America er Cement		sia Pacific er Cement	Ει	urope Building Products	В	Other usinesses	Co	onsolidated
Fiber cement revenues	\$	1,493.4	\$	370.6	\$	41.2	\$	_	\$	1,905.2
Fiber gypsum revenues				_				_		_
Other revenues		_				_		16.4		16.4
Total revenues	\$	1,493.4	\$	370.6	\$	41.2	\$	16.4	\$	1,921.6

The process by which the Company recognizes revenues is similar across each of the Company's reportable segments and is described in further detail below. Fiber cement and fiber gypsum revenues are primarily generated from the sale of siding and various boards used in internal and external applications, as well as accessories. Fiber gypsum revenues also includes the sale of cement-bonded boards in the Europe Building Products segment. Other revenues in the Other Businesses segment are generated from the sale of fiberglass products and windows in North America.

The Company recognizes revenues when the requisite performance obligation has been met, that is, when the Company transfers control of its products to customers, which depending on the terms of the underlying contract, is generally upon delivery. The Company considers shipping and handling activities that it performs as activities to fulfill the sales of its products, with amounts billed for such costs included in net sales and the associated costs incurred for such services recorded in cost of sales, in accordance with the practical expedient provided by ASC 606.

Certain of the Company's customers receive discounts and rebates as sales incentives, amounts which are recorded as a reduction to revenue at the time the revenue is recognized. These amounts are an estimate recorded by the Company based on historical experience and contractual obligations, the underlying assumptions of which are periodically reviewed and adjusted by the Company as necessary.

The Company's contracts are generally short-term in nature, generally not exceeding twelve months, with payment terms varying by the type and location of products or services offered; however, the period of time between invoicing and when payment is due is not significant.

4. Cash and Cash Equivalents, Restricted Cash and Restricted Cash - Asbestos

The following table provides a reconciliation of *Cash and cash equivalents*, *Restricted cash and Restricted cash - Asbestos* reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows:

	31 March			1
(Millions of US dollars)		2019		2018
Cash and cash equivalents	\$	78.7	\$	281.6
Restricted cash		5.1		5.0
Restricted cash - Asbestos		39.8		26.6
Total cash and cash equivalents, restricted cash and restricted cash - Asbestos	\$	123.6	\$	313.2

Included in *Restricted cash* is US\$5.1 million and US\$5.0 million related to an insurance policy at 31 March 2019 and 2018, respectively, which restricts the cash from general corporate purposes.

Included in *Restricted cash - Asbestos* is US\$39.8 million and US\$26.6 million at 31 March 2019 and 2018, respectively. The use of these assets is restricted to the settlement of asbestos claims and for the payment of the operating costs of AICF.

5. Accounts and Other Receivables

Accounts and other receivables consist of the following components:

		larch		
(Millions of US dollars)		2019		2018
Trade receivables	\$	245.5	\$	196.9
Other receivables and advances		12.0		7.1
Provision for doubtful trade debts		(2.9)		(1.3)
Total accounts and other receivables	\$	254.6	\$	202.7

The collectability of accounts receivable, consisting mainly of trade receivables, is reviewed on an ongoing basis. A provision for doubtful trade debts is provided for known and estimated bad debts by analyzing specific customer accounts and assessing the risk of uncollectability based on insolvency, disputes or other collection issues.

The following are changes in the provision for doubtful trade debts:

			31 March	
(Millions of US dollars)	20	19	2018	2017
Balance at beginning of period	\$	1.3 \$	0.9	\$ 1.1
Adjustment to provision		2.8	0.6	(0.1)
Write-offs, net of recoveries		(1.2)	(0.2)	(0.1)
Balance at end of period	\$	2.9	1.3	\$ 0.9

6. Inventories

Inventories consist of the following components:

		31 March	
(Millions of US dollars)	2	019	2018
Finished goods	\$	235.0 \$	190.3
Work-in-process		7.3	8.1
Raw materials and supplies		88.8	65.3
Provision for obsolete finished goods and raw materials		(13.7)	(8.0)
Total inventories	\$	317.4 \$	255.7

As of 31 March 2019 and 2018, US\$32.9 million and US\$30.2 million, respectively, of the Company's finished goods inventory balance was held at vendor managed inventory locations.

7. Goodwill and Other Intangible Assets

Intangible assets from acquired businesses are recognized at their estimated fair values at the date of acquisition and consist of trademarks, customer relationships and other intangible assets. Finite-lived intangibles are amortized to expense over the applicable useful lives, ranging from 2 to 13 years, based on the nature of the asset and the underlying pattern of economic benefit as reflected by future net cash inflows. The Company performs an impairment test of intangibles annually, or whenever events or changes in circumstances indicate their carrying value may be impaired.

Indefinite-Lived Intangible Assets

The following are the changes in the carrying value of indefinite-lived intangible assets for the year ended 31 March 2019:

(Millions of US dollars)	Good	dwill ¹	Trade ı	names ²	С	Other ³
Balance - 31 March 2018	\$	4.9	\$	_	\$	7.4
Acquired during the period		220.0		126.8		_
Impairment		(4.6)		_		_
Foreign exchange impact		(19.2)		(10.7)		
Balance - 31 March 2019	\$	201.1	\$	116.1	\$	7.4

At 31 March 2019, Goodwill of US\$200.8 million and US\$0.3 million was included in the Europe Building Products segment and Asia Pacific Fiber Cement segment, respectively. At 31 March 2018, Goodwill of US\$4.6 million and US\$0.3 million was included in the Other Businesses segment and the Asia Pacific Fiber Cement segment, respectively. During the year ended 31 March 2019, the Company recorded a US\$4.6 million goodwill impairment charge in the Other Businesses segment due to the Company's decision to cease production of its fiberglass windows business. The Company did not record any goodwill impairment charges for the years ended 31 March 2018 and 2017.

Amortizable Intangible Assets

The following are the changes in the carrying value of amortizable intangible assets primarily held in the Europe Building Products segment for the year ended 31 March 2019:

(Millions of US dollars)	Gross Carrying Am	ount	Accumulated Amortization	Net Carrying Amount
Customer relationships:				
Balance - 31 March 2018	\$	— \$	_	\$
Acquired during the period		57.8	_	57.8
Amortization		_	(4.8)	(4.8)
Foreign exchange impact		(5.8)	0.5	(5.3)
Balance - 31 March 2019	\$	52.0 \$	(4.3)	\$ 47.7

² Trade names are included in the Europe Building Products segment at 31 March 2019.

Other indefinite-lived intangible assets are included in the North America Fiber Cement segment at 31 March 2019 and 2018.

(Millions of US dollars)	Gross Ca	arrying Amount	Accumulated Amortization and Impairment	Net C	arrying Amount
Other intangibles:					
Balance - 31 March 2018	\$	9.7	\$ (4.8)	\$	4.9
Acquired during the period		2.4	_		2.4
Amortization		_	(1.3)		(1.3)
Impairment		_	(2.6)		(2.6)
Foreign exchange impact		(0.3)	0.1		(0.2)
Balance - 31 March 2019	\$	11.8	\$ (8.6)	\$	3.2

The amortization of intangible assets was US\$6.1 million, US\$0.9 million and US\$0.8 million for the years ended 31 March 2019, 2018 and 2017, respectively.

During the year ended 31 March 2019, the Company recorded total impairment charges on amortizable intangible assets of US\$2.6 million. An impairment charge of US\$2.2 million was recorded to the intangible assets associated with the Other Businesses segment due to the Company's decision to cease production of its fiberglass windows business in the second quarter of fiscal year 2019. Also, the Company made the decision to exit its MCT product line, and as such, recorded an impairment charge in the North America Fiber Cement segment of US\$0.4 million on intangible assets associated with this product line. The Company did not record any intangible asset impairment charges for the years ended 31 March 2018 and 2017.

At 31 March 2019 and 2018, the weighted-average remaining useful life of the Company's amortizable intangible assets is as follows:

(In Years)	31 March 2019	31 March 2018
Customer Relationships	12.0	_
Other Intangibles	7.5	6.1
Total	11.7	6.1

At 31 March 2019, the estimated future amortization of intangible assets is as follows:

Years ended 31 March (Millions of US dollars):

2020	\$ 3.2
2021	2.8
2022	3.6
2023	4.4
2024	4.7

8. Property, Plant and Equipment

Property, plant and equipment consist of the following components:

(Millions of US dollars)					Machinery and	Construction in	
Cost or valuation:	Land		Buildings		Equipment	Progress ¹	Total
At 31 March 2017	\$ 69.5	\$	344.5	\$	1,175.7	\$ 56.6	\$ 1,646.3
Additions ²	_		7.9		83.8	126.1	217.8
Disposals ³	(1.4)		(5.6)		(24.3)	(3.6)	(34.9)
Exchange differences	0.1		_		0.9	(0.2)	0.8
At 31 March 2018	\$ 68.2	\$	346.8	\$	1,236.1	\$ 178.9	\$ 1,830.0
Additions	1.6		58.9		203.6	76.7	340.8
Acquisitions	19.2		44.1		159.5	7.5	230.3
Transfers ⁴	_		(6.0)		2.2	(6.5)	(10.3)
Disposals ³	(0.2)		(5.9)		(48.1)	(1.2)	(55.4)
Exchange differences	(5.0)		(5.1)		(45.7)	1.8	(54.0)
At 31 March 2019	\$ 83.8	\$	432.8	\$	1,507.6	\$ 257.2	\$ 2,281.4
				_			
Accumulated depreciation:							
At 31 March 2017	\$ _	\$	(128.0)	\$	(639.3)	\$ _	\$ (767.3)
Charge for the year	_		(11.3)		(77.6)	_	(88.9)
Disposals ³	_		1.9		16.6	_	18.5
Exchange differences	 		<u> </u>		(0.2)		(0.2)
At 31 March 2018	\$ _	\$	(137.4)	\$	(700.5)	\$ _	\$ (837.9)
Charge for the year	_		(14.6)		(95.0)	_	(109.6)
Transfers ⁴	_		0.8		3.7	_	4.5
Disposals ³	_		4.1		23.3	_	27.4
Exchange differences			3.2		19.4		22.6
At 31 March 2019	\$ <u> </u>	\$	(143.9)	\$	(749.1)	\$ 	\$ (893.0)
Net book amount:	_					_	
At 31 March 2018	\$ 68.2	\$	209.4	\$	535.6	\$ 178.9	\$ 992.1
At 31 March 2019	\$ 83.8	\$	288.9	\$	758.5	\$ 257.2	\$ 1,388.4

¹ Construction in progress is presented net of assets transferred into service.

Depreciation expense for the years ended 31 March 2019, 2018 and 2017 was US\$109.6 million, US\$88.9 million and US\$80.3 million, respectively.

² Additions include US\$5.4 million and US\$4.8 million of capitalized interest for the years ended 31 March 2019 and 2018, respectively.

The US\$28.0 million net book value of disposals in fiscal year 2019 includes US\$13.7 million of usage of replacement parts, US\$6.1 million of impairment due to the Company's decision to cease production of its fiberglass windows business, US\$2.6 million of impairment related to the discontinuance of its MCT product line, US\$0.4 million of impairment charges on individual assets and US\$5.2 million of disposals of assets no longer in use. The US\$16.4 million net book value of disposals in fiscal year 2018 includes US\$13.9 million of usage of replacement parts and US\$0.7 million of impairment charges on individual assets. The remaining net book value of disposals of US\$1.8 million is related to the disposal of assets no longer in use.

Transfers include the net book value of *Property, plant and equipment, net* associated with our fiberglass windows business, which was classified as held for sale at 31 March 2019. This net book value of US\$5.8 million was removed from *Property, plant and equipment, net* and was included in the *Prepaid expenses and other current assets* on the consolidated balance sheets at 31 March 2019

Impairment of Long-Lived Assets

The Company performs an asset impairment review on a quarterly basis in connection with its assessment of production capabilities and the Company's ability to meet market demand.

During the years ended 31 March 2019, 2018 and 2017, the Company recorded total impairment charges on property, plant and equipment of US\$9.1 million, US\$0.7 million and US\$0.5 million, respectively. An impairment charge of US\$8.7 million was recorded during the year ended 31 March 2019 associated with the Company's decision to cease production of its fiberglass windows business and to discontinue its MCT product line, which is included in *Asset impairments* on the consolidated statements of operations and comprehensive income. Other impairment charges related to individual assets of US\$0.4 million, US\$0.7 million and US\$0.5 million during years ended 31 March 2019, 2018 and 2017, respectively, were included in *Cost of goods sold* on the consolidated statements of operations and comprehensive income.

9. Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities consist of the following components:

	31 N	larch	
(Millions of US dollars)	2019		2018
Trade creditors	\$ 142.4	\$	111.8
Accrued interest	8.8		12.5
Other creditors and accruals	104.3		69.0
Total accounts payable and accrued liabilities	\$ 255.5	\$	193.3

10. Long-Term Debt

At 31 March 2019, the Company held two forms of debt: an unsecured revolving credit facility and senior unsecured notes due 2025, 2026 and 2028. At 31 March 2018, the Company had three forms of debt: an unsecured revolving credit facility; a 364-day term loan facility (the "Term Loan Facility"); and senior unsecured notes due 2025 and 2028. The effective weighted average interest rate on the Company's total debt was 4.4% and 4.7% at 31 March 2019 and 31 March 2018, respectively. The weighted average term of the unsecured revolving credit facility and senior unsecured notes, including undrawn facilities, was 6.3 years and 6.9 years at 31 March 2019 and 2018, respectively.

Unsecured Revolving Credit Facility

In December 2015, James Hardie International Finance Designated Activity Company ("JHIF") and James Hardie Building Products Inc. ("JHBP"), each a wholly-owned subsidiary of JHI plc, entered into a US\$500.0 million unsecured revolving credit facility (the "Revolving Credit Facility") with certain commercial banks and HSBC Bank USA, National Association, as administrative agent. The Revolving Credit Facility was initially set to expire in December 2020, however, in December 2017, the Revolving Credit Facility was amended to, among other things, extend the maturity date to December 2022. The size of the Revolving Credit Facility may be increased by up to US\$250.0 million through the exercise of an accordion option.

Debt issuance costs in connection with the Revolving Credit Facility are recorded as an offset to *Long-Term Debt* in the Company's consolidated balance sheets and are being amortized as interest expense using the effective interest method over the stated term of 5 years. At 31 March 2019 and 2018, the Company's total debt issuance costs have an unamortized balance of US\$2.6 million and US\$3.3 million, respectively.

The amount drawn under the Revolving Credit Facility was US\$150.0 million and US\$100.0 million at 31 March 2019 and 2018, respectively.

The effective weighted average interest rate on the Company's total outstanding Revolving Credit Facility was 4.3% and 3.2% at 31 March 2019 and 2018, respectively.

Borrowings under the Revolving Credit Facility bear interest at per annum rates equal to, at the borrower's option, either: (i) the London Interbank Offered Rate ("LIBOR") plus an applicable margin for LIBOR loans; or (ii) a base rate plus an applicable margin for base rate loans. The base rate is calculated as the highest of (x) the rate that the administrative agent announces from time to time as its prime lending rate, as in effect from time to time, (y) 1/2 of 1% in excess of the overnight Federal Funds Rate, and (z) LIBOR for an interest period of one month plus 1.00%. The applicable margin is calculated based on a pricing grid that in each case is linked to our consolidated net leverage ratio. For LIBOR Loans, the applicable margin ranges from 1.25% to 2.00%, and for base rate loans it ranges from 0.25% to 1.00%. The Company also pays a commitment fee of between 0.20% and 0.35% on the actual daily amount of the unutilized revolving loans. The applicable commitment fee percentage is based on a pricing grid linked to the Company's consolidated net leverage ratio.

In the event that JHIF's or James Hardie International Group Limited's ("JHIGL"), as applicable, long-term senior unsecured non-credit enhanced rating from each of Standard & Poor's Ratings Services ("S&P"), and Moody's Investors Service, Inc. ("Moody's") is at least BBB- from S&P, and at least Baa3 from Moody's, at JHIF's election, for new borrowings under the Revolving Credit Facility, an alternate applicable rate may be applied with respect to the commitment fee of 0.25% per annum and an alternative margin may be applied with respect to: (a) LIBOR Loans, 1.50%; and (b) base rate loans, 0.50%.

The Revolving Credit Facility is guaranteed by each of JHIGL and James Hardie Technology Limited ("JHTL"), each of which are wholly-owned subsidiaries of JHI plc.

The Revolving Credit Facility agreement contains certain covenants that, among other things, restrict JHIGL and its restricted subsidiaries' ability to incur indebtedness and grant liens other than certain types of permitted indebtedness and permitted liens, make certain restricted payments, and undertake certain types of mergers or consolidations actions. In addition, the Company: (i) must not exceed a maximum ratio of net debt to earnings before interest, tax, depreciation and amortization, excluding all asbestos-related liabilities, assets, income, gains, losses and charges other than AICF payments, all AICF selling, general and administrative ("SG&A") expenses, all Australian Securities and Investment Commission ("ASIC")-related expenses, all recoveries and asset impairments, and all New Zealand product liability expenses and (ii) must meet or exceed a minimum ratio of earnings before interest, tax, depreciation and amortization to interest charges, excluding all income, expense and other profit and loss statement impacts of asbestos income, gains, losses and charges, all AICF SG&A expenses, all ASIC-related expenses, all recoveries and asset impairments, and all New Zealand product liability expenses. At 31 March 2019, the Company was in compliance with all covenants contained in the Revolving Credit Facility agreement.

Term Loan Facility

In December 2017, JHIF and JHBP entered into the Term Loan Facility with certain commercial banks and HSBC Bank USA, National Association, as administrative agent. On 3 April 2018, the Company drew €400.0 million (US\$492.4 million based on the exchange rate on 3 April 2018) on this Term Loan Facility, and used these funds to complete the Fermacell acquisition. On 3 October 2018, JHIF repaid all €400.0 million aggregate principal amount and accrued interest of its Term Loan Facility following the completion of the sale of €400.0 million (US\$458.8 million, based on the exchange rate at 3 October 2018) aggregate principal amount of 3.625% senior unsecured notes due 2026. In connection with this repayment, the Company

recorded a loss on early debt extinguishment of US\$1.0 million during the year ended 31 March 2019 associated with the unamortized portion of the deferred financing fees.

2026 Senior Notes

In October 2018, JHIF completed the sale of €400.0 million (US\$449.4 million, based on the exchange rate at 31 March 2019) aggregate principal amount of senior unsecured notes due 1 October 2026 (the "2026 Notes"). The 2026 Notes were issued at par and the proceeds from the offering were used to repay the outstanding borrowings under the Term Loan Facility, and to pay related transaction fees and expenses.

Debt issuance costs in connection with the 2026 Notes are recorded as an offset to *Long-Term Debt* on the Company's consolidated balance sheet.

Debt issuance costs in connection with the 2026 Notes have an unamortized balance of US\$5.7 million at 31 March 2019. The debt issuance costs are being amortized as interest expense using the effective interest method over the stated term of 8 years. Interest is payable semi-annually in arrears on 1 October and 1 April of each year at a rate of 3.625% with first payment made on 1 April 2019.

The 2026 Notes are guaranteed by JHIGL, JHBP and JHTL, each of which are wholly-owned subsidiaries of JHI plc.

The indenture governing the 2026 Notes contains covenants that, among other things, limit the ability of the guarantors and their restricted subsidiaries to incur liens on assets, make certain restricted payments, engage in certain sale and leaseback transactions and merge or consolidate with or into other companies. These covenants are subject to certain exceptions and qualifications as described in the indenture. At 31 March 2019, the Company was in compliance with all of its requirements under the indenture related to the 2026 Notes.

The Company's 2026 Notes have an estimated fair value of US\$456.9 million (based on EUR/USD exchange rate at 31 March 2019) based on the trading price observed in the market at or near the balance sheet date and are categorized as Level 1 within the fair value hierarchy.

2023 Senior Notes

In February 2015, JHIF completed the sale of US\$325.0 million aggregate principal amount of 5.875% senior unsecured notes due 15 February 2023.

In July 2016, JHIF completed the re-offering and sale of an additional US\$75.0 million aggregate principal amount of its 5.875% senior notes due 2023. Following the completion of this re-offering, the aggregate principal amount of senior notes due in 2023 was US\$400.0 million.

In December 2017, JHIF redeemed all US\$400.0 million aggregate principal amount of its 5.875% senior notes due 2023. In connection with this redemption, the Company recorded a loss on early debt extinguishment of US\$26.1 million during the year ended 31 March 2018, which included US\$19.5 million of call redemption premiums and US\$6.6 million of unamortized financing costs associated with these notes.

2025 and 2028 Senior Notes

In December 2017, JHIF completed the sale of US\$800.0 million aggregate principal amount of senior unsecured notes. The sale of the senior notes were issued at par with US\$400.0 million due 15 January 2025 (the "2025 Notes") and the remaining US\$400.0 million due 15 January 2028 (the "2028 Notes").

The proceeds from the offering were used for general corporate purposes, including funding the redemption of all US\$400.0 million aggregate principal amount of its 2023 senior unsecured notes and the payment of related transaction fees and expenses, the repayment of outstanding borrowings under the Revolving Credit Facility and capital expenditures. The Company also used part of the net proceeds from this offering to finance a portion of the Fermacell acquisition. Refer to Note 20 for further details on the Fermacell acquisition.

Debt issuance costs in connection with the 2025 and 2028 Notes are recorded as an offset to *Long-Term Debt* on the Company's consolidated balance sheets.

Debt issuance costs in connection with the 2025 Notes have an unamortized balance of US\$5.2 million and US\$6.1 million at 31 March 2019 and 2018, respectively. The debt issuance costs are being amortized as interest expense using the effective interest method over the stated term of 7 years. Interest is payable semi-annually in arrears on 15 January and 15 July of each year at a rate of 4.75% with first payment made on 15 July 2018.

Debt issuance costs in connection with the 2028 Notes have an unamortized balance of US\$5.6 million and US\$6.2 million at 31 March 2019 and 2018, respectively. The debt issuance costs are being amortized as interest expense using the effective interest method over the stated term of 10 years. Interest is payable semi-annually in arrears on 15 January and 15 July of each year at a rate of 5.00% with first payment made on 15 July 2018.

The 2025 and 2028 Notes are guaranteed by JHIGL, JHBP and JHTL, each of which are wholly-owned subsidiaries of JHI plc.

The indenture governing the 2025 and 2028 Notes contains covenants that, among other things, limit the ability of the guarantors and their restricted subsidiaries to incur liens on assets, make certain restricted payments, engage in certain sale and leaseback transactions and merge or consolidate with or into other companies. These covenants are subject to certain exceptions and qualifications as described in the indenture. At 31 March 2019, the Company was in compliance with all of its requirements under the indenture related to the 2025 and 2028 Notes.

The Company's 2025 and 2028 Notes have an estimated fair value of US\$774.0 million at 31 March 2019, based on the trading price observed in the market at or near the balance sheet date and are categorized as Level 1 within the fair value hierarchy.

Off Balance Sheet Arrangements

As of 31 March 2019, the Company had a total borrowing base capacity under the Revolving Credit Facility of US\$500.0 million with outstanding borrowings of US\$150.0 million, and US\$9.5 million of drawn letters of credit and bank guarantees. These letters of credit and bank guarantees relate to various operational matters including insurance, performance bonds and other items, leaving the Company with US\$340.5 million of available borrowing capacity under the Revolving Credit Facilities.

Global Exchange Market Listing

On 7 February 2019, the 2026 Notes of €400.0 million were admitted to listing on the Global Exchange Market ("GEM") which is operated by Euronext Dublin. Interest paid on the senior notes quoted on the GEM is not subject to Irish withholding tax.

On 25 April 2018, the 2025 and 2028 Notes of US\$800.0 million were admitted to listing on the GEM. Interest paid on the senior notes quoted on the GEM is not subject to Irish withholding tax. On 19 January 2018, the 5.875% senior notes due 2023 (issued on 10 February 2015 and redeemed in December 2017) were delisted from the GEM.

11. Product Warranties

The Company offers various warranties on its products, including a 30-year limited warranty on certain fiber cement siding products in the United States. A typical warranty program requires the Company to replace defective products within a specified time period from the date of sale. It is possible that future warranty costs could differ from those estimates.

The following are the changes in the product warranty provision:

		31 Mar	ch	
(Millions of US dollars)	2019	2018	1	2017
Balance at beginning of period	\$ 52.8	\$	46.6	\$ 45.3
(Decrease) increase for product warranties accrual	(0.8)		13.1	17.0
Acquired during the period	0.5		_	_
Settlements made in cash or in kind	(5.9)		(6.9)	(15.7)
Balance at end of period	\$ 46.6	\$	52.8	\$ 46.6

12. Asbestos

The AFFA was approved by shareholders in February 2007 to provide long-term funding to AICF. For a discussion of the AFFA and the accounting policies utilized by the Company related to the AFFA and AICF, see Note 2.

Asbestos Adjustments

The Asbestos adjustments included in the consolidated statements of operations and comprehensive income comprise the following:

		Years Ended 31 March							
(Millions of US dollars)	;	2019	2018	2017					
Change in estimates:	, ,								
Change in actuarial estimate - asbestos liability	\$	(73.8) \$	(152.1) \$	44.7					
Change in actuarial estimate - insurance receivable		_	1.2	(8.2)					
Change in estimate - AICF claims-handling costs		1.1	(0.5)	2.1					
Subtotal - Change in estimates		(72.7)	(151.4)	38.6					
Effect of foreign exchange on Asbestos net liabilities		49.5	(5.3)	2.8					
(Loss) gain on foreign currency forward contracts		(8.0)	1.4	(1.0)					
Adjustments in insurance receivable		2.0	_	_					
Asbestos research and education contribution			(1.1)						
Total Asbestos Adjustments	\$	(22.0) \$	(156.4) \$	40.4					

James Hardie Industries plc

Notes to Consolidated Financial Statements (continued)

In December 2017, the Company, AICF and the NSW Government executed an AFFA Amending Deed which in effect excludes the recovery of gratuitous services costs (colloquially referred to as Sullivan v Gordon damages) that arose following the promulgation of the Wrongs (Part VB) (Dust and Tobacco-Related Claims) Regulation 2016 by the State of Victoria. As a result of the amendment, AICF reduced the Asbestos liability by A\$56.8 million (US\$43.6 million based upon the exchange rate at 31 March 2018) in the third quarter of fiscal year 2018. This adjustment is reflected in *Asbestos adjustments* in the consolidated statements of operations and comprehensive income during the year ended 31 March 2018.

Actuarial Study; Claims Estimate

AICF commissioned an updated actuarial study of potential asbestos-related liabilities as of 31 March 2019. Based on KPMGA's assumptions, KPMGA arrived at a range of possible total cash flows and calculated a central estimate, which is intended to reflect a probability-weighted expected outcome of those actuarially estimated future cash flows.

The following table sets forth the central estimates, net of insurance recoveries, calculated by KPMGA as of 31 March 2019:

	Year Ended 31 M	March 2019		
(Millions of US and Australian dollars, respectively)	US\$	A\$		
Central Estimate – Discounted and Inflated	1,325.9	1,868.4		
Central Estimate – Undiscounted but Inflated	1,574.3	2,218.5		
Central Estimate – Undiscounted and Uninflated	993.3	1,399.8		

The asbestos liability has been revised to reflect the most recent undiscounted and uninflated actuarial estimate prepared by KPMGA as of 31 March 2019.

In estimating the potential financial exposure, KPMGA has made a number of assumptions, including, but not limited to, assumptions related to the total number of claims that are reasonably estimated to be asserted through 2072, the typical cost of settlement (which is sensitive to, among other factors, the industry in which a plaintiff claims exposure, the alleged disease type, the age of the claimant and the jurisdiction in which the action is brought), the legal costs incurred in the litigation of such claims, the rate of receipt of claims, the settlement strategy in dealing with outstanding claims and the timing of settlements.

Due to inherent uncertainties in the legal and medical environment, the number and timing of future claim notifications and settlements, the recoverability of claims against insurance contracts, and estimates of future trends in average claim awards, as well as the extent to which the above named entities will contribute to the overall settlements, the actual liability could differ materially from that which is currently recorded.

The potential range of costs as estimated by KPMGA is affected by a number of variables such as nil settlement rates, peak year of claims, past history of claims numbers, average settlement rates, past history of Australian asbestos-related medical injuries, current number of claims, average defense and plaintiff legal costs, base wage inflation and superimposed inflation. The potential range of losses disclosed includes both asserted and unasserted claims.

A sensitivity analysis performed by KPMGA to determine how the actuarial estimates would change if certain assumptions (i.e., the rate of inflation and superimposed inflation, the average costs of claims and legal fees, and the projected numbers of claims) were different from the assumptions used to determine the central estimates. The sensitivity analysis performed in the actuarial report is specifically in regards to the discounted but inflated central estimate. This analysis shows that

the discounted (but inflated) central estimates could be in a range of A\$1.4 billion (US\$1.0 billion) to A\$3.1 billion (US\$2.2 billion). The undiscounted (but inflated) estimates could be in a range of A\$1.6 billion (US\$1.1 billion) to A\$3.9 billion (US\$2.8 billion) as of 31 March 2019. The actual cost of the liabilities could be outside of that range depending on the results of actual experience relative to the assumptions made.

During fiscal year 2019, mesothelioma claims reporting activity was favorable compared to actuarial expectations and the prior corresponding period. One of the more significant assumptions is the estimated peak period of mesothelioma disease claims, which was assumed to have occurred during the period 1 April 2014 through 31 March 2017. In fiscal year 2018, KPMGA formed the view that the increases in the mesothelioma claims reporting seen in recent years was a permanent effect, and therefore increased the projected number of future mesothelioma claims at 31 March 2018. The revised KPMGA modeling approach for mesothelioma claims considered the claimant's age which resulted in a higher number of projected claims, partially offset by a reduction in projected average claim size.

At 31 March 2019, KPMGA has formed the view that although the mix of claimants by age was slightly favorable relative to expectations, at this time it is too early to reflect changes to the valuation adjustments given that 2018/2019 was the first year of the new model. However, changes to the valuation assumptions may be necessary in future periods should mesothelioma claims reporting escalate or decline.

Potential variation in the estimated peak period of claims has an impact much greater than the other assumptions used to derive the discounted central estimate. In performing the sensitivity assessment of the estimated incidence pattern reporting for mesothelioma, if the pattern of incidence was shifted by two years, the central estimate could increase by approximately 19% on a discounted basis.

Claims Data

The following table shows the activity related to the numbers of open claims, new claims and closed claims during each of the past five years and the average settlement per settled claim and case closed:

	For the Years Ended 31 March									
	2019	2018	2017	2016	2015					
Number of open claims at beginning of period	336	352	426	494	466					
Number of new claims	568	562	557	577	665					
Number of closed claims	572	578	631	645	637					
Number of open claims at end of period	332	336	352	426	494					
Average settlement amount per settled claim	A\$262,108	A\$253,431	A\$223,535	A\$248,138	A\$254,209					
Average settlement amount per case closed	A\$234,156	A\$217,038	A\$167,563	A\$218,900	A\$217,495					
Average settlement amount per settled claim	US\$191,236	US\$196,093	US\$168,300	US\$182,763	US\$222,619					
Average settlement amount per case closed	US\$170,842	US\$167,934	US\$126,158	US\$161,229	US\$190,468					

Under the terms of the AFFA, the Company has rights of access to actuarial information produced for AICF by the actuary appointed by AICF, which is currently KPMGA. The Company's disclosures with respect to claims statistics are subject to it obtaining such information, however, the AFFA does not provide the Company an express right to audit or otherwise require independent verification of such information or the methodologies to be adopted by the approved actuary. As such, the Company relies on the accuracy and completeness of the information provided by AICF to the approved actuary and the resulting information and analysis of the approved actuary when making disclosures with respect to claims statistics.

Asbestos-Related Assets and Liabilities

The Company has included on its consolidated balance sheets the asbestos-related assets and liabilities of AICF under the terms of the AFFA. These amounts are detailed in the table below, and the net total of these asbestos-related assets and liabilities is referred to by the Company as the "Net AFFA Liability."

	31 March				
(Millions of US dollars)	2019	2018			
Asbestos liability – current	\$ (110.5)	\$	(114.1)		
Asbestos liability – non-current	(979.1)		(1,101.0)		
Asbestos liability – Total	(1,089.6)		(1,215.1)		
Insurance receivable – current	7.5		5.1		
Insurance receivable – non-current	43.7		52.8		
Insurance receivable – Total	 51.2		57.9		
Workers' compensation asset – current	2.0		2.1		
Workers' compensation asset – non-current	25.8		28.8		
Workers' compensation liability – current	(2.0)		(2.1)		
Workers' compensation liability – non-current	(25.8)		(28.8)		
Workers' compensation – Total	_		_		
Other net liabilities	(2.1)		(2.2)		
Restricted cash and cash equivalents of AICF	39.8		26.6		
Restricted short-term investments of AICF	17.7		38.4		
Net Unfunded AFFA liability	\$ (983.0)	\$	(1,094.4)		
Deferred income taxes – non-current	349.3		382.9		
Income tax payable	25.3		21.1		
Net Unfunded AFFA liability, net of tax	\$ (608.4)	\$	(690.4)		

The following is a detailed rollforward of the Net Unfunded AFFA liability, net of tax, for the year ended 31 March 2019:

(Millions of US dollars)	Asbestos Liability	Insurance Receivables	Restricted Cash and Investments	Other Assets and Liabilities	Net Unfunded AFFA Liability	Deferred Tax Assets	Income Tax Payable	Net Unfunded AFFA Liability, net of tax
Opening Balance - 31 March 2018	\$ (1,215.1)	\$ 57.9	\$ 65.0	\$ (2.2)	\$ (1,094.4)	\$ 382.9	\$ 21.1	\$ (690.4)
Asbestos claims paid ¹	107.6	_	(107.6)	_	_	_	_	_
Payment received in accordance with AFFA ²	_	_	103.0	_	103.0	_	_	103.0
AICF claims-handling costs incurred (paid)	1.2	_	(1.2)	_	_	_	_	_
AICF operating costs paid - non claims-handling	_	_	(1.5)	_	(1.5)	_	_	(1.5)
Change in actuarial estimate	(73.9)	_	_	_	(73.9)	_	_	(73.9)
Change in claims handling cost estimate	1.1	_	_	_	1.1	_	_	1.1
Impact on deferred income tax due to change in actuarial estimate	_	_	_	_	_	21.2	_	21.2
Insurance recoveries	_	(2.5)	4.8	_	2.3	_	_	2.3
Movement in income tax payable	_	_	_	_	_	(26.0)	5.2	(20.8)
Other movements	_	_	1.6	_	1.6	(0.2)	(0.3)	1.1
Effect of foreign exchange	89.5	(4.2)	(6.6)	0.1	78.8	(28.6)	(0.7)	49.5
Closing Balance - 31 March 2019	\$ (1,089.6)	\$ 51.2	\$ 57.5	\$ (2.1)	\$ (983.0)	\$ 349.3	\$ 25.3	\$ (608.4)

¹ Claims paid of US\$107.6 million reflects A\$147.5 million converted at the average exchange rate for the period based on the assumption that these transactions occurred evenly throughout the period.

AICF Funding

We anticipate that we will make a contribution of approximately US\$100.9 million to AICF on 1 July 2019. This amount represents 35% of our free cash flow which is equivalent to our operating cash flows of US\$287.6 million plus an adjustment of US\$0.8 million, resulting in free cash flow of US\$288.4 million for fiscal year 2019, as defined by the AFFA.

The following table summarizes the AICF contributions during the fiscal years 2019, 2018 and 2017:

Payment Date	Payment Amount A\$ Millions	Payment Amount US\$ Millions	Operating Cash flow US\$ Millions	Free Cash Flow US\$ Millions
2 July 2018	138.4	103.0	295.0	294.2
3 July 2017	135.1	102.2	292.1	292.1
1 July 2016	120.7	91.1	260.4	260.4

The payment received in accordance with AFFA of US\$103.0 million reflects the US dollar equivalent of the A\$138.4 million payment, translated at the exchange rate set five days before the day of payment.

Restricted Short-Term Investments

In July 2017, AICF invested A\$100.0 million of its excess cash in time deposits. During the year ended 31 March 2018, A\$50.0 million of these time deposits matured and were reclassified to *Restricted cash and cash equivalents - Asbestos* on the consolidated balance sheet. During the year ended 31 March 2019, the remaining time deposits of A\$50.0 million matured and were reclassified to *Restricted cash and cash equivalents - Asbestos* on the consolidated balance sheets.

In July 2018, AICF invested A\$120.0 million of its excess cash in time deposits. During the year ended 31 March 2019, A\$95.0 million of these time deposits matured and were classified to *Restricted cash and cash equivalents - Asbestos* on the consolidated balance sheet. The remaining time deposits of A\$25.0 million (US\$17.7 million, based on the exchange rate at 31 March 2019) bear a fixed interest rate of 2.5% and mature on 31 May 2019. These time deposits are reflected within *Restricted short-term investments - Asbestos* on the consolidated balance sheet as of 31 March 2019 and have been classified as available-for-sale. At 31 March 2019, AICF's short-term investments were revalued resulting in a mark-to-market fair value adjustment of nil.

AICF - NSW Government Secured Loan Facility

AICF may borrow, subject to certain conditions, up to an aggregate amount of A\$320.0 million (US\$227.1 million, based on the exchange rate at 31 March 2019). The AICF Loan Facility is available to be drawn for the payment of claims through 1 November 2030, at which point, all outstanding borrowings must be repaid. Borrowings made under the AICF Loan Facility are classified as current, as AICF intends to repay the debt within one year.

At 31 March 2019 and 2018, AICF had an outstanding balance under the AICF Loan Facility of nil.

To the extent the NSW Government sources funding for the AICF Loan Facility from the Commonwealth of Australia (the "Commonwealth"), the interest rate on the AICF Loan Facility is calculated by reference to the cost of NSW's borrowings from the Commonwealth for that purpose, being calculated with reference to the Commonwealth Treasury fixed coupon bond rate for a period determined as appropriate by the Commonwealth.

To the extent that NSW's source of funding is not from the Commonwealth, the interest rate on drawings under the AICF Loan Facility is calculated as (i) during the period to (but excluding) 1 May 2020, a yield percent per annum calculated at the time of the first drawdown of the AICF Loan Facility by reference to the NSW Treasury Corporation's 6% 1/05/2020 Benchmark Bonds, (ii) during the period after 1 May 2020, a yield percent per annum calculated by reference to NSW Treasury Corporation bonds on issue at that time and maturing in 2030, or (iii) in any case, if the relevant bonds are not on issue, a yield percent per annum in respect of such other source of funding for the AICF Loan Facility determined by the NSW Government in good faith to be used to replace those bonds, including any guarantee fee payable to the Commonwealth in respect of the bonds (where the bonds are guaranteed by the Commonwealth) or other source of funding.

Under the AICF Loan Facility, the Former James Hardie Companies each guarantee the payment of amounts owed by AICF and AICF's performance of its obligations under the AICF Loan Facility. Each Obligor has granted the NSW Government a security interest in certain property including cash accounts, proceeds from insurance claims, payments remitted by the Company to AICF and contractual rights under certain documents including the AFFA. Each Obligor may not deal with the secured property until all amounts outstanding under the AICF Loan Facility are paid, except as permitted under the terms of the security interest.

Under the terms of the AICF Loan Facility, each Obligor must, upon receipt of proceeds from insurance claims and payments remitted by the Company under the AFFA, apply all of such proceeds in repayment of amounts owing under the AICF Loan Facility. NSW may, at its sole discretion, waive or postpone (in such manner and for such period as it determines) the requirement for the Obligors to apply proceeds of insurance claims and payments remitted by the Company to repay amounts owed under the AICF Loan Facility to ensure AICF has sufficient liquidity to meet its future cash flow needs.

The Obligors are subject to certain operating covenants under the AICF Loan Facility and the terms of the security interest, including, without limitation, (i) positive covenants relating to providing corporate reporting documents, providing particular notifications and complying with the terms of the AFFA, and (ii) negative covenants restricting them from voiding, cancelling, settling, or adversely affecting existing insurance policies, disposing of assets and granting security to secure any other financial indebtedness, other than in accordance with the terms and conditions of the AICF Loan Facility.

Upon an event of default, NSW may cancel the commitment and declare all amounts outstanding as immediately due and payable. The events of default include, without limitation, failure to pay or repay amounts due in accordance with the AICF Loan Facility, breach of covenants, misrepresentation, cross default by an Obligor and an adverse judgment (other than a personal asbestos or Marlew claim) against an Obligor.

13. Derivative Instruments

Interest Rate Swaps

The fair value of interest rate swap contracts is calculated based on the fixed rate, notional principal, settlement date and present value of the future cash inflows and outflows based on the terms of the agreement and the future floating interest rates as determined by a future interest rate yield curve. The model used to value the interest rate swap contracts is based upon well recognized financial principles, and interest rate yield curves can be validated through readily observable data by external sources. Although readily observable data is used in the valuations, different valuation methodologies could have an effect on the estimated fair value. Accordingly, the interest rate swap contracts are categorized as Level 2 within the fair value hierarchy.

For interest rate swap contracts, the Company has agreed to pay fixed interest rates while receiving a floating interest rate. At 31 March 2019 and 2018, the Company had interest rate swap contracts with total notional principal of US\$75.0 million and US\$100.0 million, respectively.

At 31 March 2019, the weighted average fixed interest rate of these contracts is 2.2% and the weighted average remaining life is 0.8 years. These contracts have a fair value of US\$0.3 million at 31 March 2019, and US\$0.4 million at 31 March 2018, which are included in *Accounts and other receivables*. For the years ended 31 March 2019, 2018 and 2017, the Company included in *Other income* an unrealized gain of nil, US\$1.5 million and US\$2.6 million, respectively, on interest rate swap contracts. Also included in *Other income* for the years ended 31 March 2019, 2018 and 2017 was a realized gain on interest rate swap contracts of US\$0.1 million, a realized loss of US\$0.8 million and a realized loss US\$1.3 million, respectively.

Foreign Currency Forward Contracts

The Company's foreign currency forward contracts are valued using models that maximize the use of market observable inputs including interest rate curves and both forward and spot prices for currencies and are categorized as Level 2 within the fair value hierarchy. At 31 March 2019, the Company did not have any foreign currency forward contracts.

For the years ended 31 March 2019 and 2018, the forward contracts not designated as a cash flow hedging arrangement had an unrealized gain of nil.

The notional amount of interest rate swap contracts and foreign currency forward contracts represents the basis upon which payments are calculated and are reported on a net basis when a legal and enforceable right of set-off exists. The following table sets forth the total outstanding notional amount and the fair value of the Company's derivative instruments held at 31 March 2019 and 2018.

						Fair Value as of						
(Millions of US dollars)		Notional Amount				31 Marc	ch 2	2019	31 March 2018			
	31 Ma	rch 2019	31 March 2018			Assets		Liabilities		Assets		Liabilities
Derivatives not accounted for as hedges												
Interest rate swap contracts	\$	75.0	\$	100.0	\$	0.3	\$	_	\$	0.4	\$	_
Foreign currency forward contracts		_		0.8		_		_		_		_
Total	\$	75.0	\$	100.8	\$	0.3	\$		\$	0.4	\$	

14. Commitments and Contingencies

The Company is involved from time to time in various legal proceedings and administrative actions related to the normal conduct of its business, including general liability claims, putative class action lawsuits and litigation concerning its products.

Although it is impossible to predict the outcome of any pending legal proceeding, management believes that such proceedings and actions should not, individually or in the aggregate, have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows, except as they relate to asbestos and New Zealand product liability claims as described in these consolidated financial statements.

New Zealand Weathertightness Claims

Since fiscal year 2002, the Company's New Zealand subsidiaries have been joined in a number of weathertightness claims in New Zealand that relate to residential buildings (single dwellings and apartment complexes) and a small number of non-residential buildings, primarily constructed from 1998 to 2004. The claims often involve multiple parties and allege that losses were incurred due to excessive moisture penetration of the buildings' structures. The claims typically include allegations of poor building design, inadequate certification of plans, inadequate construction review and compliance certification and deficient work by sub-contractors.

The Company recognizes a liability for asserted New Zealand weathertightness claims in the period in which the loss becomes probable and estimable. The amount of reasonably possible loss is dependent on a number of factors including, without limitation, the specific facts and circumstances unique to each claim brought against the Company's subsidiaries, the existence of any co-defendants involved in defending the claim, the solvency of such co-defendants (including the ability of such co-defendants to remain solvent until the related claim is ultimately resolved), the availability of claimant compensation under a government compensation scheme, the amount of loss estimated to be allocable to the Company's subsidiaries and the extent to which the co-defendants and the Company's subsidiaries have access to third-party recoveries to cover a portion of the costs incurred in defending and resolving such actions. In addition to the above limitations, the total loss incurred is also dependent on the manner and extent to which statutory limitation periods will apply to any received claims.

James Hardie Industries plc

Notes to Consolidated Financial Statements (continued)

Historically, the Company's New Zealand subsidiaries have been joined to these claims as one of several co-defendants, including local government entities responsible for enforcing building codes and practices, resulting in the Company's New Zealand subsidiaries becoming liable for only a portion of each claim. In addition, the Company's New Zealand subsidiaries have had access to third-party recoveries to defray a portion of the costs incurred in resolving such claims. However, in 2015 the Company's New Zealand subsidiaries were named as the sole defendants in four claims on behalf of multiple defendants, each of which allege that the New Zealand subsidiaries' products were inherently defective. In two of these claims, three non-New Zealand Subsidiaries and the Company were named as defendants along with the two New Zealand subsidiaries and their direct New Zealand holding company.

The Company has established a provision for asserted New Zealand weathertightness claims within the current portion of *Other liabilities*, with a corresponding estimated receivable for third-party recoveries being recognized within *Accounts and other receivables*.

To the extent that it is probable and estimable, the estimated loss for these matters, net of estimated third-party recoveries, incorporates assumptions that are subject to the foregoing uncertainties and are principally derived from, but not exclusively based on, historical claims experience together with facts and circumstances unique to each claim. If the nature and extent of the resolution of claims in future periods differ from the historical claims experience, then the actual amount of loss may be materially higher or lower than estimated losses accrued at 31 March 2019.

Environmental and Legal

The operations of the Company, like those of other companies engaged in similar businesses, are subject to a number of laws and regulations on air and water quality, waste handling and disposal. The Company's policy is to accrue for environmental costs when it is determined that it is probable that an obligation exists and the amount can be reasonably estimated.

Operating Leases and Commitments

The following table summarizes contractual obligations and commitments as of 31 March 2019:

Years ending 31 March (Millions of US dollars):	2020	2021	2022		2023	2024	Thereafter	Total
Operating leases ¹	\$ 18.4 \$	15.3	\$ 11.	7 \$	7.5 \$	5.1	\$ 8.2	\$ 66.2
Purchase commitments ²	0.4	0.4	0.4	4	0.4	0.4	8.2	10.2
Capital commitments ³	5.2	_	_	_	_	_	_	5.2

¹ Future lease payments for non-cancellable operating leases having a remaining term in excess of one year at 31 March 2019. As the lessee, the Company principally enters into property, building and equipment leases.

Rental expense amounted to US\$30.7 million, US\$20.6 million and US\$18.4 million for the years ended 31 March 2019, 2018 and 2017, respectively.

² Represents unconditional purchase obligations that include agreements to purchase goods or services, primarily gypsum, that are enforceable and legally binding on us and that specify all significant terms, including fixed or minimum quantities to be purchased, fixed, minimum or variable price provisions, and approximate timing of the transaction. Purchase obligations exclude agreements that are cancellable without penalty.

³ Represents total outstanding purchase obligations under purchase orders as of 31 March 2019 in connection with future capital expenditures in connection with our capacity expansion projects.

15. Income Taxes

Income tax expense includes income taxes currently payable and those deferred because of temporary differences between the financial statement and tax bases of assets and liabilities. Income tax expense consists of the following components:

	Years Ended 31 March					
(Millions of US dollars)	2	019	201	8	2017	
Income before income taxes:						
Domestic	\$	196.4	\$	155.1	\$	172.2
Foreign		104.2		19.2		194.8
Income before income taxes:	\$	300.6	\$	174.3	\$	367.0
Income tax expense:						
Current:						
Domestic	\$	(26.6)	\$	(14.8)	\$	(15.2)
Foreign		(6.5)		(69.4)		(36.0)
Current income tax expense		(33.1)		(84.2)		(51.2)
Deferred:						
Domestic		(1.3)		(1.8)		(4.0)
Foreign		(37.4)		57.8		(35.3)
Deferred income tax (expense) benefit		(38.7)		56.0		(39.3)
Total income tax expense	\$	(71.8)	\$	(28.2)	\$	(90.5)

Income tax expense computed at the statutory rates represents taxes on income applicable to all jurisdictions in which the Company conducts business, calculated at the statutory income tax rate in each jurisdiction multiplied by the pre-tax income attributable to that jurisdiction.

Income tax expense is reconciled to the tax at the statutory rates as follows:

	Years Ended 31 March				
(Millions of US dollars)		2019	2018		2017
Income tax expense computed at the statutory tax rates	\$	(48.9)	\$ (24.6)	\$	(84.4)
US state income taxes, net of the federal benefit		(3.1)	(4.3)		(3.0)
Asbestos - effect of foreign exchange		14.9	(1.8)		0.8
Expenses not deductible		(4.9)	(4.7)		(2.5)
US manufacturing deduction		_	2.5		2.2
Foreign taxes on domestic income		(34.5)	(34.2)		(2.1)
Amortization of intangibles		_	12.4		2.8
Taxes on foreign income		4.5	(3.0)		(5.4)
Net deferred tax liability revaluation		0.2	27.7		_
Other items		_	1.8		1.1
Total income tax expense	\$	(71.8)	\$ (28.2)	\$	(90.5)
Effective tax rate		23.9%	16.2%		24.7%

Deferred tax balances consist of the following components:

	31 March			
(Millions of US dollars)		2019		2018
Deferred tax assets:				
Intangible assets	\$	1,209.8	\$	_
Asbestos liability		349.3		382.9
Other provisions and accruals		55.6		37.7
Net operating loss carryforwards		69.9		25.5
Foreign and research tax credit carryforwards		115.5		126.1
Total deferred tax assets		1,800.1		572.2
Valuation allowance		(267.6)		(129.6)
Total deferred tax assets net of valuation allowance		1,532.5		442.6
Deferred tax liabilities:				
Depreciable and amortizable assets		(132.2)		(81.6)
Other		(38.5)		(14.6)
Total deferred tax liabilities		(170.7)		(96.2)
Total deferred taxes, net	\$	1,361.8	\$	346.4

21 March

The Company adopted ASU No. 2016-16 starting with the fiscal year beginning 1 April 2018, and recorded an increase in gross deferred income tax assets of US\$1,313.0 million, a valuation allowance of US\$148.2 million and a decrease in other assets of US\$4.5 million. The deferred income tax asset is a result of the internal restructuring transaction implemented during the year ended 31 March 2018 relating to the alignment of certain intangible assets with its US business and other transactions involving intangible assets undertaken in prior years. Intangible assets have an amortizable life of 15 years for US federal tax purposes. At 31 March 2019 the Company had a valuation allowance against the intangible related deferred tax asset which has an indefinite life for US income tax purposes.

Deferred income taxes include net operating loss carry-forwards. At 31 March 2019, the Company had US tax loss carry-forwards of approximately US\$37.0 million, Australian tax loss carry-forwards of approximately US\$23.7 million and European tax loss carry-forwards of approximately US\$9.2 million that are available to offset future taxable income in the respective jurisdiction. The Company establishes a valuation allowance against a deferred tax asset if it is more likely than not that some portion or all of the deferred tax asset will not be realized.

At 31 March 2019, the Company had a valuation allowance against a portion of the European tax loss carry-forwards in respect of which realization is not more likely than not. At 31 March 2019, the Company had European tax loss carry-forwards of approximately US\$5.7 million which will never expire and approximately US\$3.5 million which will expire in fiscal years 2020 through 2028.

The Australian tax loss carry-forwards primarily result from current and prior year tax deductions for contributions to AICF. James Hardie 117 Pty Limited, the performing subsidiary under the AFFA, is able to claim a tax deduction for its contributions to AICF over a five-year period commencing in the year the contribution is incurred. At 31 March 2019, the Company recognized a tax deduction of US\$86.9 million (A\$119.1 million) for the current year relating to total contributions to AICF of US\$472.1 million (A\$595.3 million) incurred in tax years 2015 through 2019.

At 31 March 2019, the Company had foreign tax credit carry-forwards of US\$114.6 million and research credits of US\$0.9 million that are available to offset future taxes payable. At 31 March 2019, the Company had a 100% valuation allowance against the foreign tax credit carry-forwards.

In determining the need for and the amount of a valuation allowance in respect of the Company's asbestos related deferred tax asset, management reviewed the relevant empirical evidence, including the current and past core earnings of the Australian business and forecast earnings of the Australian business considering current trends. Although realization of the deferred tax asset will occur over the life of the AFFA, which extends beyond the forecast period for the Australian business, Australia provides an unlimited carry-forward period for tax losses. Based upon managements' review, the Company believes that it is more likely than not that the Company will realize its asbestos related deferred tax asset and that no valuation allowance is necessary as of 31 March 2019. In the future, based on review of the empirical evidence by management at that time, if management determines that realization of its asbestos related deferred tax asset is not more likely than not, the Company may need to provide a valuation allowance to reduce the carrying value of the asbestos related deferred tax asset to its realizable value.

Income taxes payable represents taxes currently payable which are computed at statutory income tax rates applicable to taxable income derived in each jurisdiction in which the Company conducts business.

At 31 March 2019, the Company had income taxes payable of US\$38.6 million, after taking into account total income tax and withholding tax paid, net of refunds received, during the year ended 31 March 2019 of US\$26.3 million.

Due to the size and nature of its business, the Company is subject to ongoing reviews by taxing jurisdictions on various tax matters. The Company accrues for tax contingencies based upon its best estimate of the taxes ultimately expected to be paid, which it updates over time as more information becomes available. Such amounts are included in taxes payable or other non-current liabilities, as appropriate. If the Company ultimately determines that payment of these amounts is unnecessary, the Company reverses the liability and recognizes a tax benefit during the period in which the Company determines that the liability is no longer necessary. The Company records additional tax expense in the period in which it determines that the recorded tax liability is less than the ultimate assessment it expects.

The Company or its subsidiaries files income tax returns in various jurisdictions including Ireland, the United States, Germany, the Netherlands, Spain, Australia, New Zealand and the Philippines. The Company is no longer subject to US federal examinations by the US Internal Revenue Service ("IRS") for tax years prior to tax year 2016 and Australian federal examinations by the Australian Taxation Office ("ATO"), for tax years prior to tax year 2015.

Taxing authorities from various jurisdictions in which the Company operates are in the process of reviewing and auditing the Company's respective jurisdictional tax returns for various ranges of years. The Company accrues tax liabilities in connection with ongoing audits and reviews based on knowledge of all relevant facts and circumstances, taking into account existing tax laws, its experience with previous audits and settlements, the status of current tax examinations and how the tax authorities view certain issues.

Unrecognized Tax Benefits

A reconciliation of the beginning and ending amount of unrecognized tax benefits and interest and penalties are as follows:

Balance at 31 March 2016\$ 0.7\$ -Additions for tax positions of the current year0.1-Reductions in tax positions of prior year(0.1)-Balance at 31 March 2017\$ 0.7\$ -Additions for tax positions of the current yearReductions in tax positions of prior year	(Millions of US Dollars)	Unrecognized tax benefits	Interest and Penalties
Reductions in tax positions of prior year Balance at 31 March 2017 Additions for tax positions of the current year Reductions in tax positions of prior year Color of the current year Reductions in tax positions of prior year Color of the current year	Balance at 31 March 2016	\$ 0.7	\$
Balance at 31 March 2017 Additions for tax positions of the current year Reductions in tax positions of prior year — — — —	Additions for tax positions of the current year	0.1	_
Additions for tax positions of the current year Reductions in tax positions of prior year	Reductions in tax positions of prior year	(0.1) —
Reductions in tax positions of prior year	Balance at 31 March 2017	\$ 0.7	\$
	Additions for tax positions of the current year	_	_
	Reductions in tax positions of prior year	_	_
Balance at 31 March 2018 \$ 0.7 \ \\$ = -	Balance at 31 March 2018	\$ 0.7	\$ —
Additions for tax positions of the current year 0.1 0.	Additions for tax positions of the current year	0.1	0.1
Reductions in tax positions of prior year	Reductions in tax positions of prior year	_	_
Reductions applicable to lapse of statute of limitations (0.2)	Reductions applicable to lapse of statute of limitations	(0.2) —
Balance at 31 March 2019 \$ 0.6 \$ 0.	Balance at 31 March 2019	\$ 0.6	\$ 0.1

At 31 March 2019, the total amount of unrecognized tax benefits and the total amount of interest and penalties accrued by the Company related to unrecognized tax benefits that, if recognized, would affect the tax expense is US\$0.6 million and US\$0.1 million, respectively.

The Company recognizes penalties and interest accrued related to unrecognized tax benefits in *Income tax expense*. During the years ended 31 March 2019, 2018 and 2017, income of US\$0.1 million, nil and nil, respectively, relating to interest and penalties was recognized within income tax expense arising from movements in unrecognized tax benefits.

The liabilities associated with uncertain tax benefits are included in *Other liabilities* on the Company's consolidated balance sheets.

A number of years may elapse before an uncertain tax position is audited or ultimately resolved. It is difficult to predict the ultimate outcome or the timing of resolution for uncertain tax positions. It is reasonably possible that the amount of unrecognized tax benefits could significantly increase or decrease within the next twelve months. These changes could result from the completion of ongoing examinations, the expiration of the statute of limitations, or other circumstances. At this time, an estimate of the range of the reasonably possible change cannot be made.

16. Stock-Based Compensation

Total stock-based compensation expense consists of the following:

	Years Ended 31 March					
(Millions of US dollars)		2019		2018		2017
Liability Awards (Income) Expense	\$	(0.6)	\$	5.6	\$	5.4
Equity Awards Expense		12.5		11.1		9.3
Total stock-based compensation expense	\$	11.9	\$	16.7	\$	14.7

As of 31 March 2019, the unrecorded future stock-based compensation expense related to outstanding equity awards was US\$18.3 million and will be recognized over an estimated weighted average amortization period of 2.2 years.

2001 Equity Incentive Plan

Under the Company's 2001 Equity Incentive Plan (the "2001 Plan"), the Company can grant equity awards in the form of nonqualified stock options, performance awards, restricted stock grants, stock appreciation rights, dividend equivalent rights, phantom stock or other stock-based benefits such as restricted stock units. The 2001 Plan was first approved by the Company's shareholders in 2001 and was reapproved to continue until September 2021 at the 2011 Annual General Meeting. The Company is authorized to issue 45,077,100 shares under the 2001 Plan.

Under the 2001 Plan, grants have been made at fair market value to management and other employees of the Company. Each grant confers the right to subscribe for one ordinary share in the capital of JHI plc. Primarily, the grants may be exercised as follows: 25% after the first year; 25% after the second year; and 50% after the third year.

Restricted stock units may not be sold, transferred, assigned, pledged or otherwise encumbered so long as such units remain restricted. The Company determines the conditions or restrictions of any restricted stock units, which include requirements of continued employment. At 31 March 2019, there were 910,386 restricted stock units outstanding under this plan.

Long-Term Incentive Plan 2006

At the 2006 Annual General Meeting, the Company's shareholders approved the establishment of a Long-Term Incentive Plan 2006 (the "LTIP") to provide incentives to certain members of senior management ("Executives"). The shareholders also approved, in accordance with certain LTIP rules, the issue of options in the Company to executives of the Company. At the Company's 2008 Annual General Meeting, the shareholders amended the LTIP to also allow restricted stock units to be granted under the LTIP. The LTIP was re-approved by the Company's shareholders with certain amendments at each of the 2008, 2012, 2015 and 2018 Annual General Meetings.

As of 31 March 2019, the Company had granted 13,571,439 restricted stock units under the LTIP. These restricted stock units may not be sold, transferred, assigned, pledged or otherwise encumbered so long as such units remain restricted. The Company determines the conditions or restrictions of any restricted stock awards, which may include requirements of continued employment, individual performance or the Company's financial performance or other criteria. Restricted stock units either vest or expire as set out in the grant documents or LTIP rules. At 31 March 2019, there were 4,261,508 restricted stock units outstanding under the LTIP.

The following table summarizes the Company's shares available for grant as options, restricted stock units or other equity instruments under the LTIP and 2001 Plan at 31 March 2019, 2018 and 2017:

	Shares Available for Grant
Balance at 31 March 2017	27,238,814
Granted	(1,779,904)
Balance at 31 March 2018	25,458,910
Granted	(1,714,094)
Balance at 31 March 2019	23,744,816

Stock Options

There were no stock options granted during the years ended 31 March 2019 and 2018. The following table summarizes the Company's stock options activity during the noted periods:

	Outstanding Options				
	Number	Weighted Average Exercise Price (A\$)			
Balance at 31 March 2017	48,896		6.38		
Exercised	(48,896)		6.38		
Balance at 31 March 2018	_				
Exercised	_				
Balance at 31 March 2019	_				

The total intrinsic value of stock options exercised was nil and A\$0.8 million for the years ended 31 March 2019 and 2018, respectively.

Windfall tax benefits realized in the United States from stock options exercised and included in cash flows from financing activities in the consolidated statements of cash flows were nil, nil and US\$3.0 million for the years ended 31 March 2019, 2018 and 2017, respectively.

Restricted Stock Units

The Company estimates the fair value of restricted stock units on the date of grant and recognizes this estimated fair value as compensation expense over the periods in which the restricted stock vests.

The following table summarizes the Company's restricted stock unit activity during the noted period:

	Restricted Stock Units	Weighted Average Fair Value at Grant Date (A\$)
Non-vested at 31 March 2017	3,340,245	14.80
Granted	1,779,904	14.04
Vested	(615,334)	12.05
Forfeited	(367,223)	14.12
Non-vested at 31 March 2018	4,137,592	14.63
Granted	1,714,094	14.12
Vested	(745,787)	15.53
Forfeited	(844,391)	13.71
Non-vested at 31 March 2019	4,261,508	14.47

Restricted Stock Units - service vesting

During fiscal year 2019 and 2018, 617,793 and 332,262 restricted stock units (service vesting) were granted to employees under the 2001 Plan, respectively. The fair value of each restricted stock unit (service vesting) is equal to the market value of the Company's common stock on the date of the grant, adjusted for the fair value of estimated dividends as the restricted stock unit holder is not entitled to dividends over the vesting period.

During fiscal year 2019 and 2018, 242,964 and 237,480 restricted stock units (service vesting) that were previously granted as part of the 2001 Plan became fully vested and the underlying common stock was issued, respectively.

Restricted Stock Units – performance vesting

The Company granted 357,797 and 515,249 restricted stock units with a performance vesting condition under the LTIP to senior executives and managers of the Company on 17 August 2018 and 21 August 2017, respectively. The Company also granted 25,385 restricted stock units with a performance vesting condition under the LTIP to senior executives and managers of the Company on 6 September 2018. The vesting of the restricted stock units is subject to a return on capital employed ("ROCE") performance hurdle being met and is subject to negative discretion by the Board. The Board's discretion will reflect the Board's judgment of the quality of the returns balanced against management's delivery of market share growth and a scorecard of key qualitative and quantitative performance objectives. During fiscal year 2019, after exercise of negative discretion by the Board, 284,350 restricted stock units (performance vesting) that were granted on 16 September 2015 as part of the fiscal year 2016 long-term incentive award became fully vested and the underlying common stock was issued. The remaining 199,162 unvested restricted stock units from this grant were cancelled on 17 September 2018.

When the Board reviews the awards and determines whether any negative discretion should be applied at the vesting date, the award recipients may receive all, some, or none of their awards. The Board may only

exercise negative discretion and may not enhance the maximum award that was originally granted to the award recipient.

The fair value of each restricted stock unit (performance vesting) is adjusted for changes in JHI plc's common stock price at each balance sheet date and for the fair value of estimated dividends as the restricted stock unit holder is not entitled to dividends over the vesting period until the performance conditions are applied at the vesting date.

Restricted Stock Units - market condition

Under the terms of the LTIP, the Company granted 663,738 and 932,393 restricted stock units (market condition) to senior executives and managers of the Company on 17 August 2018 and 21 August 2017, respectively. The Company also granted 49,381 restricted stock units (market condition) to senior executives and managers of the Company on 6 September 2018. The vesting of these restricted stock units is subject to a market condition as outlined in the relevant notice of meeting.

The fair value of each of these restricted stock units (market condition) granted under the LTIP is estimated using a binomial lattice model that incorporates a Monte Carlo simulation (the "Monte Carlo" method). The following table includes the assumptions used for restricted stock grants (market condition) valued during the year ended 31 March 2019 and 2018, respectively:

Vesting Condition:	Market	Market	Market
	FY19	FY19	FY18
Date of grant	6 Sep 2018	17 Aug 2018	21 Aug 2017
Dividend yield (per annum)	3.0%	3.0%	3.0%
Expected volatility	26.8%	28.1%	30.1%
Risk free interest rate	2.7%	2.7%	1.5%
Expected life in years	2.9	3.0	3.3
JHX stock price at grant date (A\$)	20.87	22.00	17.91
Number of restricted stock units	49,381	663,738	932,393

During fiscal year 2019, 218,473 restricted stock units (market condition) that were previously granted became fully vested and the underlying common stock was issued. During fiscal year 2018, 156,812 restricted stock units (market condition) that were previously granted became fully vested and the underlying common stock was issued.

Scorecard LTI – cash settled units

Under the terms of the LTIP, the Company granted awards equivalent to 1,073,396 and 1,545,750 Scorecard LTI units on 17 August 2018 and 21 August 2017, respectively. The Company also granted awards equivalent to 76,155 on 6 September 2018 and 28,558 on 31 January 2019. These awards provide recipients a cash incentive based on an average 20 trading-day closing price of JHI plc's common stock price and each executive's scorecard rating. The vesting of awards is measured on individual performance conditions based on certain performance measures. Compensation expense recognized for awards are based on the fair market value of JHI plc's common stock on the date of grant and recorded as a liability. The expense is recognized ratably over the vesting period and the liability is adjusted for subsequent changes in JHI plc's common stock price at each balance sheet date adjusted for the fair value of estimated dividends as the restricted stock unit holder is not entitled to dividends over the vesting period.

James Hardie Industries plc

Notes to Consolidated Financial Statements (continued)

On 17 August 2018, 153,667 of the 456,995 Scorecard LTI units that were previously granted on 16 September 2015 as part of the FY2016 long-term incentive award became fully vested and the balance cancelled as a result of the Board's determination of management's performance against the FY2016-18 Scorecard. The cash amount paid to award recipients was based on an average 20 trading-day closing price of JHI plc's common stock price.

On 18 September 2017, 197,800 of the 454,179 Scorecard LTI units that were previously granted on 16 September 2014 as part of the FY2015 long-term incentive award became fully vested and the balance cancelled as a result of the Board's determination of management's performance against the FY2015-17 Scorecard. The cash amount paid to award recipients was based on an average 20 trading-day closing price of JHI plc's common stock price.

17. Capital Management and Dividends

The following table summarizes the dividends paid during the fiscal years 2019, 2018 and 2017:

(Millions of US dollars)	US Cents/Security	US\$ Millions Total Amount	Announcement Date	Record Date	Payment Date
FY 2019 first half dividend	0.10	43.6	8 November 2018	12 December 2018	22 February 2019
FY 2018 second half dividend	0.30	128.5	22 May 2018	7 June 2018	3 August 2018
FY 2018 first half dividend	0.10	46.2	9 November 2017	13 December 2017	23 February 2018
FY 2017 second half dividend	0.28	131.3	18 May 2017	8 June 2017	4 August 2017
FY 2017 first half dividend	0.10	46.6	17 November 2016	21 December 2016	24 February 2017
FY 2016 second half dividend	0.29	130.2	19 May 2016	9 June 2016	5 August 2016

During fiscal year 2017, the Company announced a share buyback program (the "fiscal 2017 program") to acquire up to US\$100.0 million of its issued capital in the twelve months through May 2017. Under this program, the Company repurchased and cancelled 6,090,133 shares of its common stock during the second quarter of fiscal year 2017. The aggregate cost of the shares repurchased and cancelled was A\$131.4 million (US\$99.8 million), at an average market price of A\$21.58 (US\$16.40).

Subsequent to 31 March 2019, the Company announced an ordinary dividend of US26.0 cents per security, with a record date of 6 June 2019 and a payment date of 2 August 2019.

18. Operating Segment Information and Concentrations of Risk

During the first quarter of fiscal year 2019, the Company changed its reportable operating segments. Previously, the Company maintained four operating segments: (i) North America Fiber Cement; (ii) International Fiber Cement; (iii) Other Businesses; and (iv) Research and Development. Beginning in the first quarter of fiscal year 2019, the Company replaced the International Fiber Cement segment with two new segments: (i) Asia Pacific Fiber Cement; and (ii) Europe Building Products. There were no changes to the North America Fiber Cement; Other Businesses; and Research and Development segments. The Company has revised its historical segment information at 31 March 2018 and for the years ended 31 March 2018 and 2017 to be consistent with the current reportable segment structure. The change in reportable segments had no effect on the Company's financial position, results of operations or cash flows for the periods presented.

The Company has reported its operating segment information in the format that the operating segment information is available to and evaluated by the CODM. The North America Fiber Cement segment manufactures fiber cement interior linings, exterior siding products and related accessories in the United States; these products are sold in the United States and Canada. The Asia Pacific Fiber Cement segment includes all fiber cement products manufactured in Australia, New Zealand and the Philippines, and sold in Australia, New Zealand, Asia, the Middle East and various Pacific Islands. The Europe Building Products

segment includes the newly acquired Fermacell business and fiber cement product manufactured in the United States that is sold in Europe. The Other Businesses segment includes certain non-fiber cement manufacturing and sales activities in North America, including fiberglass windows. The Research and Development segment represents the cost incurred by the research and development centers. General Corporate costs primarily consist of *Asbestos adjustments*, officer and employee compensation and related benefits, professional and legal fees, administrative costs and rental expense, net of rental income, on the Company's corporate offices.

Operating Segments

The following is the Company's operating segment information:

	Net Sales to Customers Years Ended 31 March					
(Millions of US dollars)		2019	2018		2017	
North America Fiber Cement	\$	1,676.9	\$ 1,578.1	\$	1,493.4	
Asia Pacific Fiber Cement		446.8	425.4		370.6	
Europe Building Products		368.3	36.3		41.2	
Other Businesses		14.6	14.7		16.4	
Worldwide total	\$	2,506.6	\$ 2,054.5	\$	1,921.6	

	Income Before Income Taxes Years Ended 31 March				
(Millions of US dollars)	2	019	2018	2017	
North America Fiber Cement ^{1,10}	\$	382.5 \$	381.9 \$	343.9	
Asia Pacific Fiber Cement ¹		99.8	108.1	93.8	
Europe Building Products ^{1,7}		10.0	0.3	1.3	
Other Businesses ¹⁰		(30.9)	(8.6)	(6.7)	
Research and Development ¹		(29.0)	(27.8)	(25.5)	
Segments total		432.4	453.9	406.8	
General Corporate ^{2,6}		(80.8)	(224.7)	(13.6)	
Total operating income		351.6	229.2	393.2	
Net interest expense ³		(50.1)	(29.5)	(27.5)	
Loss on early debt extinguishment		(1.0)	(26.1)	_	
Other income		0.1	0.7	1.3	
Worldwide total	\$	300.6 \$	174.3 \$	367.0	

	Total Identifiable Assets 31 March			
(Millions of US dollars)	2019		2018	
North America Fiber Cement	\$ 1,280.2	\$	1,070.7	
Asia Pacific Fiber Cement	328.8		328.8	
Europe Building Products	717.7		22.8	
Other Businesses	10.9		30.1	
Research and Development	8.1		7.5	
Segments total	2,345.7		1,459.9	
General Corporate 4,5	 1,686.9		891.1	
Worldwide total	\$ 4,032.6	\$	2,351.0	

The following is the Company's geographical information:

Net Sales to Customers Years Ended 31 March

(Millions of US dollars)	2019		2018		2017
North America ⁹	\$	1,691.5	\$	1,592.8	\$ 1,509.9
Australia		315.1		301.1	252.5
Germany		137.1		2.1	2.7
New Zealand		79.1		76.8	73.3
Other Countries ⁸		283.8		81.7	83.2
Worldwide total	\$	2,506.6	\$	2,054.5	\$ 1,921.6

Total Identifiable Assets 31 March

(Millions of US dollars)	2019	2018
North America ⁹	\$ 1,294.6	\$ 1,103.6
Australia	235.4	242.6
Germany	512.3	0.5
New Zealand	39.2	34.8
Other Countries ⁸	264.2	78.4
Segments total	2,345.7	1,459.9
General Corporate ^{4,5}	 1,686.9	891.1
Worldwide total	\$ 4,032.6	\$ 2,351.0

¹ Research and development expenditures are expensed as incurred and are summarized by segment in the following table:

Years Ended 31 March (Millions of US dollars) 2019 2018 2017 North America Fiber Cement \$ 6.5 \$ \$ 6.2 6.1 Asia Pacific Fiber Cement 2.1 1.5 1.8 **Europe Building Products** 2.6 Research and Development^a 26.7 25.4 22.6 \$ 37.9 \$ 33.3 30.3

The principal components of General Corporate costs are officer and employee compensation and related benefits, professional and legal fees, administrative costs, and rental expense on the Company's corporate offices. Also included in General Corporate costs are the following:

(Millions of US dollars)	2	2019	2018	2017
Asbestos adjustments	\$	(22.0) \$	(156.4) \$	40.4
AICF SG&A expenses		(1.5)	(1.9)	(1.5)
Gain on sale of Fontana building		_	3.4	_
Fermacell acquisition costs		_	10.0	

The Company does not report net interest expense for each operating segment as operating segments are not held directly accountable for interest expense. Included in net interest expense is net AICF interest (income) expense of US\$(2.0) million, US \$(1.9) million and US\$1.1 million in fiscal years 2019, 2018 and 2017, respectively.

^a The Research and Development segment also included *Selling, general and administrative* expenses of US\$2.3 million, US\$2.4 million and US\$2.9 million in fiscal years 2019, 2018 and 2017, respectively.

James Hardie Industries plc

Notes to Consolidated Financial Statements (continued)

- 4 Included in General Corporate costs are deferred tax assets for each operating segment that are not held directly accountable for deferred income taxes.
- Asbestos-related assets at 31 March 2019 and 2018 are US\$486.8 million and US\$537.7 million, respectively, and are included in the General Corporate costs.
- Included in the General Corporate costs are New Zealand weathertightness legal costs of US\$3.3 million, nil and nil for the years ended 31 March 2019, 2018 and 2017, respectively.
- Included in the Europe Building Products segment are Fermacell transaction and integration costs of US\$21.8 million and the amortization of the inventory fair value adjustment of US\$7.3 million for the year ended 31 March 2019. As this inventory was sold during the first quarter of fiscal year 2019, the entire adjustment was recognized into cost of goods sold during the same period.
- Included are all other countries that account for less than 5% of net sales and total identifiable assets individually, primarily in the Philippines, Switzerland and other European countries.
- 9 The amounts disclosed for North America are substantially all related to the USA.
- The following table summarizes asset impairment costs by segment:

	Years Ended 31 March						
(Millions of US dollars)	2019		2018			2017	
North America Fiber Cement ^a	\$	3.0	\$	_	\$		_
Other Businesses ^b	1	12.9					_
	\$	5.9	\$		\$		_

V- --- F-- I- -I 04 M----I-

Concentrations of Risk

The distribution channels for the Company's fiber cement products are concentrated. If the Company were to lose one or more of its major customers, there can be no assurance that the Company will be able to find a replacement. Therefore, the loss of one or more customers could have a material adverse effect on the Company's consolidated financial position, results of operations and cash flows.

We have one customer who contributes greater than 10% of our net sales in each of the past three fiscal years.

This customer's accounts receivable represented 8.5% and 9.0% of the Company's accounts receivable at 31 March 2019 and 2018, respectively. The following is net sales generated by this customer, which is from the North America Fiber Cement segment:

	Years Ended 31 March							
(Millions of US dollars)		2019		2018		2017		
Customer A	\$	260.5	10.4% \$	246.9	12.0% \$	226.0	10.3%	

Approximately 36%, 22% and 21% of the Company's net sales in fiscal year 2019, 2018 and 2017, respectively, were from outside the United States. Consequently, changes in the value of foreign currencies could significantly affect the consolidated financial position, results of operations and cash flows of the Company's non-US operations on translation into US dollars.

^a For the year ended 31 March 2019, the Company recorded impairment charges of US\$2.6 million and US\$0.4 million to *Property, plant and equipment, net* and *Intangible assets, net,* respectively, related to the discontinuance of its MCT product line.

^b For the year ended 31 March 2019, the Company recorded impairment charges of US\$4.6 million, US\$6.1 million and US\$2.2 million to the *Goodwill, Property, Plant and equipment, net* and *Intangible assets, net*, respectively, due to the Company's decision to cease production of its fiberglass windows business in the second quarter of fiscal year 2019.

19. Accumulated Other Comprehensive Loss

During the year ended 31 March 2019 there were the following reclassifications out of *Accumulated other comprehensive loss:*

(Millions of US dollars)	Cash Flow Hedges	Foreign Currency Translation Adjustments	Total
Balance at 31 March 2018	\$ 0.3	\$ (1.6)	\$ (1.3)
Other comprehensive loss	(0.1)	(28.9)	(29.0)
Balance at 31 March 2019	\$ 0.2	\$ (30.5)	\$ (30.3)

20. Business Combinations

Fermacell Acquisition

On 3 April 2018, the Company completed its acquisition of the Fermacell business with Xella International S.A. for a purchase price of €516.4 million (US\$635.6 million based on the exchange rate at 3 April 2018). The acquisition was pursuant to the Sales and Purchase Agreement dated 7 November 2017, and was structured as a stock purchase, resulting in 100% ownership of Fermacell. The Company financed the acquisition through a combination of cash on hand and borrowings of €400.0 million (US\$492.4 million based on the exchange rate at 3 April 2018) from the Term Loan Facility. See Note 10 for more information.

Headquartered in Dusseldorf, Germany, Fermacell operates six manufacturing plants across Germany, the Netherlands and Spain, with a sales force in 13 countries and revenues generated primarily from countries in Western Europe. Fermacell is a provider of innovative building solutions, producing and distributing high quality fiber gypsum boards and cement-bonded boards, which are two complementary products in the high performance board space. Management believes this acquisition will generate significant value by providing the Company with a significant European presence and a differentiated platform to position the Company for meaningful long-term growth in Europe.

In connection with this acquisition, the Company incurred related transaction and integration costs of US \$21.8 million during the year ended 31 March 2019, which have been recorded in the consolidated statements of operations and comprehensive income in *Selling*, *general and administrative expenses*.

James Hardie Industries plc

Notes to Consolidated Financial Statements (continued)

The following is the purchase price allocation for Fermacell:

(Millions of US dollars)	
Cash and cash equivalents	\$ 76.9
Accounts and other receivable	43.7
Inventories	39.7
Other assets	4.1
Property, plant and equipment	230.3
Intangible assets	187.0
Accounts payable	(40.5)
Other liabilities	(41.2)
Deferred tax liabilities	 (84.4)
Net assets acquired	\$ 415.6
Goodwill	 220.0
Total consideration	\$ 635.6

The purchase price allocation set forth above reflects fair value of the net assets acquired based on analysis performed by management.

The following table summarizes the estimated fair value of acquired identifiable intangible assets:

(Millions of US dollars)	Estimated remaining useful life (years)	Fair Value
Trade name	Indefinite	\$ 126.8
Customer relationships	13	57.8
Other intangible assets	2 - 13	2.4
Total		\$ 187.0

Intangible assets will be evaluated for impairment annually or more frequently if an event occurs or circumstances change that indicate it may be impaired, by comparing its fair value to its carrying amount to determine if a write-down to fair value is required.

Goodwill is attributable primarily to the benefits from the increased scale of the Company as a result of the Fermacell acquisition. Goodwill arising from the Fermacell acquisition is not deductible for income tax purposes.

We recorded adjustments to the preliminary purchase price allocation during the year as the Company had up to one year from the acquisition date to finalize its purchase price allocation. The Company has finalized its purchase price allocation as of 31 March 2019 and does not expect further changes. During the year ended 31 March 2019, the Company recorded net adjustments of €0.5 million related to property, plant and equipment, other liabilities and deferred taxes valuations, with a corresponding increase in goodwill.

Supplemental Pro Forma Results of Operations

The following unaudited supplemental pro forma information presents the results of operations of the Company, after giving effect to the Fermacell acquisition, as if the Company had completed the Fermacell acquisition and related financing (as described in Note 10) on 1 April 2017, but using the fair values of the assets acquired and liabilities assumed as of the closing dates of the acquisition. These unaudited pro forma results are presented for informational purposes only and are not necessarily indicative of what the actual results of operations of the Company would have been if the Fermacell acquisition and related financing had occurred on the date assumed, nor are they indicative of future results of operations.

James Hardie Industries Consolidated Pro Forma

	Years End	Years Ended 31 March			
	2019		2018		
(Millions of US dollars)	(Unaudited)		(Unaudited)		
Net sales	\$ 2,506.6	\$	2,367.0		
Income before income taxes	329.7		203.6		

Europe Building Products Pro Forma

	Years En	Years Ended 31 March			
	2019		2018		
(Millions of US dollars)	(Unaudited)		(Unaudited)		
Net sales	\$ 368.3	\$	348.8		
Income before income taxes	39.		29.0		

The unaudited pro forma results include the depreciation and amortization of the fair value of the acquired property, plant and equipment, customer relationships and other intangible assets and interest expense on the Term Loan Facility used to acquire Fermacell. The unaudited pro forma results exclude the impact of transaction and integration costs of US\$21.8 million for the year ended 31 March 2019. The unaudited pro forma results also excludes the impact of the inventory fair value adjustment of US\$7.3 million for the year ended 31 March 2019.